CLINICAL TRIAL: NCT00856765

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => [
                                                    'Netherlands: Ministry of Health, Welfare and Sport',
                                                    'Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)'
                                                  ]
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'March 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '6 months',
                                      'measure' => 'Angiographic in-segment late lumen loss (expressed in millimeters)  as determined by quantitative coronary analysis (QCA)',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => 'Dior (EuroCor)',
                                     'intervention_type' => 'Device',
                                     'arm_group_label' => '1',
                                     'description' => 'Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel',
                                     'intervention_name' => 'Drug eluting balloon'
                                   },
                                   {
                                     'other_name' => 'Magic (EuroCor)',
                                     'intervention_type' => 'Device',
                                     'arm_group_label' => [
                                                          '1',
                                                          '3'
                                                        ],
                                     'description' => 'Bare metal stent',
                                     'intervention_name' => 'Bare metal stent'
                                   },
                                   {
                                     'other_name' => "Taxus Libert\x{e9} (Boston scientific)",
                                     'intervention_type' => 'Device',
                                     'arm_group_label' => '2',
                                     'description' => 'Paclitaxel eluting stent',
                                     'intervention_name' => 'Drug eluting stent'
                                   }
                                 ],
                 'has_expanded_access' => 'No',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Drug eluting balloon followed immediately by implantation of bare metal stent',
                                  'arm_group_label' => '1'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'Drug eluting stent',
                                  'arm_group_label' => '2'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'Bare metal stent',
                                  'arm_group_label' => '3'
                                }
                              ],
                 'number_of_arms' => '3',
                 'overall_official' => {
                                       'affiliation' => 'UMC Utrecht',
                                       'role' => 'Principal Investigator',
                                       'last_name' => 'Pieter Stella, MD'
                                     },
                 'brief_title' => 'Drug-eluting Balloon in Acute Myocardial Infarction',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Giuseppe M Sangiorgi, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'last_name' => 'Giuseppe M Sangiorgi, MD'
                                            },
                                 'facility' => {
                                               'name' => 'University of Modena, Department of Cardiology',
                                               'address' => {
                                                            'country' => 'Italy',
                                                            'city' => 'Modena'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Pierfrancesco Agostoni, MD, PhD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Eric Van Belle, MD, PhD'
                                                   },
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Pieter Stella, MD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'p.stella@umcutrecht.nl',
                                              'phone' => '+31887556167',
                                              'last_name' => 'Pieter Stella, MD'
                                            },
                                 'facility' => {
                                               'name' => 'UMC Utrecht',
                                               'address' => {
                                                            'country' => 'Netherlands',
                                                            'zip' => '3584 cx',
                                                            'city' => 'Utrecht'
                                                          }
                                             }
                               }
                             ],
                 'acronym' => 'DEB-AMI',
                 'id_info' => {
                              'nct_id' => 'NCT00856765',
                              'org_study_id' => 'METC 08-255'
                            },
                 'firstreceived_date' => 'March 5, 2009',
                 'overall_contact' => {
                                      'email' => 'p.stella@umcutrecht.nl',
                                      'phone' => '+31887556167',
                                      'last_name' => 'Pieter Stella, MD'
                                    },
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'March 2009',
                 'source' => 'UMC Utrecht',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'UMC Utrecht'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'March 2018',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Randomized Comparison of Drug Eluting Balloon/Bare Metal Stent Versus Drug Eluting Stent Versus Bare Metal Stent for the Treatment of Patients With Acute ST-elevation Myocardial Infarction',
                 'enrollment' => {
                                 'content' => '150',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Atherosclerosis',
                                                      'Coronary Artery Disease',
                                                      'Myocardial Ischemia',
                                                      'Coronary Disease',
                                                      'Infarction',
                                                      'Myocardial Infarction',
                                                      'Thrombosis'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The investigators hypothesize that patients with Acute ST Elevation Myocardial Infarction
      may benefit from primary angioplasty with use of a drug eluting balloon/bare metal stent
      combination without impairing the process of normal vascular healing and endothelial
      function.

      The goals of this study are:

        1. To compare 6-month angiographic outcome after primary angioplasty using drug eluting
           balloon/bare metal stent combination versus drug eluting stent versus bare metal stent.

        2. To compare stent apposition and stent endothelialization after primary angioplasty
           using drug eluting balloon/bare metal stent versus drug eluting stent versus bare metal
           stent.

        3. To compare coronary endothelial function after primary angioplasty using drug eluting
           balloon/bare metal stent versus drug eluting stent versus bare metal stent.
    '
                                  },
                 'location_countries' => {
                                         'country' => [
                                                      'Italy',
                                                      'Netherlands'
                                                    ]
                                       },
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => '6 months',
                                          'measure' => 'Binary restenosis using QCA',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '6 months',
                                          'measure' => 'stent malapposition and re-endothelialization assessed by Optical Coherence Tomography (OCY)',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => '6 months',
                                          'measure' => 'coronary endothelial dysfunction after acetylcholine infusion',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => '5 years',
                                          'measure' => 'Clinical outcomes (death, myocardial infarction, repeated revascularization procedures)',
                                          'safety_issue' => 'Yes'
                                        }
                                      ],
                 'responsible_party' => {
                                        'name_title' => 'Dr. Pieter Stella',
                                        'organization' => 'UMC Utrecht'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  STEMI within 12 hours of onset of complaints

          -  Candidate for primary PCI with stent-implantation

          -  Successful thrombus aspiration defined by no angiographic signs of thrombus a the
             site of plaque rupture and TIMI flow more or equal 1

        Exclusion Criteria:

          -  Unable to give written informed consent

          -  Diabetes and Type C- coronary lesion

          -  Previous PCI or CABG of infarct related vessel

          -  Left main stenosis more than 50%.

          -  Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries

          -  Target vessel reference diameter less than 2.5 and more than 4.0 mm

          -  Target lesion length more than 25 mm

          -  Intolerance for aspirin or clopidogrel

          -  Life expectancy less than 12 months

          -  Women with child bearing potential
      '
                                              },
                                  'maximum_age' => '80 Years',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 2/Phase 3',
                 'lastchanged_date' => 'June 29, 2010',
                 'start_date' => 'March 2009',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT00856765',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => [
                                'Coronary Artery Disease',
                                'Atherosclerosis',
                                'Thrombosis',
                                'Acute Myocardial Infarction'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Randomized Comparison of Drug Eluting Balloon/Bare Metal Stent Versus Drug Eluting Stent Versus Bare Metal Stent for the Treatment of Patients With Acute ST-elevation Myocardial Infarction
time_frame	6 months
measure	Angiographic in-segment late lumen loss (expressed in millimeters)  as determined by quantitative coronary analysis (QCA)
safety_issue	No
other_name	Dior (EuroCor)
intervention_type	Device
arm_group_label	1
description	Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
intervention_name	Drug eluting balloon
other_name	Magic (EuroCor)
intervention_type	Device
arm_group_label	1
arm_group_label	3

description	Bare metal stent
intervention_name	Bare metal stent
other_name	Taxus Liberté (Boston scientific)
intervention_type	Device
arm_group_label	2
description	Paclitaxel eluting stent
intervention_name	Drug eluting stent
Keyword	NOT FOUND
Lead sponsor: Other; UMC Utrecht
Intervention MeSH	NOT FOUND
Condition MeSH:Atherosclerosis; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Infarction; Myocardial Infarction; Thrombosis
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01322009

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => 'United States: Institutional Review Board'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      Specific Aim: Define the capacity of the combination of probenecid and NAC to safely and
      synergistically preserve levels of GSH and reduce oxidative stress in children with severe
      TBI. We will enroll 20 children age 2 to less than 18 years old (less than 216 months) after
      severe TBI in a randomized, controlled study of administration of the combinational therapy
      and test if the administration of these drugs is safe and if antioxidant reserve can be
      preserved within the serum and CSF.

      Probenecid (at the same dose that is used as an adjunct to antibiotic therapy) and NAC (at
      the same dose that is used for acetaminophen-induced liver disease), or vehicles will be
      given for 3 days. The primary outcomes of the study will be the safety of drug
      administration and the CSF and serum levels anti-oxidant reserve (AOR), with the presumption
      that maintaining anti-oxidant levels within the brain may prove neuroprotective. Other
      secondary outcomes (CSF and serum probenecid, NAC, GSH and phenytoin concentrations) will
      also be tested. Adverse events occuring during treatment with these drugs after TBI will be
      monitored by a local Data Safety Monitoring Board.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'March 2014',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '14 days after drug administration',
                                      'measure' => 'Adverse Events',
                                      'description' => 'A number of a prior defined adverse events have been defined. The number of adverse events in the treatment arms will be calculated and compared.',
                                      'safety_issue' => 'Yes'
                                    },
                 'intervention' => [
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Drug',
                                     'description' => 'After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.',
                                     'intervention_name' => 'Probenecid and N-acetyl cysteine'
                                   },
                                   {
                                     'other_name' => 'Ora Plus',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Placebo',
                                     'description' => 'After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.',
                                     'intervention_name' => 'Placebo'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Acetylcysteine',
                                                         'N-monoacetylcystine',
                                                         'Probenecid'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Probenecid and N-acetyl cysteine will be administered at standard doses for the first 4 days after TBI.',
                                  'arm_group_label' => 'Drug'
                                },
                                {
                                  'arm_group_type' => 'Placebo Comparator',
                                  'description' => 'Placebos will be prepared for the two experimental drugs and administered at identical time periods.',
                                  'arm_group_label' => 'Placebo'
                                }
                              ],
                 'overall_official' => [
                                       {
                                         'affiliation' => 'University of Pittsburgh',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Michael J Bell, MD'
                                       },
                                       {
                                         'affiliation' => 'University of Pittsburgh',
                                         'role' => 'Study Director',
                                         'last_name' => 'Robert SB Clark, MD'
                                       }
                                     ],
                 'brief_title' => 'Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment',
                 'location' => {
                               'investigator' => [
                                                 {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Michael J Bell, MD'
                                                 },
                                                 {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Robert SB Clark, MD'
                                                 }
                                               ],
                               'status' => 'Recruiting',
                               'contact' => {
                                            'email' => 'bellmj4@upmc.edu',
                                            'phone' => '412-692-5164',
                                            'last_name' => 'Michael J Bell, MD'
                                          },
                               'facility' => {
                                             'name' => 'Children\'s Hospital of Pittsburgh of UPMC',
                                             'address' => {
                                                          'country' => 'United States',
                                                          'zip' => '15213',
                                                          'city' => 'Pittsburgh',
                                                          'state' => 'Pennsylvania'
                                                        }
                                           }
                             },
                 'acronym' => 'Pro-NAC',
                 'id_info' => {
                              'secondary_id' => '1R01NS069247-01',
                              'nct_id' => 'NCT01322009',
                              'org_study_id' => 'NS069247'
                            },
                 'overall_contact' => {
                                      'email' => 'bellmj4@upmc.edu',
                                      'phone' => '412-692-5164',
                                      'last_name' => 'Michael J Bell, MD'
                                    },
                 'firstreceived_date' => 'March 22, 2011',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'March 2011',
                 'keyword' => [
                              'Children',
                              'Brain injury',
                              'Trauma'
                            ],
                 'source' => 'University of Pittsburgh',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'University of Pittsburgh'
                                               },
                               'collaborator' => [
                                                 {
                                                   'agency_class' => 'NIH',
                                                   'agency' => 'National Institutes of Health (NIH)'
                                                 },
                                                 {
                                                   'agency_class' => 'NIH',
                                                   'agency' => 'National Institute of Neurological Disorders and Stroke (NINDS)'
                                                 }
                                               ]
                             },
                 'completion_date' => {
                                      'content' => 'March 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Overcoming Membrane Transporters to Improve CNS Drug Delivery',
                 'enrollment' => {
                                 'content' => '20',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Brain Injuries'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The overall purpose of this research study is to investigate the safety of pharmacological
      therapies that may potentially improve pediatric outcomes after traumatic brain injury.
      Traumatic brain injuries are the leading cause of death and disability among children and
      young adults.

      Hypothesis: Combinational therapy with a membrane transporter and antioxidant are safe after
      TBI and can overcome barriers to the brain and synergistically improve bioavailability and
      efficacy the antioxidant content of the body and CNS after TBI.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'secondary_outcome' => {
                                        'time_frame' => 'Within 5 days of injury',
                                        'measure' => 'Antioxidant Reserve',
                                        'description' => 'Antioxidant reserves in CSF and serum will be calculated in both treatment arms and compared.',
                                        'safety_issue' => 'No'
                                      },
                 'responsible_party' => {
                                        'name_title' => 'Michael Bell/Associate Professor of Critical Care Medicine, Neurological Surgery and Pediatrics',
                                        'organization' => 'University of Pittsburgh'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '2 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  Children (age 2 - 18 y) with severe TBI (GCS < or = 8) with an externalized
             ventricular drain placed for measurement of intracranial pressure

        Exclusion Criteria:

          1. Brain dead on admission to ICU

          2. Pregnancy

          3. Contraindications to enteral medications

          4. Contraindications to probenecid:

               -  status epilepticus

               -  blood dyscrasias

               -  under 2 years-of-age

               -  coadministration of salicylates

               -  renal dysfunction or urate kidney stones

               -  hypersensitivity to probenecid

          5. Contraindications to N-acetylcysteine: hypersensitivity to N-acetylcysteine

          6. Family unwilling to consent
      '
                                              },
                                  'maximum_age' => '18 Years',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'March 23, 2011',
                 'phase' => 'Phase 1/Phase 2',
                 'start_date' => 'March 2011',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01322009',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => 'Pediatric Traumatic Brain Injury'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Overcoming Membrane Transporters to Improve CNS Drug Delivery
time_frame	14 days after drug administration
measure	Adverse Events
description	A number of a prior defined adverse events have been defined. The number of adverse events in the treatment arms will be calculated and compared.
safety_issue	Yes
intervention_type	Drug
arm_group_label	Drug
description	After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
intervention_name	Probenecid and N-acetyl cysteine
other_name	Ora Plus
intervention_type	Drug
arm_group_label	Placebo
description	After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
intervention_name	Placebo
Keywords:Children; Brain injury; Trauma
Lead sponsor: Other; University of Pittsburgh
Collaborator: NIH; National Institutes of Health (NIH)
Collaborator: NIH; National Institute of Neurological Disorders and Stroke (NINDS)
Intervention MeSH:Acetylcysteine; N-monoacetylcystine; Probenecid
Condition MeSH:Brain Injuries
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01372254

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'No',
                                     'authority' => 'United States: Institutional Review Board'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      This project will take place in two phases. In the first phase, the investigators will
      utilize pilot testing with 10 participants (two groups of 5 individuals) to integrate two
      existing behavioral activation manuals to develop the Behavioral Activation for Drug Abusing
      Smokers (BA-DAS). In Phase II, the investigators will randomize 80 patients to either: 1)
      standard smoking cessation treatment (ST) and nicotine replacement therapy (NRT) or 2)
      BA-DAS (which includes ST and NRT). Based on the outcome of this preliminary trial, the
      BA-DAS protocol will be further refined and readied for larger-scale clinical trials to
      develop a comprehensive approach to treating smoking among low income, largely  minority,
      depressed smokers in residential drug use treatment, which may be instrumental in reducing
      smoking among this especially at risk group.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'December 2014',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '26 weeks post quit date',
                                      'measure' => 'Smoking abstinence based on expired carbon monoxide tests, saliva cotinine tests, and self-report',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => 'ST',
                                     'intervention_type' => 'Behavioral',
                                     'arm_group_label' => 'Standard smoking cessation treatment (ST)',
                                     'description' => 'Participants will receive a standard, individual smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 5, 90-minute group sessions over an 4-5 week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day\'s events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BAD-AS condition.',
                                     'intervention_name' => 'Standard Treatment'
                                   },
                                   {
                                     'other_name' => 'BAD-AS',
                                     'intervention_type' => 'Behavioral',
                                     'arm_group_label' => 'Behavioral Activation for Substance Abusing Smokers (BA-DAS)',
                                     'description' => 'BAD-AS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 5, 90-minute individual sessions over a 4-5 week period.',
                                     'intervention_name' => 'BAD-AS'
                                   },
                                   {
                                     'other_name' => 'Nicoderm CQ',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => [
                                                          'Standard smoking cessation treatment (ST)',
                                                          'Behavioral Activation for Substance Abusing Smokers (BA-DAS)'
                                                        ],
                                     'description' => '8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant\'s initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant\'s initial nicotine level.',
                                     'intervention_name' => 'Transdermal Nicotine Patch'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Nicotine',
                                                         'Nicotine polacrilex'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'Participants will receive a standard, group smoking cessation treatment based on the most recent clinical practice guideline from USDHHS, Treating Tobacco Use and Dependence. Treatment will be delivered in five, 90-minute individual sessions, and 2, 4, 8, 16, and 26 weeks post quit.',
                                  'arm_group_label' => 'Standard smoking cessation treatment (ST)'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'The BA-DAS treatment protocol will incorporate elements of the ST and NRT along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions and 2, 4, 8, 16, and 26 weeks post-quit.',
                                  'arm_group_label' => 'Behavioral Activation for Substance Abusing Smokers (BA-DAS)'
                                }
                              ],
                 'overall_official' => {
                                       'affiliation' => 'University of Maryland College Park, Center for Addictions, Personality, and Emotions Research (CAPER)',
                                       'role' => 'Principal Investigator',
                                       'last_name' => 'Laura MacPherson, PhD'
                                     },
                 'brief_title' => 'Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment',
                 'location' => {
                               'status' => 'Recruiting',
                               'facility' => {
                                             'name' => 'Salvation Army Harbor Light Center',
                                             'address' => {
                                                          'country' => 'United States',
                                                          'zip' => '20002',
                                                          'city' => 'Washington',
                                                          'state' => 'District of Columbia'
                                                        }
                                           }
                             },
                 'acronym' => 'BA-DAS',
                 'id_info' => {
                              'nct_id' => 'NCT01372254',
                              'org_study_id' => 'RSGT1101101CPPD'
                            },
                 'overall_contact' => {
                                      'email' => 'lmacpherson@psyc.umd.edu',
                                      'last_name' => 'Laura MacPherson, PhD'
                                    },
                 'firstreceived_date' => 'June 10, 2011',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'July 2011',
                 'keyword' => [
                              'Cigarette Smoking',
                              'Drug Use',
                              'Depressed Mood'
                            ],
                 'source' => 'University of Maryland',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'University of Maryland'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'American Cancer Society, Inc.'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'December 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment',
                 'enrollment' => {
                                 'content' => '90',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Smoking',
                                                      'Depression'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The objective of the proposed project is to develop a novel, behavioral approach to smoking
      cessation that can be integrated with residential drug use treatment for low income
      substance using smokers with elevated depressive symptoms. The approach utilizes behavioral
      activation strategies which have been shown to reduce smoking among community samples and
      which can be easily targeted for the particular needs of low income substance users.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'secondary_outcome' => {
                                        'time_frame' => 'Baseline to 26 weeks post quit date',
                                        'measure' => 'Changes in Mood and Depressive Symptoms',
                                        'safety_issue' => 'No'
                                      },
                 'responsible_party' => {
                                        'name_title' => 'Dr. Laura MacPherson',
                                        'organization' => 'University of Maryland'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => "
        Inclusion Criteria:

          -  between 18 and 65 years of age

          -  regular smoker for at least one year

          -  currently smoking an average \x{2265} 10 cigarettes (also cigarellos, bidis, or  Black and
             Milds included) per day

          -  report motivation to quit smoking in the next month

          -  report elevated depressive symptoms

        Exclusion Criteria:

          -  physical concerns contraindicating the nicotine patch

          -  limited mental competency and/or the inability to give informed, voluntary, written
             consent to participate

          -  current use of pharmacotherapy for smoking cessation not provided by the researchers
             during the quit attempt

          -  use of psychotropic medication for < 3 months

          -  primary use of other tobacco products (specifically: chewing tobacco, cigars, and
             pipes)

          -  psychotic symptoms

          -  current pregnancy or plans to become pregnant within the following three months
      "
                                              },
                                  'maximum_age' => '65 Years',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'July 12, 2011',
                 'phase' => 'Phase 1/Phase 2',
                 'start_date' => 'January 2011',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01372254',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'overall_contact_backup' => {
                                             'email' => 'ehoffma5@psyc.umd.edu',
                                             'last_name' => 'Elana Hoffman, B.A.'
                                           },
                 'condition' => [
                                'Cigarette Smoking',
                                'Drug Use'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment
time_frame	26 weeks post quit date
measure	Smoking abstinence based on expired carbon monoxide tests, saliva cotinine tests, and self-report
safety_issue	No
other_name	ST
intervention_type	Behavioral
arm_group_label	Standard smoking cessation treatment (ST)
description	Participants will receive a standard, individual smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 5, 90-minute group sessions over an 4-5 week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BAD-AS condition.
intervention_name	Standard Treatment
other_name	BAD-AS
intervention_type	Behavioral
arm_group_label	Behavioral Activation for Substance Abusing Smokers (BA-DAS)
description	BAD-AS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 5, 90-minute individual sessions over a 4-5 week period.
intervention_name	BAD-AS
other_name	Nicoderm CQ
intervention_type	Drug
arm_group_label	Standard smoking cessation treatment (ST)
arm_group_label	Behavioral Activation for Substance Abusing Smokers (BA-DAS)

description	8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
intervention_name	Transdermal Nicotine Patch
Keywords:Cigarette Smoking; Drug Use; Depressed Mood
Lead sponsor: Other; University of Maryland
Collaborator: Other; American Cancer Society, Inc.
Intervention MeSH:Nicotine; Nicotine polacrilex
Condition MeSH:Smoking; Depression
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01090505

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'No',
                                     'authority' => 'China: Ethics Committee'
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'December 2012',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '5 years',
                                      'measure' => 'overall survival',
                                      'safety_issue' => 'Yes'
                                    },
                 'intervention' => {
                                   'other_name' => [
                                                   'S-1:Taiho',
                                                   "Oxaliplatin\x{ff1a}sanofi-aventis"
                                                 ],
                                   'intervention_type' => 'Drug',
                                   'arm_group_label' => [
                                                        'Drug:S-1:80mg/m2;oxaliplatin 130mg/m2',
                                                        'surgery'
                                                      ],
                                   'description' => 'Drug:S-1:80mg/m2;oxaliplatin 130mg/m2',
                                   'intervention_name' => 'Drug: S-1 and  oxaliplatin'
                                 },
                 'intervention_browse' => {
                                          'mesh_term' => 'Oxaliplatin'
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy',
                                  'arm_group_label' => 'Drug:S-1:80mg/m2;oxaliplatin 130mg/m2'
                                },
                                {
                                  'arm_group_type' => 'No Intervention',
                                  'description' => 'Procedure/Surgery: Gastrectomy with  D2 dissection',
                                  'arm_group_label' => 'surgery'
                                }
                              ],
                 'brief_title' => 'Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer',
                 'study_design' => 'Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => {
                               'status' => 'Recruiting',
                               'contact' => {
                                            'phone' => '86-10-66938328',
                                            'last_name' => 'Fu xing road 28#'
                                          },
                               'facility' => {
                                             'name' => 'China PLA General Hospital',
                                             'address' => {
                                                          'country' => 'China',
                                                          'zip' => '100853',
                                                          'city' => 'Beijing',
                                                          'state' => 'Beijing'
                                                        }
                                           }
                             },
                 'id_info' => {
                              'nct_id' => 'NCT01090505',
                              'org_study_id' => 'GC-ChinaPLAGH-2010'
                            },
                 'firstreceived_date' => 'March 16, 2010',
                 'overall_contact' => {
                                      'email' => 'litbj301@sina.com',
                                      'phone' => '86-10-66938028',
                                      'last_name' => 'L Chen, MD'
                                    },
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'November 2009',
                 'source' => 'Chinese PLA General Hospital',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Chinese PLA General Hospital'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'December 2015',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Phase 2 Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced',
                 'enrollment' => {
                                 'content' => '160',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Stomach Neoplasms'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The purpose of this study is to determine whether S-1 and oxaliplatin as neoadjuvant
      chemotherapy may improve survival benefit compared with control.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'China'
                                       },
                 'secondary_outcome' => {
                                        'time_frame' => '3 months',
                                        'measure' => 'response rate',
                                        'safety_issue' => 'Yes'
                                      },
                 'responsible_party' => {
                                        'name_title' => 'L Chen',
                                        'organization' => 'Chinese PLA General Hospital'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '20 Years',
                                  'criteria' => {
                                                'textblock' => "
        Inclusion Criteria:

          1. DISEASE CHARACTERISTICS:

             Histologically confirmed gastric adenocarcinoma Locally advanced disease:Clinical
             stage T3-4, N0-3, M0 (according to the Japanese gastric cancer classification)

          2. Planning to undergo gastric cancer D2 surgery after neoadjuvant chemotherapy

          3. Age:20 to 75

          4. Performance status:ECOG 0-2

          5. Life expectancy:Not specified

          6. Hematopoietic:WBC 4,000-12,000/mm^3\x{ff1b}Granulocyte count \x{2265} 2,000/mm^3\x{ff1b}Platelet count \x{2265}
             100,000/mm^3\x{ff1b}Hemoglobin \x{2265} 9.0 g/dL;Hepatic:AST and ALT \x{2264} 100 U/L\x{ff1b}Bilirubin \x{2264} 1.5
             mg/dL

          7. Adequate organ function

          8. Able to swallow oral medication

          9. Written informed consent

        Exclusion Criteria:

          1. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ

          2. Pregnant or breast-feeding women

          3. Severe mental disease

          4. Systemic administration of corticosteroids, flucytosine, phenytoin or warfarin

          5. Other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary
             fibrosis, or ischemic heart disease

          6. Myocardial infarction within six disease-free months
      "
                                              },
                                  'maximum_age' => '75 Years',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 2',
                 'lastchanged_date' => 'March 19, 2010',
                 'start_date' => 'November 2009',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01090505',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => 'Gastric Cancer'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Phase 2 Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced
time_frame	5 years
measure	overall survival
safety_issue	Yes
other_name	S-1:Taiho
other_name	Oxaliplatinï¼sanofi-aventis

intervention_type	Drug
arm_group_label	Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
arm_group_label	surgery

description	Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
intervention_name	Drug: S-1 and  oxaliplatin
Keyword	NOT FOUND
Lead sponsor: Other; Chinese PLA General Hospital
Intervention MeSH:Oxaliplatin
Condition MeSH:Stomach Neoplasms
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01268215

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => 'United States: Institutional Review Board'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      Bronchopulmonary Dysplasia (BPD) is still one of the most common complications of ventilated
      premature infants. Lung inflammation plays a major role in its pathogenesis. Systemic
      steroids can be given to control this inflammatory process but their widespread use is
      limited by their systemic side effects and concerns for long neurodevelopmental adverse
      sequelae. Delivering steroids by inhalation which has been proven to be effective in young
      infants with asthma has been shown to be unsatisfactory for ELBW infants with BPD. This may
      be due to the fact that current delivery devices do not meet the requirements of the
      specific anatomical and physiologic characteristics of the airways and breathing patterns in
      this special group of patients.  A novel approach to facilitate delivery directly to the
      lungs, thereby avoiding systemic concerns has been demonstrated in a recent study in which
      budesonide ( a topical steroid) was given to ventilated preterm infants using surfactant as
      a vehicle.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'June 2012',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => 'Supplemental oxygen requirement at 36 weeks\' postmenstrual age (PMA)',
                                      'measure' => 'To measure the effect of surfactant with and without Budesonide on the development of BPD in ELBW infants.',
                                      'description' => 'The main goal of the study is to determine whether endotracheal instillation of surfactant (Infasurf) with or without potent topical steroid (Budesonide) reduces the development of Bronchopulmonary Dysplasia (BPD) in Extremely Low Birth Weight (ELBW) infants at high risk of BPD.',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => 'Calfactant',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => [
                                                          'A (two study drugs group)',
                                                          'B (one study drug group)'
                                                        ],
                                     'description' => 'Endotracheal instillation of Infasurf once per week for three weeks',
                                     'intervention_name' => 'Infasurf'
                                   },
                                   {
                                     'other_name' => 'Budesonide',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'A (two study drugs group)',
                                     'description' => 'Endotracheal instillation, once per week for three weeks',
                                     'intervention_name' => 'Pulmicort'
                                   },
                                   {
                                     'other_name' => 'Air Sham',
                                     'intervention_type' => 'Other',
                                     'arm_group_label' => 'C (no study drug group)',
                                     'description' => 'None instilled through the endotracheal tube',
                                     'intervention_name' => 'Sham'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Budesonide',
                                                         'Calfactant'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '3',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'The standard management +  two study drugs (endotracheal instillation of a mixture containing budesonide and Infasurf)',
                                  'arm_group_label' => 'A (two study drugs group)'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'The standard management +  one study drug (endotracheal instillation of Infasurf only).',
                                  'arm_group_label' => 'B (one study drug group)'
                                },
                                {
                                  'arm_group_type' => 'Sham Comparator',
                                  'description' => 'The standard management only.',
                                  'arm_group_label' => 'C (no study drug group)'
                                }
                              ],
                 'overall_official' => [
                                       {
                                         'affiliation' => 'Pitt County Memorial Hospital/Brody School of Medicine at East Carolina University',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Waleed M Maamoun, MD'
                                       },
                                       {
                                         'affiliation' => 'Pitt County Memorial Hospital/Brody School of Medicine at East Carolina University',
                                         'role' => 'Study Director',
                                         'last_name' => 'James Cummings, MD'
                                       },
                                       {
                                         'affiliation' => 'Pitt County Memorial Hospital/Brody School of Medicine at East Carolina University',
                                         'role' => 'Study Chair',
                                         'last_name' => 'Scott MacGilvray, MD'
                                       },
                                       {
                                         'affiliation' => 'Pitt County Memorial Hospital/Brody School of Medicine at East Carolina University',
                                         'role' => 'Study Chair',
                                         'last_name' => 'Karl Kaminski, RRT-NPS'
                                       }
                                     ],
                 'brief_title' => 'Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention',
                 'location' => {
                               'status' => 'Recruiting',
                               'facility' => {
                                             'name' => 'NICU-Pitt County Memorial Hospital',
                                             'address' => {
                                                          'country' => 'United States',
                                                          'zip' => '27834',
                                                          'city' => 'Greenville',
                                                          'state' => 'North Carolina'
                                                        }
                                           }
                             },
                 'id_info' => {
                              'nct_id' => 'NCT01268215',
                              'org_study_id' => 'UMCIRB # 10-0250'
                            },
                 'overall_contact' => {
                                      'email' => 'maamounw@ecu.edu',
                                      'phone' => '1-252-744-3945',
                                      'last_name' => 'Waleed Maamoun, MD'
                                    },
                 'firstreceived_date' => 'December 28, 2010',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'July 2010',
                 'keyword' => [
                              'Bronchopulmonary Dysplasia',
                              'Budesonide',
                              'Infasurf'
                            ],
                 'source' => 'East Carolina University',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'East Carolina University'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'December 2013',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'The Effect of Endotracheal Instillation of Surfactant With and Without Budesonide on the Development of Bronchopulmonary Dysplasia in Ventilator-dependent, Extremely Low Birth Weight Infants: A Pilot Study',
                 'enrollment' => {
                                 'content' => '45',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Bronchopulmonary Dysplasia'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      A Pilot study to evaluate the safety and the efficacy of endotracheal instillation of
      pulmonary surfactant, with or without topical steroid (Budesonide), as a prophylactic
      treatment for Bronchopulmonary Dysplasia (a form of chronic lung disease) in extremely low
      birth weight infants. Cytokines (a group of inflammatory mediators) are measured in the
      tracheal aspirate before and after instillation of the study drugs.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'secondary_outcome' => {
                                        'time_frame' => 'The measurement of cytokines in tracheal aspirate samples will be done at the end of the study.',
                                        'measure' => 'To measure the effect of surfactant with and without Budesonide on the  inflammatory cytokines in tracheal aspirates.',
                                        'description' => 'Tracheal aspirate samples will be collected before instillation of each dose of the study drug, 7 days after the last dose if the infant is still intubated, and prior to elective extubation regardless of when extubation occurs. Tracheal aspirate samples will be obtained from the control (standard management) group in the same way and using the same time frame as the treatment groups',
                                        'safety_issue' => 'No'
                                      },
                 'responsible_party' => {
                                        'name_title' => 'Waleed Mohammed Maamoun, MD',
                                        'organization' => 'Neonatology Section, Pediatric Department, Brody School of Medicine at East Carolina University'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '24 Weeks',
                                  'criteria' => {
                                                'textblock' => "
        Inclusion Criteria:

          1. Birth weight 501-1000 g and \x{2264} 28 weeks gestational age

          2. Diagnosed as RDS requiring mechanical ventilation and surfactant therapy      during
             the first 4 hours after birth

          3. Still ventilated on day 5-9 of life.

          4. An interval of at least 24 hours' duration between the last dose of indomethacin and
             the endotracheal instillation of study drug.

        Exclusion Criteria:

          1. Congenital or chromosomal anomalies

          2. Occurrence of perinatal sepsis

          3. Use of intravenous steroids > 7 days
      "
                                              },
                                  'maximum_age' => '28 Weeks',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'December 28, 2010',
                 'phase' => 'Phase 2',
                 'start_date' => 'July 2010',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01268215',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'overall_contact_backup' => {
                                             'email' => 'CummingsJ@ecu.edu',
                                             'phone' => '1-252-744-4787',
                                             'last_name' => 'James Cummings, MD'
                                           },
                 'condition' => 'Bronchopulmonary Dysplasia'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: The Effect of Endotracheal Instillation of Surfactant With and Without Budesonide on the Development of Bronchopulmonary Dysplasia in Ventilator-dependent, Extremely Low Birth Weight Infants: A Pilot Study
time_frame	Supplemental oxygen requirement at 36 weeks' postmenstrual age (PMA)
measure	To measure the effect of surfactant with and without Budesonide on the development of BPD in ELBW infants.
description	The main goal of the study is to determine whether endotracheal instillation of surfactant (Infasurf) with or without potent topical steroid (Budesonide) reduces the development of Bronchopulmonary Dysplasia (BPD) in Extremely Low Birth Weight (ELBW) infants at high risk of BPD.
safety_issue	No
other_name	Calfactant
intervention_type	Drug
arm_group_label	A (two study drugs group)
arm_group_label	B (one study drug group)

description	Endotracheal instillation of Infasurf once per week for three weeks
intervention_name	Infasurf
other_name	Budesonide
intervention_type	Drug
arm_group_label	A (two study drugs group)
description	Endotracheal instillation, once per week for three weeks
intervention_name	Pulmicort
other_name	Air Sham
intervention_type	Other
arm_group_label	C (no study drug group)
description	None instilled through the endotracheal tube
intervention_name	Sham
Keywords:Bronchopulmonary Dysplasia; Budesonide; Infasurf
Lead sponsor: Other; East Carolina University
Intervention MeSH:Budesonide; Calfactant
Condition MeSH:Bronchopulmonary Dysplasia
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01199575

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => 'United States: Food and Drug Administration'
                                   },
                 'detailed_description' => {
                                           'textblock' => "
      The Chronic Lymphocytic Leukemia (CLL) Research Consortium (CRC) is conducting a two-arm,
      multicenter phase II trial of Revlimid\x{ae} and rituximab for Relapsed or Refractory Chronic
      Lymphocytic Leukemia (CLL) for patients under the age of 65 and patients 65 years and older.

      Revlimid\x{ae} (lenalidomide) a derivative of thalidomide with immune-modulating properties.
      Revlimid\x{ae} is FDA approved for treatment of relapsed multiple myeloma and 5q- myelodysplastic
      syndrome. Revlimid\x{ae} has promising clinical activity, in both previously treated and
      treatment naive CLL in early clinical trials. However, the mechanism(s) whereby Revlimid\x{ae} is
      active in CLL is unknown. Rituximab (Rituxan\x{ae}) is a monoclonal antibody that binds to CD20
      expressed on normal and leukemia B cells. Rituximab is approved for the treatment of CLL.

      In preclinical models of lymphoma Revlimid improved the activity of Rituximab. In clinical
      studies of relapsed and/or refractory CLL the combination Revlimid and Rituximab was
      associated with better therapeutic effects compared with what was historically observed with
      either agent alone.

      The purpose of this study is to evaluate the safety and activity of the combination of
      Revlimid\x{ae} and rituximab in relapsed or refractory CLL, elucidate the mechanism of action of
      Revlimid\x{ae} in CLL, and to assess whether prognostic factors might predict those patients
      likely to benefit from this therapy in the future.

      The primary objective of this study is to determine the overall response rate (ORR) of the
      combination of Revlimid\x{ae} and rituximab in previously treated CLL patients for those age 65
      years and above and those younger than 65.

      Secondary objectives will evaluate the safety of the combination of Revlimid\x{ae} and Rituximab,
      response duration, improvement in hematologic parameters, activity of the combination in
      high-risk CLL subsets,  the significance of the tumor flare reaction and to compare the
      activity of this regimen when administered to previously treated patients to our protocol in
      the front line setting and to compare these outcomes for both arms of the study.

      All patients will receive treatment with Revlimid\x{ae} starting at a low dose that will be
      slowly dose escalated based on individual patient tolerability.   The combination of
      Revlimid and Rituximab will be administered for a maximum of 7 cycles. Patients with
      residual leukemia following seven cycles of treatment with the combination may elect to
      continue on protocol for an additional 6 cycles of single agent Revlimid\x{ae} consolidation.

      All patients will have baseline assessment of known CLL prognostic factors through the CRC
      tissue core. These known prognostic features in CLL together with novel prognostic factors
      will be evaluated for the ability to predict response to treatment with Revlimid\x{ae} and the
      combination of Revlimid\x{ae} and Rituximab.
    "
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'December 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => 'nine months',
                                      'measure' => 'iwCLL working group response rate assessed after completion of 7 cycles of treatment.',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => [
                                                     'Chronic Lymphocytic Leukemia',
                                                     'Relapsed',
                                                     'Refractory',
                                                     'Revlimid(lenalidomide)',
                                                     'Rituximab (rituxan)'
                                                   ],
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'A: Subjects younger than 65 years old.',
                                     'description' => 'Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.',
                                     'intervention_name' => 'Revlimid, rituximab'
                                   },
                                   {
                                     'other_name' => [
                                                     'Chronic Lymphocytic Leukemia',
                                                     'Relapsed',
                                                     'Refractory',
                                                     'Revlimid(lenalidomide)',
                                                     'Rituximab (rituxan)'
                                                   ],
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'B: Subjects age 65 years and older',
                                     'description' => 'Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.',
                                     'intervention_name' => 'Relapsed or refractory CLL. Lenalidomide and Rituximab'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Rituximab',
                                                         'Thalidomide',
                                                         'Lenalidomide'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'A: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.
Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.',
                                  'arm_group_label' => 'A: Subjects younger than 65 years old.'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'B: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle and escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.
Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.',
                                  'arm_group_label' => 'B: Subjects age 65 years and older'
                                }
                              ],
                 'overall_official' => [
                                       {
                                         'affiliation' => 'Director of the CLL Research Consortium and University of California San Diego',
                                         'role' => 'Study Director',
                                         'last_name' => 'Thomas J Kipps, MD, PhD'
                                       },
                                       {
                                         'affiliation' => 'CLL Research Consortium and University of California San Diego',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Danelle F James, MD, MAS'
                                       }
                                     ],
                 'brief_title' => "Multi-center Trial of Revlimid\x{ae} and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",
                 'study_design' => 'Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Danelle F James, MD'
                                                   },
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Thomas Kipps, MD, PhD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'mcarpenter@ucsd.edu',
                                              'phone' => '858-822-5635',
                                              'last_name' => 'Mary Carpenter, CRC'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'avranceanu@ucsd.edu',
                                                     'last_name' => 'Alice K Vranceanu, Coordinator'
                                                   },
                                 'facility' => {
                                               'name' => 'University of California, San Diego',
                                               'address' => {
                                                            'country' => 'United States',
                                                            'zip' => '92093',
                                                            'city' => 'La Jolla',
                                                            'state' => 'California'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Jennifer Brown, MD'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'last_name' => 'Jennifer Brown, MD'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'kekeho@partners.org',
                                                     'phone' => '617-582-8480',
                                                     'last_name' => 'Kay Kehoe, Coordinator'
                                                   },
                                 'facility' => {
                                               'name' => 'Dana Farber/Harvard Cancer Center at Dana farber Cancer Institute',
                                               'address' => {
                                                            'country' => 'United States',
                                                            'zip' => '02115',
                                                            'city' => 'Boston',
                                                            'state' => 'Massachusetts'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Kanti Rai, MD'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'last_name' => 'Kanti Rai, MD'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'Ndriscol@lij.edu',
                                                     'phone' => '516-470-4050',
                                                     'last_name' => 'Nancy Driscoll, RPA-C'
                                                   },
                                 'facility' => {
                                               'name' => 'Long Island Jewish Medical Center',
                                               'address' => {
                                                            'country' => 'United States',
                                                            'zip' => '11042',
                                                            'city' => 'New Hyde Park',
                                                            'state' => 'New York'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Jeffrey Jones, MD'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'last_name' => 'Jeffrey Jones, MD'
                                            },
                                 'facility' => {
                                               'name' => 'Ohio state University',
                                               'address' => {
                                                            'country' => 'United States',
                                                            'zip' => '43210',
                                                            'city' => 'Columbus',
                                                            'state' => 'Ohio'
                                                          }
                                             }
                               }
                             ],
                 'id_info' => {
                              'nct_id' => 'NCT01199575',
                              'org_study_id' => 'CRC022'
                            },
                 'overall_contact' => {
                                      'email' => 'mcarpenter@ucsd.edu',
                                      'phone' => '858-822-5635',
                                      'last_name' => 'Mary Carpenter, CRC'
                                    },
                 'firstreceived_date' => 'August 31, 2010',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'September 2010',
                 'keyword' => [
                              'Chronic Lymphocytic Leukemia',
                              'CLL',
                              'Relapsed or Refractory',
                              'previously treated'
                            ],
                 'source' => 'Chronic Lymphocytic Leukemia Research Consortium',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Chronic Lymphocytic Leukemia Research Consortium'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'Industry',
                                                 'agency' => 'Celgene Corporation'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'June 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => "A Two-Arm, Multi-center Trial of Revlimid\x{ae} and Rituximab, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",
                 'enrollment' => {
                                 'content' => '80',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Leukemia',
                                                      'Leukemia, Lymphocytic, Chronic, B-Cell',
                                                      'Leukemia, Lymphoid'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => "
      The Chronic Lymphocytic Leukemia (CLL) Research Consortium (CRC) is conducting a two-arm,
      multi-center phase II trial of Revlimid\x{ae} and rituximab for Relapsed or Refractory CLL for
      patients under the age of 65 and patients 65 years and older.

      Lenalidomide (Revlimid) is an immunomodulatory agent with promising clinical activity in CLL
      and is FDA approved for treatment of relapsed multiple myeloma and 5q-myelodysplastic
      syndrome. Rituximab (Rituxan) is a monoclonal antibody to CD20 that is approved for the
      treatment of CLL.

      The primary objective of this study is to determine the overall response rate of the
      combination of Revlimid\x{ae} and rituximab in previously treated CLL patients. All patients will
      receive treatment with Revlimid\x{ae} starting at a low dose that will be dose escalated based on
      individual patient tolerability.   The combination of Revlimid and Rituximab will be
      administered for a maximum of 7 cycles. Patients with residual leukemia following seven
      cycles of treatment with the combination may elect to continue on protocol for an additional
      6 cycles of single agent Revlimid\x{ae} consolidation.
    "
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'is_section_801' => 'Yes',
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => 'one year',
                                          'measure' => 'adverse events to study treatment',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => '2 years',
                                          'measure' => 'progression free survival.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '13 cycles',
                                          'measure' => 'Conversion of MRD-positive complete response or partial response (PR) to a MRD-negative complete response (CR) or complete response (CR) respectively following an additional 6 cycles of Revlimid consolidation',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'one year',
                                          'measure' => 'changes in hematological parameters',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '9 months',
                                          'measure' => 'Overall response in relationship to molecular and genetic prognostic factors',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'two years',
                                          'measure' => 'Chronic Lymphocytic Leukemia up-regulated protein 1 (CLLU1)',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '4 years',
                                          'measure' => 'overall survival.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '2 years',
                                          'measure' => 'treatment free survival.',
                                          'safety_issue' => 'No'
                                        }
                                      ],
                 'responsible_party' => {
                                        'name_title' => 'Danelle James, MD, MAS',
                                        'organization' => 'University of California San Diego'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => "
        Inclusion Criteria:

          1. Diagnosis of chronic lymphocytic leukemia (CLL).

          2. Subjects must have active disease appropriate for therapy.

          3. Previous treatment for CLL

          4. Understand and voluntarily sign an informed consent form.

          5. Age \x{2265}18 years at the time of signing the informed consent form.

          6. Able to adhere to the study visit schedule and other protocol requirements.

          7. ECOG performance status of \x{2264} 2 at study entry (see Appendix B).

          8. Laboratory test results within these ranges: Absolute neutrophil count \x{2265} 1.0 x
             109/L,Platelet count \x{2265} 50 x 109/L, Total bilirubin \x{2264} 1.5 mg/dL, AST (SGOT) and ALT
             (SGPT) \x{2264} 2 x ULN, Creatinine clearance estimated to be \x{2265} 30 ml/min

          9. Disease free of prior malignancies for \x{2265} 2 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma in situ\" of the cervix
             or breast.

         10. Females of childbearing potential (FCBP)\x{2020} must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of starting Revlimid\x{ae} and must either commit to continued
             abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
             control, one highly effective method and one additional effective method AT THE SAME
             TIME, at least 28 days before she starts taking Revlimid\x{ae}.  FCBP must also agree to
             ongoing pregnancy testing.  Men must agree to use a latex condom during sexual
             contact with a FCBP even if they have had a successful vasectomy.  All patients must
             be counseled at a minimum of every 28 days about pregnancy precautions and risks of
             fetal exposure.  See Appendix: Risks of Fetal Exposure, Pregnancy Testing Guidelines
             and Acceptable Birth Control Methods, AND also Appendix: Education and Counseling
             Guidance Document.

        Exclusion Criteria:

          1. Known Hepatitis B Ag positive, Hepatitis C positive patients.

          2. Known HIV positive patients.

          3. Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) or autoimmune
             thrombocytopenia (ITP).

          4. Inability to provide informed consent.

          5. Concurrent malignancy (excluding basal and squamous cell skin cancers).

          6. Active fungal, bacterial, and/or viral infection.

          7. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          8. Pregnant or breast-feeding females. (Lactating females must agree not to breast feed
             while taking Revlimid\x{ae}).

          9. Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

         10. Use of any other experimental drug or therapy within 28 days of baseline.

         11. Known hypersensitivity to thalidomide.

         12. The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

         13. Concurrent use of other anti-cancer agents or treatments.

         14. Patients with history of deep venous thrombus or pulmonary embolism. Patients who are
             at increased risk of thrombosis during treatment with Revlimid\x{ae} including those
             taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids are also
             excluded.

         15. Patients with a history of embolic events (e.g. TIA) from arrhythmia or peripheral
             arterial disease or of recent mycocardial infarction whether or not treated with
             anti-platelet drugs.
      "
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 2',
                 'lastchanged_date' => 'September 9, 2010',
                 'start_date' => 'August 2010',
                 'link' => [
                           {
                             'url' => 'http://cllresearch.com/',
                             'description' => 'Website for the CLL Research Consortium'
                           },
                           {
                             'url' => 'http://cancer.ucsd.edu/',
                             'description' => 'Moore\'s UCSD Cancer Center'
                           }
                         ],
                 'is_fda_regulated' => 'Yes',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01199575',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'results_reference' => [
                                        {
                                          'PMID' => '17088571',
                                          'citation' => 'Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6.'
                                        },
                                        {
                                          'PMID' => '16750498',
                                          'citation' => 'Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006 Jun;7(6):480-8. Review.'
                                        },
                                        {
                                          'PMID' => '18334676',
                                          'citation' => 'Ferrajoli A, Lee BN, Schlette EJ, O\'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl SH, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Mar 11; [Epub ahead of print]'
                                        }
                                      ],
                 'overall_contact_backup' => {
                                             'email' => 'dfjames@ucsd.edu',
                                             'phone' => '858-822-7894',
                                             'last_name' => 'Danelle F James, MD'
                                           },
                 'condition' => [
                                'Chronic Lymphocytic Leukemia',
                                'CLL'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
time_frame	nine months
measure	iwCLL working group response rate assessed after completion of 7 cycles of treatment.
safety_issue	No
other_name	Chronic Lymphocytic Leukemia
other_name	Relapsed
other_name	Refractory
other_name	Revlimid(lenalidomide)
other_name	Rituximab (rituxan)

intervention_type	Drug
arm_group_label	A: Subjects younger than 65 years old.
description	Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
intervention_name	Revlimid, rituximab
other_name	Chronic Lymphocytic Leukemia
other_name	Relapsed
other_name	Refractory
other_name	Revlimid(lenalidomide)
other_name	Rituximab (rituxan)

intervention_type	Drug
arm_group_label	B: Subjects age 65 years and older
description	Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
intervention_name	Relapsed or refractory CLL. Lenalidomide and Rituximab
Keywords:Chronic Lymphocytic Leukemia; CLL; Relapsed or Refractory; previously treated
Lead sponsor: Other; Chronic Lymphocytic Leukemia Research Consortium
Collaborator: Industry; Celgene Corporation
Intervention MeSH:Rituximab; Thalidomide; Lenalidomide
Condition MeSH:Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01246557

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => [
                                                    "Spain: Agencia Espa\x{f1}ola de Medicamentos y Productos Sanitarios",
                                                    'Spain: Ethics Committee'
                                                  ]
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'March 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => 'At the finalization of the second cycle of the treatment of the last patient (average 5 months of last patient inclusion date)',
                                      'measure' => 'To assess the safety of the association of lenalidomide and dexamethasone in patients with relapsed or refractory CLL',
                                      'description' => 'The first step will be an interim analysis of toxicity to determine the safety of the first lenalidomide cohort dosage (2.5 mg/day). This analysis will be performed after six subjects complete 3 months of treatment.  A second analysis of toxicity will be performed after the second lenalidomide dosage cohort (six patients with 5mg/day) complete 3 months of treatment.',
                                      'safety_issue' => 'Yes'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => "REVLIMID\x{ae}",
                                     'intervention_type' => 'Drug',
                                     'description' => "Lenalidomide - Revlimid\x{ae}: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 \x{301}-aminoisoindoline-1 \x{301}ona)-1- piperidine-2,6-dione.
REVLIMID\x{ae} (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.",
                                     'intervention_name' => 'Lenalidomide'
                                   },
                                   {
                                     'other_name' => 'Commercial drug according to standard clinical practices of the center.',
                                     'intervention_type' => 'Drug',
                                     'description' => 'Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.',
                                     'intervention_name' => 'Dexamethasone'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Dexamethasone acetate',
                                                         'Dexamethasone',
                                                         'Dexamethasone 21-phosphate',
                                                         'Lenalidomide',
                                                         'Thalidomide',
                                                         'BB 1101'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '1',
                 'brief_title' => 'Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment',
                 'study_design' => 'Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'status' => 'Active, not recruiting',
                                 'facility' => {
                                               'name' => 'Hospital de la Santa Creu i Sant Pau',
                                               'address' => {
                                                            'country' => 'Spain',
                                                            'zip' => '08025',
                                                            'city' => 'Barcelona'
                                                          }
                                             }
                               },
                               {
                                 'status' => 'Active, not recruiting',
                                 'facility' => {
                                               'name' => 'Hospital Clinico Universitario de Barcelona',
                                               'address' => {
                                                            'country' => 'Spain',
                                                            'zip' => '08036',
                                                            'city' => 'Barcelona'
                                                          }
                                             }
                               },
                               {
                                 'status' => 'Active, not recruiting',
                                 'facility' => {
                                               'name' => "Centro M\x{e9}dico Teknon",
                                               'address' => {
                                                            'country' => 'Spain',
                                                            'zip' => '08022',
                                                            'city' => 'Barcelona'
                                                          }
                                             }
                               },
                               {
                                 'status' => 'Active, not recruiting',
                                 'facility' => {
                                               'name' => 'Hospital Universitari Valle Hebron',
                                               'address' => {
                                                            'country' => 'Spain',
                                                            'zip' => '08035',
                                                            'city' => 'Barcelona'
                                                          }
                                             }
                               },
                               {
                                 'status' => 'Active, not recruiting',
                                 'facility' => {
                                               'name' => 'Hospital Joan XXIII',
                                               'address' => {
                                                            'country' => 'Spain',
                                                            'zip' => '43007',
                                                            'city' => 'Tarragona'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => "M\x{aa} Jos\x{e9} Terol, MD"
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'terol39@mail.ono.es',
                                              'phone' => '627 91 01 98',
                                              'last_name' => "M\x{aa} Jos\x{e9} Terol, MD"
                                            },
                                 'facility' => {
                                               'name' => "Hospital Cl\x{ed}nico Universitario de Valencia",
                                               'address' => {
                                                            'country' => 'Spain',
                                                            'zip' => '46010',
                                                            'city' => 'Valencia'
                                                          }
                                             }
                               }
                             ],
                 'acronym' => 'LENDEX-LLC-09',
                 'id_info' => {
                              'secondary_id' => '2009-012571-95',
                              'nct_id' => 'NCT01246557',
                              'org_study_id' => 'LENDEX-LLC-09'
                            },
                 'firstreceived_date' => 'September 30, 2010',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'February 2011',
                 'source' => 'Hospital Universitari Vall d\'Hebron Research Institute',
                 'keyword' => 'Patients with Chronic Lymphatic Leukemia relapsing or resistant to treatment',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Hospital Universitari Vall d\'Hebron Research Institute'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'March 2015',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Open Label Multi-center Pilot Phase I/II Non-controlled Clinical Trial to Assess Safety and Efficieecy of the Lenalidomide and Dexamethasone Association in Patients With Chronic Relapse or Treatment Resistant Lymphatic Leukemia Following Treatment Containing Fludarabine.',
                 'enrollment' => {
                                 'content' => '20',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Leukemia',
                                                      'Leukemia, Lymphocytic, Chronic, B-Cell',
                                                      'Leukemia, Lymphoid'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      Despite certain notable progress, treatment of patients with Chronic Lymphatic Leukemia
      (CLL) is still disappointing. Although thanks to the use of treatment of (immune)
      chemotherapy, mainly based on fludarabine, rituximab and alemtuzumab, the rate of complete
      response (CR) has increased from minus 10% observed when clorambucil was the core of the
      therapy to a 60-70%, with time all patients relapse and most of them die at the end due to
      the disease or to involvements related to the treatment. Progress when understanding the CLL
      biology have cleared a series of aspects: 1) there is a significant proportion of CLL cells
      actively copying themselves, contrary to the opinion that most of CLL cells are in G0 phase
      of the cell cycle; 2) Immune regulatory mechanism basically measured by T cells and NK cells
      have an important role in the continuous accumulation of CLL cells in the body; 3) Cells of
      the stroma are essential to maintain survival of CLL cells through a series of cytokines or
      chemokines. Under the light of this evidence, it is worth studying new treatment modes
      directed not only to CLL cells but also to the microenvironment and immune functions.

      Lenalidomide is being investigated as treatment for several oncologic indications including
      myelodysplastic syndromes, multiple myeloma and non-Hodgkin lymphoma. Within the scope of
      CLL, it has been proved that lenalidomide is active in patients with relapsing / treatment
      resistant CLL patients. Forty five patients with relapsing CLL, 51% resistant to
      fludarabine, where included in a phase II study and were treated orally with 25 mg of
      lenalidomide on days 1 to 21 of a cycle of 28 days. The total response rate was of 47% with
      up to a 9% of complete responses.

      The combination of lenalidomide with dexamethasone is being investigated in multiple myeloma
      and has revealed as a highly efficient treatment in relapsing/ treatment resistant patients
      as well as in those newly diagnosed. Bearing in mind that both drugs, lenalidomide and
      dexamethasone, are clinically active in CLL the investigators have designed a study with
      this combination in relapsing or treatment resistant patients following treatments
      containing fludarabine which do not meet the requirements for an intensive rescue treatment.

      Given initial doses of 10 and 25 mg of lenalidomide daily may be associated with tumor lysis
      cases, it is proposed a low initial dose of lenalidomide in the first cycle 2.5mg., with
      further increases to prevent the occurrence of tumor lysis syndrome
    '
                                  },
                 'location_countries' => {
                                         'country' => 'Spain'
                                       },
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => 'Average of 20 months from the last patient inclusion.',
                                          'measure' => 'To assess the efficacy of lenalidomide and dexamethasone in patients with Chronic Lymphocytic Leukemia (CLL) relapsing of resistant to treatment.',
                                          'description' => 'Efficacy endpoint: Duration of response.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Average of 9 months from the last patient inclusion.',
                                          'measure' => 'To assess the efficacy  of lenalidomide and dexamethasone in patients with Chronic Lymphocytic Leukemia (CLL) relapsing of resistant to treatment.',
                                          'description' => 'Efficacy endpoint: Time to response.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Average of 20 months from the last patient inclusion.',
                                          'measure' => 'To assess the efficacy  of lenalidomide and dexamethasone in patients with Chronic Lymphocytic Leukemia (CLL) relapsing of resistant to treatment.',
                                          'description' => 'Efficacy endpoint: Progresion-free survival.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Average of 20 months from the last patient inclusion.',
                                          'measure' => 'To assess the efficacy of lenalidomide and dexamethasone in patients with Chronic Lymphocytic Leukemia (CLL) relapsing of resistant to treatment.',
                                          'description' => 'Efficacy endpoint: Treatment response.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Average of 20 months from the last patient inclusion.',
                                          'measure' => 'To assess the efficacy  of lenalidomide and dexamethasone in patients with Chronic Lymphocytic Leukemia (CLL) relapsing of resistant to treatment.',
                                          'description' => 'Efficacy endpoint: Overall survival.',
                                          'safety_issue' => 'No'
                                        }
                                      ],
                 'responsible_party' => {
                                        'name_title' => 'Hospital Universitari Vall d\'Hebron Research Institute.',
                                        'organization' => 'Investigator'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => "
        Inclusion Criteria:

        The patients will have to meet the following inclusion criteria in order to be included in
        the study:

          1. To understand and voluntarily sign an informed consent form.

          2. To be \x{2265} 18 years old upon the signature of the informed consent form.

          3. To be able to fulfill the visits program of the study and other protocol
             requirements.

          4. To have a CLL documented diagnose (NCI/WG criteria) relapsing or resistant to at
             least one prior treatment and not to meet the requirements for an intensive rescue
             therapy. Prior treatment(s) will have to include fludarabine.

          5. All prior anti-cancer therapies, including radiation, hormonal therapy and surgery,
             will have to be interrupted at leas 4 weeks before the treatment in this study.

          6. Functional state 0-2 (ECOG).

          7. Women with childbearing potential (FCBP) will have to:

             understand the teratogenic risk of the study drug. accept the simultaneous use of two
             reliable contraception methods or to practice the abstinence of heterosexual
             relations during the following periods of time related to this study: 1) during at
             least 4 weeks before starting the drug of the study; 2) while participating in the
             study; y 3) during at least 4 weeks following the interruption of the study. The two
             reliable contraceptive methods will have to include one highly effective (this is,
             intrauterine device (IUD), hormonal (pills injections or implants), tubal ligation,
             vasectomy of the partner) and an barrier effective additional method (this is, latex
             preservative, diaphragm, cervical cap). Women with a childbearing potential will have
             to visit a specialist in contraceptive methods if necessary.

             Before starting the drug under study: \x{2022} Women with childbearing potential will have
             to undergo two negative pregnancy tests (sensibility of at least 25 mUI/ml) before
             starting the drug under study. The first test will take place at the visit date or
             within a period of 3 days before starting the drug under study and the second.The
             patient will not receive the drug until the investigator has verified that the
             results of the tests are negative.

             Men:

               -  They will have to accept the use of latex preservatives during sexual relations
                  with women   with childbearing potential while they participate in the study and
                  during at least one week following the interruption of the study, if it is women
                  with childbearing potential (FCBP) and no use contraception.

               -  They will have to accept to refrain from donating blood or semen during their
                  participation in the study and during at least 28 days following the
                  interruption of the study.

          8. In the event of pregnancy or positive pregnancy test in a participant in the study,
             or the partner of a male participant in the study, during his participation, the drug
             under study will be immediately interrupted.

          9. Capable of receiving Acetyl Salicylic Acid (100 or 300 mg) on a daily basis as
             prophylactic anticoagulation. (Patients who do not tolerate ASA may use acenocumarol
             or low molecular weight heparin).

        Exclusion Criteria:

        Patients will not have to fulfill any of the following exclusion criteria to be included
        in the study.

          1. Any serious medical disorder, laboratory abnormality or psychiatric disease hindering
             the signature of the informed consent by the patient.

          2. Pregnant women or in lactation period.

          3. Any disorder, including the presence of laboratory abnormalities, which puts the
             patient at unacceptable risk if he/she participates in the study or hindered the
             capacity to understand the information of the study.

          4. Use of any other experimental drug or therapy in the period of 28 days from the base
             visit.

          5. Known hyper-sensibility to thalidomide.

          6. Development of erythema nodosum if it is characterized by a descamative eruption
             while taken thalidomide or similar drugs.

          7. Any prior use of lenalidomide.

          8. A concurrent use of other agents or anticancer treatments.

          9. HIV-positive or infectious hepatitis type A, B or C.

         10. Candidates eligible for intensive rescue therapies (ex. R-CHOP plus alemtuzumab,
             allogenic transplant)

         11. Richter transformation (active) or CNS participation (active)

         12. Any of the following laboratory abnormalities:

             Neutrophil absolute count < 0.5 x 109/L Platelet count < 25 x 109/L Calculated
             Creatinine Clearance <50 mL/min Total serum bilirubin > higher normal limit (HNL) AST
             and ALT >3 x higher normal limit (HNL) Autoimmune non controlled hemolytic anemia or
             thrombocytopenia.

         13. History of another neoplastic disease during \x{2265} 5 years unless base cells or
             epidermoid carcinoma in situ of cervix or breast recently treated.
      "
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 1/Phase 2',
                 'lastchanged_date' => 'February 11, 2011',
                 'start_date' => 'December 2009',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01246557',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => 'Chronic Lymphocytic Leukemia'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Open Label Multi-center Pilot Phase I/II Non-controlled Clinical Trial to Assess Safety and Efficieecy of the Lenalidomide and Dexamethasone Association in Patients With Chronic Relapse or Treatment Resistant Lymphatic Leukemia Following Treatment Containing Fludarabine.
time_frame	At the finalization of the second cycle of the treatment of the last patient (average 5 months of last patient inclusion date)
measure	To assess the safety of the association of lenalidomide and dexamethasone in patients with relapsed or refractory CLL
description	The first step will be an interim analysis of toxicity to determine the safety of the first lenalidomide cohort dosage (2.5 mg/day). This analysis will be performed after six subjects complete 3 months of treatment.  A second analysis of toxicity will be performed after the second lenalidomide dosage cohort (six patients with 5mg/day) complete 3 months of treatment.
safety_issue	Yes
other_name	REVLIMID®
intervention_type	Drug
description	Lenalidomide - RevlimidÂ®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 Ì-aminoisoindoline-1 Ìona)-1- piperidine-2,6-dione.
REVLIMIDÂ® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
intervention_name	Lenalidomide
other_name	Commercial drug according to standard clinical practices of the center.
intervention_type	Drug
description	Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
intervention_name	Dexamethasone
Keyword:Patients with Chronic Lymphatic Leukemia relapsing or resistant to treatment
Lead sponsor: Other; Hospital Universitari Vall d'Hebron Research Institute
Intervention MeSH:Dexamethasone acetate; Dexamethasone; Dexamethasone 21-phosphate; Lenalidomide; Thalidomide; BB 1101
Condition MeSH:Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01278004

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => 'United Kingdom: Medicines and Healthcare Products Regulatory Agency'
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'December 2012',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '6 weeks',
                                      'measure' => 'Reduction in pain intensity from baseline to endpoint as assessed on a Numerical Pain Rating scale.',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Drug',
                                     'description' => 'Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.',
                                     'intervention_name' => 'Ethosuximide'
                                   },
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Placebo',
                                     'description' => 'Capsule',
                                     'intervention_name' => 'Placebo'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => 'Ethosuximide'
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Placebo Comparator',
                                  'description' => 'Placebo capsule',
                                  'arm_group_label' => 'Placebo'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'arm_group_label' => 'Drug'
                                }
                              ],
                 'brief_title' => 'Chemotherapy Induced Painful Peripheral Neuropathy Ethosuximide (The CIN-E Study)',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care',
                 'location' => [
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Julia Riley'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'phone_ext' => '1025',
                                              'phone' => '0208661',
                                              'last_name' => 'Melanie Waghorn, Research Nurse'
                                            },
                                 'facility' => {
                                               'name' => 'Royal Marsden NHS Foundation Trust',
                                               'address' => {
                                                            'country' => 'United Kingdom',
                                                            'zip' => 'SM2 5PT',
                                                            'city' => 'Sutton',
                                                            'state' => 'Surrey'
                                                          }
                                             }
                               },
                               {
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'christina.oyebode@rmh.nhs.uk',
                                              'last_name' => 'Christina Oyebode'
                                            },
                                 'facility' => {
                                               'name' => 'The Royal Marsden NHS Foundation Trust',
                                               'address' => {
                                                            'country' => 'United Kingdom',
                                                            'zip' => 'SW3 6JJ',
                                                            'city' => 'London'
                                                          }
                                             }
                               }
                             ],
                 'acronym' => 'CINE-E',
                 'id_info' => {
                              'nct_id' => 'NCT01278004',
                              'org_study_id' => 'CCR3116'
                            },
                 'firstreceived_date' => 'January 13, 2011',
                 'overall_contact' => {
                                      'phone' => '0207 80802761',
                                      'last_name' => 'Julia Riley'
                                    },
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'December 2011',
                 'source' => 'Royal Marsden NHS Foundation Trust',
                 'keyword' => 'Adult cancer patients with chemotherapy-induced painful peripheral neuropathy',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Royal Marsden NHS Foundation Trust'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Imperial College London'
                                               }
                             },
                 'official_title' => 'A Randomised Double-blind Placebo-controlled Trial of the Safety and Efficacy of Ethosuximide 250mg Capsules for the Management of Chemotherapy Induced Painful Peripheral Neuropathy',
                 'enrollment' => {
                                 'content' => '44',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Peripheral Nervous System Diseases',
                                                      'Demyelinating Diseases',
                                                      'Polyneuropathies',
                                                      'Nerve Compression Syndromes',
                                                      'Neurologic Manifestations',
                                                      'Neurotoxicity Syndromes'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      This study is a drug trial of ethosuximide as a painkiller if you develop pain as a side
      effect of chemotherapy. Ethosuximide will be compared against placebo (an inactive
      substance) to test whether any response is a true effect of the drug, and not a \'placebo
      effect\'.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United Kingdom'
                                       },
                 'responsible_party' => {
                                        'responsible_party_type' => 'Sponsor'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  Age >/= 18

          -  Diagnosis of cancer

          -  Willing and able to give informed consent to the CIN-E study and complete study
             questionnaires, this involves adequate understanding of written and spoken English
             (translators will not be used)

          -  Chemotherapy-induced painful peripheral neuropathy as diagnosed by score of >12 on
             the Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) with a pain
             intensity rating of >4, on a 11 point numeric rating scale (0= no pain, 10= worst
             possible pain).

          -  Duration of chemotherapy-induced painful peripheral neuropathy >4 weeks. Participant
             may either have completed chemotherapy, or be receiving ongoing chemotherapy.

          -  Able to attend research centre according to the required visit schedule.

          -  Diet allows bovine gelatine (present in both ethosuximide and placebo capsules)

          -  Women of child-bearing potential must be using a reliable form of contraception i.e.
             oral contraceptives, a barrier method (condom or diaphragm), intra-uterine device or
             abstinence.

        Exclusion Criteria:

          -  Renal impairment (serum creatinine >1.5x normal level)

          -  Deranged liver function (AST>3x normal level)

          -  Patients currently taking any anti-depressant medication, for example fluoxetine,
             paroxetine, citalopram, venlafaxine, amitriptyline, or within the past week.

          -  Patients currently taking any other anti-epileptic drug, including gabapentin, or
             within the past week.

          -  Pregnancy

          -  Allergy to succinimides, ethosuximide, methsuximide, phensuximide. Pre-exisitng
             painful peripheral neuropathy of any other cause.
      '
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 2',
                 'lastchanged_date' => 'December 7, 2011',
                 'start_date' => 'May 2010',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01278004',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => [
                                'Cancer',
                                'Peripheral Neuropathy'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: A Randomised Double-blind Placebo-controlled Trial of the Safety and Efficacy of Ethosuximide 250mg Capsules for the Management of Chemotherapy Induced Painful Peripheral Neuropathy
time_frame	6 weeks
measure	Reduction in pain intensity from baseline to endpoint as assessed on a Numerical Pain Rating scale.
safety_issue	No
intervention_type	Drug
arm_group_label	Drug
description	Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
intervention_name	Ethosuximide
intervention_type	Drug
arm_group_label	Placebo
description	Capsule
intervention_name	Placebo
Keyword:Adult cancer patients with chemotherapy-induced painful peripheral neuropathy
Lead sponsor: Other; Royal Marsden NHS Foundation Trust
Collaborator: Other; Imperial College London
Intervention MeSH:Ethosuximide
Condition MeSH:Peripheral Nervous System Diseases; Demyelinating Diseases; Polyneuropathies; Nerve Compression Syndromes; Neurologic Manifestations; Neurotoxicity Syndromes
### END TRIAL DATA ###

CLINICAL TRIAL: NCT00852228

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => [
                                                    "France: Afssaps - Agence fran\x{e7}aise de s\x{e9}curit\x{e9} sanitaire des produits de sant\x{e9} (Saint-Denis)",
                                                    'France: National Consultative Ethics Committee for Health and Life Sciences',
                                                    'Italy: The Italian Medicines Agency'
                                                  ]
                                   },
                 'detailed_description' => {
                                           'textblock' => "
      Primary end-point: incidence of complete macroscopic resections of liver metastases (R0+R1).

      Secondary end-points:

        -  the rate of histologic complete responses,

        -  the individual rates of R0 and R1 resections,

        -  the rate and site(s) of relapse in the resected patients throughout the 3-year span
           that follows hepatectomy,,

        -  the relapse-free survival curve and median in the resected patients,

        -  the progression-free and the overall survival in the patients receiving at least 4 full
           courses of HAI therapy and in all the patients (intent to treat),

        -  the objective response rate,

        -  the rate of adverse events,

        -  the dose intensities over 3, 6 and 9 courses,

        -  the per-operative and post-operative complications associated to liver surgery.

      The study also includes a pharmacokinetic analysis, a translational research and a
      rest/activity monitoring investigation.

      Open, label, European, non randomized, multicenter, phase II study of intravenous cetuximab
      (ERBITUX\x{ae}) and hepatic artery infusion of three-drug chemotherapy (irinotecan,
      5-fluorouracil and oxaliplatin) using conventional or chronomodulated delivery (according to
      institution experience) in patients with liver metastases from colorectal cancer.

      Patients undergo partial hepatectomy after 6 \x{b1} 3 courses of therapy whenever possible. The
      minimum of 3 and the maximum of 9 courses before liver surgery depend upon results from
      iterative onco-surgical evaluations. A minimum of 6 and up to 9 additional courses of
      therapy will be administered after surgery, depending upon results of liver surgery,
      pathology report and patient's status. Overall, the patients will receive 9 to 18 courses of
      protocol therapy.

      The interval between the last course of cetuximab-HAI chemotherapy and surgery will be 2 to
      4 weeks. Post operative treatment will be initiated 2 to 4 weeks after liver surgery.

      TRANSLATIONAL RESEARCH:

        1. Pharmacokinetics:

           For a subset of 16 patients (8 on conventional administration and 8 on
           chronotherapeutic delivery), plasma pharmacokinetics of irinotecan, 5-FU and
           oxaliplatin and main metabolites will be evaluated after the first course.

        2. Rest-Activity monitoring:

           Rest-activity will be monitored with a wrist-worn actigraph (Ambulatory Monitoring,
           USA) for 1 week prior to treatment onset and during the 2 weeks following treatment
           onset (3 weeks). This evaluation will be repeated before, during and after the 4th
           treatment course and before during and after 7th treatment course. Participation of the
           centers to this investigation will be left optional.

           Time series will be analyzed before, during and after chemotherapy course, with the
           time courses of the following parameters:

             -  Autocorrelation coefficient at 24 h (r24)

             -  Dichotomy index I<O

             -  Wavelet-based model function at baseline, and deviation from this model function
                during and after treatment course delivery.

        3. Predictive molecular factors:

      In primary tumor and/or in metastases obtained any time prior to inclusion and in resected
      metastases and non tumoral liver:

        -  EGFR immunohistochemistry and gene expression or amplification and polymorphism.

        -  K-ras mutations.

        -  Clock genes polymorphism or mRNA or protein expression.

        -  Gene polymorphisms or expression for main pharmacology determinants of irinotecan, 5-
           FU and oxaliplatin efficacy.

        -  Inflammatory and immune cell subsets infiltration. Whenever possible, a biopsy of a
           liver metastasis will also be obtained before treatment onset for documenting these
           translational endpoints.

      In serum, upon inclusion and after 3 courses:

      \x{b7} Determination of serum levels of TGFa, EGF, VEGF, IL-6, IL-8, amphiregulin and epiregulin.

      In blood cells upon inclusion:

      \x{b7} Constitutive polymorphisms for ADCC (FCII and FCIII), circadian clock and EGFR.

      STATISTICAL METHODS AND SAMPLE SIZE:

      The main endpoint will be the incidence of macroscopically complete resections of liver
      metastases (R0+R1). The confidence intervals (CI) for the response rate will be based on the
      exact binomial distribution.

      For the secondary endpoints, rate of histologic complete responses, rate of R0 resections,
      rate of R1 resections, rate of relapses, rate of objective responses, the results will be
      estimated with CI based on the exact binomial distribution. Overall survival time (OS) and
      progression free survival (PFS) will be analyzed by Kaplan Meier curve. Multivariate
      analysis will be performed using the Cox proportional hazard model. This analysis will
      include the following factors: center, performance status, gender, liver disease
      characteristics, leucocyte count and alkaline phosphatases upon inclusion and treatment
      delivery schedule, Relapse incidence (RI) is defined as the probability of having had a
      relapse before time t. Death without experiencing a relapse is a competing event. The method
      of analysis will be therefore the estimation of Cumulative Incidence curve in a competing
      risk setting. Multivariate analysis will be performed by the Fine & Gray model. All patients
      achieving complete remission will be analyzed.

      The goal is to increase the rate of complete resections (R0+R1) by 15%, i.e. from 15%
      (p0=0.15) to 30% (p1=0.30). According to the exact single-stage phase II design method, the
      trial for accepting that p1 is to be preferred to p0 (with a=5% and b=20%) requires 48
      patients assessable for response. To obtain 48 patients assessable for response, 60 patients
      will be included in the trial.

      A major additional effect expected further from this combined treatment modality is the
      increase of complete histologic responses, a secondary endpoint in this trial, from 5% (with
      systemic chemotherapy) to 20% with combined cetuximab and 3-drug HAI. This improvement
      should further reduce the risk of relapse in the liver or outside the liver by 15 %, i.e.
      from 80% to 65%.

      Therefore, the total number of patients will be 60 patients, including 48 assessable and 12
      estimated as unassessable for technical reasons (i.e. HAI catheter dysfunction within the
      first 2 months).
    "
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'June 2011',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => 'evaluation every 6th week up to 18 weeks',
                                      'measure' => 'Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy.',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => 'Erbitux',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => [
                                                          'chronomodulated HAI chemotherapy',
                                                          'conventional HAI chemotherapy'
                                                        ],
                                     'description' => "Cetuximab is administered every two weeks at the dose of 500 mg/m\x{b2} over 2h30 (150 minutes).",
                                     'intervention_name' => 'IV cetuximab'
                                   },
                                   {
                                     'other_name' => [
                                                     'Campto',
                                                     'Eloxatin'
                                                   ],
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'chronomodulated HAI chemotherapy',
                                     'description' => "Irinotecan (180 mg/m\x{b2}) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00
Oxaliplatin (85 mg/m\x{b2}) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.
5-Fluorouracil (2800 mg/m\x{b2}) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.
Treatments will be repeated every 2 weeks.",
                                     'intervention_name' => 'HAI chronomodulated chemotherapy'
                                   },
                                   {
                                     'other_name' => [
                                                     'Campto',
                                                     'Eloxatin'
                                                   ],
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'conventional HAI chemotherapy',
                                     'description' => "Irinotecan (180 mg/m\x{b2}) on day 1 as a one hour infusion, then
Oxaliplatin (85 mg/m\x{b2}) on day 1 as a two hour infusion, then
5-Fluorouracil (2800 mg/m\x{b2}) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.
Treatments will be repeated every 2 weeks.",
                                     'intervention_name' => 'HAI conventional chemotherapy'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Fluorouracil',
                                                         'Oxaliplatin',
                                                         'Cetuximab'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'arm_group_label' => 'chronomodulated HAI chemotherapy'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'arm_group_label' => 'conventional HAI chemotherapy'
                                }
                              ],
                 'overall_official' => {
                                       'affiliation' => 'Paul Brousse Hospital, Villejuif, France',
                                       'role' => 'Principal Investigator',
                                       'last_name' => "Francis A. L\x{e9}vi, M.D., Ph.D."
                                     },
                 'brief_title' => 'Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy',
                 'study_design' => 'Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Christian Focan, M.D., Ph.D.'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Gauthier Demolin, M.D.'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => "Fran\x{e7}oise Kreutz, M.D."
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Luc Longree, M.D.'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Geoffrey Matus, M.D.'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'CHRISTIAN.FOCAN@CHC.be',
                                              'phone' => '+3242248989',
                                              'last_name' => 'Christian Focan, M.D., Ph.D.'
                                            },
                                 'contact_backup' => {
                                                     'phone' => '+3242248990',
                                                     'last_name' => 'Gauthier Demolin, M.D.'
                                                   },
                                 'facility' => {
                                               'name' => 'Clinique Saint-Joseph',
                                               'address' => {
                                                            'country' => 'Belgium',
                                                            'zip' => '4000',
                                                            'city' => "Li\x{e8}ge"
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Denis Smith, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'denis.smith@chu-bordeaux.fr',
                                              'phone' => '+33 5 56 79 58 08',
                                              'last_name' => 'Denis Smith, MD'
                                            },
                                 'facility' => {
                                               'name' => "CHU de Bordeaux, H\x{f4}pital Saint-Andr\x{e9}",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '33000',
                                                            'city' => 'Bordeaux'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Philippe Rougier, M.D., Ph.D.'
                                                   },
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Bernard Nordlinger, M.D., Ph.D.'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => "C\x{e8}line Rep\x{e8}re, MD"
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Robert Malafosse, MD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Emmanuel Mitry, MD, PhD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'philippe.rougier@apr.aphp.fr',
                                              'phone' => '+33149095325',
                                              'last_name' => 'Philippe Rougier, M.D., Ph.D.'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'bernard.nordlinger@apr.aphp.fr',
                                                     'phone' => '+33149095586',
                                                     'last_name' => 'Bernard Nordlinger, M.D., Ph.D.'
                                                   },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Ambroise Par\x{e9}",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '92100',
                                                            'city' => 'Boulogne-Billancourt'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Philippe Chollet, M.D.'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'Philippe.CHOLLET@cjp.fr',
                                              'phone' => '+33473278005',
                                              'last_name' => 'Philippe Chollet, M.D.'
                                            },
                                 'facility' => {
                                               'name' => 'Centre Jean Perrin',
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '63011',
                                                            'city' => 'Clermont-Ferrand'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Mohamed Hebbar, MD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Olivier Romano, MD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => "Fran\x{e7}ois R. Pruvot, MD"
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Peggy Fournier, MD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'm-hebbar@chru-lille.fr',
                                              'phone' => '+33 3 20 44 54 61',
                                              'last_name' => 'Mohamed Hebbar, MD'
                                            },
                                 'facility' => {
                                               'name' => "CHRU de Lille, H\x{f4}pital Claude Huriez",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '59037',
                                                            'city' => 'Lille'
                                                          }
                                             }
                               },
                               {
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'phone' => '+ 33 0156093154',
                                              'last_name' => 'Philippe Rougier, MD, PhD'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Europ\x{e9}en Georges Pompidou",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '75015',
                                                            'city' => 'Paris'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Catherine Brezault, M.D.'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'catherine.brezault@cch.aphp.fr',
                                              'phone' => '+3310158411946',
                                              'last_name' => 'Catherine Brezault, M.D.'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Cochin",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '75014',
                                                            'city' => 'Paris'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Marion Deslandres, MD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Corinne Couteau, MD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'guimbaud.r@chu-toulouse.fr',
                                              'phone' => '+33 05 61 77 96 49',
                                              'last_name' => 'Rosine Guimbauld, MD'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'sirac.e@chu-toulouse.fr',
                                                     'last_name' => 'Estelle Sirach, MD'
                                                   },
                                 'facility' => {
                                               'name' => 'CHU Toulouse',
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '31059',
                                                            'city' => 'Toulouse'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => "Francis A. L\x{e9}vi, M.D., Ph.D."
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Pasquale F. Innominato, M.D.'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Mohamed Bouchahda, M.D.'
                                                   },
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => "Ren\x{e9} Adam, M.D., Ph.D."
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'francis.levi@inserm.fr',
                                              'phone' => '+33 01 45 59 38 55',
                                              'last_name' => "Francis A. L\x{e9}vi, M.D., Ph.D."
                                            },
                                 'contact_backup' => {
                                                     'email' => 'pasquale.innominato@inserm.fr',
                                                     'phone' => '+33 01 45 59 64 90',
                                                     'last_name' => 'Pasquale F. Innominato, M.D.'
                                                   },
                                 'facility' => {
                                               'name' => 'Chronotherapy Unit, Medical Oncology Department, Paul Brousse Hospital',
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '94800',
                                                            'city' => 'Villejuif'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Michel Ducreux, MD, PhD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'michel.ducreux@igr.fr',
                                              'phone' => '+33 1 42 11 43 10',
                                              'last_name' => 'Michel Ducreux, MD, PhD'
                                            },
                                 'facility' => {
                                               'name' => 'Institut Gustave Roussy',
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '94800',
                                                            'city' => 'Villejuif'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Stefano Iacobelli, M.D.'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Michele De Tursi, M.D., Ph.D.'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Consiglia Carella, M.D.'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'iacobell@unich.it',
                                              'phone' => '+3908713556732',
                                              'last_name' => 'Stefano Iacobelli, M.D.'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'detursi@unich.it',
                                                     'phone' => '+390871358243',
                                                     'last_name' => 'Michele De Tursi, M.D., Ph.D.'
                                                   },
                                 'facility' => {
                                               'name' => "Universit\x{e0} G. d'Annunzio",
                                               'address' => {
                                                            'country' => 'Italy',
                                                            'zip' => '66100',
                                                            'city' => 'Chieti'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Salvatore Tumolo, MD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Giovanni Lo Re, MD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'salvatore.tumolo@aopn.fvg.it',
                                              'phone' => '+(39) 0434 39 96 12',
                                              'last_name' => 'Salvatore Tumolo, MD'
                                            },
                                 'facility' => {
                                               'name' => 'Azienda Ospedaliera S.Maria Degli Angeli',
                                               'address' => {
                                                            'country' => 'Italy',
                                                            'zip' => '33170',
                                                            'city' => 'Pordenone'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Carlo Garufi, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'garufi@ifo.it',
                                              'phone' => '+(39) 06 52 66 56 27',
                                              'last_name' => 'Carlo Garufi, MD'
                                            },
                                 'facility' => {
                                               'name' => 'Istituto Regina Elena',
                                               'address' => {
                                                            'country' => 'Italy',
                                                            'zip' => '00144',
                                                            'city' => 'Roma'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Carlos Carvalho, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'ccarvalho@hospital-as.pt',
                                              'phone' => '+(351) 21 43 48 278',
                                              'last_name' => 'Carlos Carvalho, MD'
                                            },
                                 'facility' => {
                                               'name' => 'Hospital Fernando Fonesca',
                                               'address' => {
                                                            'country' => 'Portugal',
                                                            'zip' => '27000',
                                                            'city' => 'Amadora'
                                                          }
                                             }
                               }
                             ],
                 'acronym' => 'OPTILIV',
                 'id_info' => {
                              'secondary_id' => 'EUDRACT number: 2007-004632-24',
                              'nct_id' => 'NCT00852228',
                              'org_study_id' => 'OPTILIV07'
                            },
                 'overall_contact' => {
                                      'email' => 'francis.levi@inserm.fr',
                                      'phone' => '+33 01 45 59 38 55',
                                      'last_name' => "Francis A. L\x{e9}vi, M.D., Ph.D."
                                    },
                 'firstreceived_date' => 'February 25, 2009',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'February 2011',
                 'keyword' => [
                              'colorectal cancer',
                              'unresectable metastases',
                              'neo-adjuvant chemotherapy',
                              'liver metastases',
                              'chronotherapy',
                              'cetuximab',
                              'irinotecan',
                              'oxaliplatin',
                              '5-fluorouracil',
                              'hepatic artery infusion',
                              'Unresectable hepatic lesions',
                              '1 to 3 prior chemotherapy regimens'
                            ],
                 'source' => "Association pour la Recherche sur le Temps Biologique et la Chronoth\x{e9}rapie",
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => "Association pour la Recherche sur le Temps Biologique et la Chronoth\x{e9}rapie"
                                               },
                               'collaborator' => [
                                                 {
                                                   'agency_class' => 'Other',
                                                   'agency' => 'Gustave Roussy, Cancer Campus, Grand Paris'
                                                 },
                                                 {
                                                   'agency_class' => 'Industry',
                                                   'agency' => 'Merck Serono International SA'
                                                 },
                                                 {
                                                   'agency_class' => 'Industry',
                                                   'agency' => 'Pfizer'
                                                 },
                                                 {
                                                   'agency_class' => 'Other',
                                                   'agency' => 'CRESGE'
                                                 }
                                               ]
                             },
                 'completion_date' => {
                                      'content' => 'December 2015',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial',
                 'enrollment' => {
                                 'content' => '60',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Colorectal Neoplasms',
                                                      'Neoplasm Metastasis',
                                                      'Neoplasms, Second Primary',
                                                      'Liver Neoplasms'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The primary objective of the study is to increase by 15% the complete macroscopic resection
      rate of predominantly liver metastases from metastatic colorectal cancer through combining
      systemic cetuximab and hepatic artery infusion of three-drug chemotherapy (irinotecan,
      oxaliplatin and 5-fluorouracil).
    '
                                  },
                 'location_countries' => {
                                         'country' => [
                                                      'Belgium',
                                                      'France',
                                                      'Italy',
                                                      'Portugal'
                                                    ]
                                       },
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => 'every 2 month up to 3 years',
                                          'measure' => 'The rate and site(s) of relapse in the resected patients throughout the 3-year span that follows hepatectomy',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'every 2nd month up to 3 years',
                                          'measure' => 'The relapse-free survival in the resected patients',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'every 2nd month up to 3 years',
                                          'measure' => 'The progression-free and the overall survival in the patients receiving at least 4 full courses of HAI therapy and in all the patients (intent to treat)',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'every 6 weeks up to 18 weeks',
                                          'measure' => 'The objective response rate',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'continuous up to 30 days following end of treatment',
                                          'measure' => 'The rate of adverse events',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => 'continuous up to 3 months following surgery',
                                          'measure' => 'The per-operative and post-operative complications associated to liver surgery',
                                          'safety_issue' => 'Yes'
                                        }
                                      ],
                 'responsible_party' => {
                                        'name_title' => "Dr. Francis L\x{e9}vi",
                                        'organization' => "ARTBC International, H\x{f4}pital Paul Brousse"
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        -  Histologically or cytologically confirmed carcinoma of the colon and/or rectum with
             evidence of liver metastases (new confirmation of metastatic disease is required in
             case the time interval from last histological diagnosis to enrolment exceeds 3
             years).

          -  Patient with wild type (WT) KRAS tumor status

          -  Patient whose liver metastases are considered to be non resectable with curative
             intent in medico-surgical staff meeting. In particular patients with at least one of
             the following criteria, which prevent complete local treatment of liver metastasis
             with surgery alone or surgery plus radiofrequency ablation  because:

               -  less than 30% estimated residual liver after resection

               -  disease in contact with liver main vessels

               -  documented progressive disease on imaging documents or doubling of serum levels
                  of carcino-embryonic antigen (CEA) or CA19.9 over the past 90 days or less

          -  Patient with up to three resectable extrahepatic nodules of <= 10 mm

          -  One, two or three prior chemotherapy lines for colorectal cancer.

          -  Written informed consent.

          -  Age >=18 years.

          -  Patient must be able to comply with the protocol.

          -  Life expectancy of at least 3 months.

          -  At least one measurable metastatic liver lesion (as per RECIST criteria).

          -  World Health Organization performance status of 0 or 1.

          -  Adequate hematological function: absolute neutrophil count (ANC) >=1.0 x 10^9/L;
             platelets >=75 x 10^9/L, hemoglobin (Hb) >=8.5 g/dL.

          -  International normalized ratio (INR) <=1.5 and activated partial thromboplastin time
             (aPTT) <=1.5 x upper limit of normal (ULN) within 7 days prior to starting study
             treatment, in the absence of anticoagulant therapy.

          -  Liver function: serum bilirubin <=1.5 x ULN; alkaline phosphatase and transaminases
             <5 x ULN (liver metastases).

          -  Serum creatinine <= 1.5 x ULN.

          -  Fertile women and men of childbearing potential (<2 years after last menstruation in
             women) must use effective means of contraception (oral contraceptives, intrauterine
             contraceptive device, barrier method of contraception in conjunction with spermicidal
             jelly or surgically sterile).

        Exclusion Criteria:

          -  Patient whose primary tumor or metastasis displays mutation of K-Ras (codon 12 and/or
             13).

          -  Unresectable extrahepatic diseases.

          -  More than three resectable extrahepatic nodules.

          -  Size of extra hepatic nodules > 1 cm

          -  Prior HAI of the 3 drugs.

          -  More than 2 prior surgical attempts for metastatic disease

          -  Prior radiotherapy for metastatic disease

          -  Known documented intolerance or hypersensitivity to any of the drugs used.

          -  Sensory neuropathy grade 3 (National Cancer Institute-Common Terminology Criteria for
             Adverse Events -NCI-CTCAE, Version 3.0).

          -  Past or current history (within the last 2 years prior to treatment start) of
             malignancy other than colorectal cancer (patients with curatively treated basal and
             squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible).

          -  Serious, non healing wound, ulcer, or bone fracture.

          -  Evidence of any other disease, metabolic dysfunction, physical examination finding or
             laboratory finding giving reasonable suspicion of a disease or condition that puts
             the patient at high risk for treatment-related complications.

          -  Pregnancy or lactation

          -  Fertile women (< 2 years after last menstruation) and men of childbearing potential
             not willing to use effective means of contraception.

        Prior systemic administration of cetuximab or other anti-EGFR agent is not an exclusion
        criterion.
      '
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'February 4, 2011',
                 'phase' => 'Phase 2',
                 'start_date' => 'July 2008',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT00852228',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'overall_contact_backup' => {
                                             'email' => 'abdoulaye.karaboue@inserm.fr',
                                             'phone' => '+33 01 45 59 35 53',
                                             'last_name' => "Abdoulaye Karabou\x{e9}, M.D."
                                           },
                 'condition' => [
                                'Metastatic Colorectal Cancer',
                                'Liver Metastases',
                                'Hepatic Lesions'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial
time_frame	evaluation every 6th week up to 18 weeks
measure	Incidence of complete macroscopic resections (R0+R1) of unresectable liver metastases following chemotherapy.
safety_issue	No
other_name	Erbitux
intervention_type	Drug
arm_group_label	chronomodulated HAI chemotherapy
arm_group_label	conventional HAI chemotherapy

description	Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
intervention_name	IV cetuximab
other_name	Campto
other_name	Eloxatin

intervention_type	Drug
arm_group_label	chronomodulated HAI chemotherapy
description	Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00
Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.
5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.
Treatments will be repeated every 2 weeks.
intervention_name	HAI chronomodulated chemotherapy
other_name	Campto
other_name	Eloxatin

intervention_type	Drug
arm_group_label	conventional HAI chemotherapy
description	Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then
Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then
5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.
Treatments will be repeated every 2 weeks.
intervention_name	HAI conventional chemotherapy
Keywords:colorectal cancer; unresectable metastases; neo-adjuvant chemotherapy; liver metastases; chronotherapy; cetuximab; irinotecan; oxaliplatin; 5-fluorouracil; hepatic artery infusion; Unresectable hepatic lesions; 1 to 3 prior chemotherapy regimens
Lead sponsor: Other; Association pour la Recherche sur le Temps Biologique et la Chronothérapie
Collaborator: Other; Gustave Roussy, Cancer Campus, Grand Paris
Collaborator: Industry; Merck Serono International SA
Collaborator: Industry; Pfizer
Collaborator: Other; CRESGE
Intervention MeSH:Fluorouracil; Oxaliplatin; Cetuximab
Condition MeSH:Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Liver Neoplasms
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01455246

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'No',
                                     'authority' => 'Italy: Ministry of Health'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      Spontaneous bacterial peritonitis (SBP) is a well known complication in patients with liver
      cirrhosis and ascites. Nosocomial SBP is defined as SBP that occurs after 48 hours of
      hospitalization. It has been shown that patients with nosocomial SBP have a worse prognosis
      than patients with community-acquired SBP. It has also been shown that nosocomial SBP is
      frequently caused by multi drug resistant bacteria such as extended-spectrum-beta-lactamase
      (ESBL) producing enterobacteria or meticillin - resistant staphylococcus aureus. Currently
      the empirical treatment of SBP is the use of third generation cephalosporins or
      amoxicillin/clavulanic acid. In patients affected by nosocomial SBP these treatment could be
      ineffective. Up to now an empirical approach with a broader spectrum strategy (such as an
      association between meropenem and daptomycin) has never been compared to standard therapy in
      the treatment of nosocomial SBP. Thus, the aim of the study is to compare daptomycin +
      meropenem vs ceftazidime in the treatment of nosocomial SBP in patients with cirrhosis.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'October 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '48 hours and seven days',
                                      'measure' => 'The primary end-point of the study is the response to therapy',
                                      'description' => "The response to therapy is defined as the reduction of  polymorphonuclear leukocytes (PMN) count in ascitic fluid more than 25 % from baseline after 48 hours and as a PMN count in ascitic fluid less then 250/mm\x{b3} after seven days.",
                                      'safety_issue' => 'Yes'
                                    },
                 'intervention' => [
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Daptomycin + Meropenem',
                                     'description' => 'Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50  ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.',
                                     'intervention_name' => 'Daptomycin + Meropenem'
                                   },
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Ceftazidime',
                                     'description' => 'Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours  by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50  ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm',
                                     'intervention_name' => 'Ceftazidime'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Ceftazidime',
                                                         'Daptomycin',
                                                         'Meropenem'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => '30 patients with cirrhosis and nosocomial SBP',
                                  'arm_group_label' => 'Daptomycin + Meropenem'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => '30 patients with cirrhosis and nosocomial SBP',
                                  'arm_group_label' => 'Ceftazidime'
                                }
                              ],
                 'overall_official' => {
                                       'affiliation' => 'Dept. of Clinical and Experimenatl Medicine, University of Padova, Italy',
                                       'role' => 'Principal Investigator',
                                       'last_name' => 'Paolo Angeli, MD, PhD'
                                     },
                 'brief_title' => 'Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => {
                               'investigator' => [
                                                 {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Paolo Angeli, MD, PhD'
                                                 },
                                                 {
                                                   'role' => 'Sub-Investigator',
                                                   'last_name' => 'Salvatore Piano, MD'
                                                 }
                                               ],
                               'status' => 'Recruiting',
                               'contact' => {
                                            'email' => 'pangeli@unipd.it',
                                            'phone' => '+39-049-8212004',
                                            'last_name' => 'Paolo Angeli, MD, PhD'
                                          },
                               'contact_backup' => {
                                                   'email' => 'salvatoresilvio.piano@unipd.it',
                                                   'phone' => '+39-049-8211836',
                                                   'last_name' => 'Salvatore Piano, MD'
                                                 },
                               'facility' => {
                                             'name' => 'Dept. of Clinical and Experimental Medicine, University of Padova',
                                             'address' => {
                                                          'country' => 'Italy',
                                                          'zip' => '35128',
                                                          'city' => 'Padova',
                                                          'state' => 'PD'
                                                        }
                                           }
                             },
                 'id_info' => {
                              'secondary_id' => '2010-019625-34',
                              'nct_id' => 'NCT01455246',
                              'org_study_id' => '2059P'
                            },
                 'overall_contact' => {
                                      'email' => 'pangeli@unipd.it',
                                      'phone' => '+39-049-8212004',
                                      'last_name' => 'Paolo Angeli, MD, PhD'
                                    },
                 'firstreceived_date' => 'October 13, 2011',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'October 2011',
                 'keyword' => [
                              'Cirrhosis',
                              'Nosocomial Spontaneous Bacterial Peritonitis',
                              'Ascites',
                              'Daptomycin',
                              'Meropenem',
                              'Ceftazidime',
                              'Nosocomial infection',
                              'Multi drug resistant bacteria',
                              'Sepsis',
                              'Albumin'
                            ],
                 'source' => 'University of Padova',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'University of Padova'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'January 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial',
                 'enrollment' => {
                                 'content' => '60',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Ascites',
                                                      'Liver Cirrhosis',
                                                      'Fibrosis',
                                                      'Peritonitis'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      Nosocomial spontaneous bacterial peritonitis (SBP) is frequently caused by multi drug
      resistant bacteria. Standard treatment of SBP could be ineffective. The aim of the study is
      to compare daptomycin + meropenem vs ceftazidime in the treatment of nosocomial SBP.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'Italy'
                                       },
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => 'participants will be followed for the duration of hospital stay, an expected average of 6 weeks',
                                          'measure' => 'Mortality during hospitalization',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => '30 days',
                                          'measure' => '30 days mortality',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => '90 days',
                                          'measure' => '90 days mortality',
                                          'safety_issue' => 'Yes'
                                        }
                                      ],
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  Patients with liver cirrhosis and ascites

          -  Meets all criteria for nosocomial SBP as outlined below

               -  Ascitic fluid polymorphonuclear cells count >250/mm3

               -  Onset of signs and symptoms of infection after 72 hours of hospitalization

        Exclusion Criteria:

          -  Hepatocellular carcinoma beyond the Milan criteria

          -  Abdominal surgery within 4 weeks

          -  Evidence of secondary peritonitis, pancreatitis or peritoneal carcinomatosis

          -  Significant heart or respiratory failure

          -  Allergy to ceftazidime, meropenem or daptomycin
      '
                                              },
                                  'maximum_age' => '75 Years',
                                  'gender' => 'Both'
                                },
                 'reference' => [
                                {
                                  'PMID' => '10673079',
                                  'citation' => "Rimola A, Garc\x{ed}a-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000 Jan;32(1):142-53. Review. No abstract available."
                                },
                                {
                                  'PMID' => '17187409',
                                  'citation' => "Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, Salinas F, Don\x{e0} S, Fagiuoli S, Sticca A, Zanus G, Cillo U, Frasson I, Destro C, Gatta A. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007 Jan;45(1):223-9."
                                },
                                {
                                  'PMID' => '16393283',
                                  'citation' => 'Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, Antona C, Brollo L, Franchin M, Cillo U, Merkel C, Gatta A. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther. 2006 Jan 1;23(1):75-84.'
                                },
                                {
                                  'PMID' => '19302016',
                                  'citation' => 'Cheong HS, Kang CI, Lee JA, Moon SY, Joung MK, Chung DR, Koh KC, Lee NY, Song JH, Peck KR. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis. 2009 May 1;48(9):1230-6.'
                                }
                              ],
                 'lastchanged_date' => 'October 17, 2011',
                 'phase' => 'Phase 2/Phase 3',
                 'start_date' => 'October 2010',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01455246',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'overall_contact_backup' => {
                                             'email' => 'salvatoresilvio.piano@unipd.it',
                                             'phone' => '+39-049-8211836',
                                             'last_name' => 'Salvatore Piano, MD'
                                           },
                 'condition' => [
                                'Cirrhosis',
                                'Ascites',
                                'Nosocomial Spontaneous Bacterial Peritonitis'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis: an Open, Randomized, Controlled Clinical Trial
time_frame	48 hours and seven days
measure	The primary end-point of the study is the response to therapy
description	The response to therapy is defined as the reduction of  polymorphonuclear leukocytes (PMN) count in ascitic fluid more than 25 % from baseline after 48 hours and as a PMN count in ascitic fluid less then 250/mm³ after seven days.
safety_issue	Yes
intervention_type	Drug
arm_group_label	Daptomycin + Meropenem
description	Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50  ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
intervention_name	Daptomycin + Meropenem
intervention_type	Drug
arm_group_label	Ceftazidime
description	Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours  by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50  ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
intervention_name	Ceftazidime
Keywords:Cirrhosis; Nosocomial Spontaneous Bacterial Peritonitis; Ascites; Daptomycin; Meropenem; Ceftazidime; Nosocomial infection; Multi drug resistant bacteria; Sepsis; Albumin
Lead sponsor: Other; University of Padova
Intervention MeSH:Ceftazidime; Daptomycin; Meropenem
Condition MeSH:Ascites; Liver Cirrhosis; Fibrosis; Peritonitis
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01503346

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'No',
                                     'authority' => 'Taiwan: Department of Health'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      Intervention group

        -  1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed
           and separated into four packages;

        -  2. each package was given to each patient four times a day (three time after meal and
           one time before sleep);

        -  3. each patient received the usual medication of the hospice ward at the same time;

        -  4. record the patients\' score of pre-test, mid-test and after-test of QIPCTP at the 1st
           day, the 3rd day and the 6th day;

        -  5. record the patients\' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative
           Oncology Group Performance Status) at the 1st day and the 6th day.

      Control group

        -  1. each patient received the usual medication of the hospice ward during the trial
           interval;

        -  2. record the patients\' score of receive pre-test, mid-test and after-test of QIPCTP at
           the 1st day, the 3rd day and the 6th day;

        -  3. record the patients\' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative
           Oncology Group Performance Status) at at the 1st day and the 6th day.

      Medicine DaHuang herbal abstract powder is produced by Sun Ten Pharmaceutical Co., Ltd, and
      it\'s product serial number: 276001. GanCao herbal abstract powder is also produced by Sun
      Ten Pharmaceutical Co., Ltd, and it\'s product serial number: 185645. Each herbal abstract
      powder is qualified with the data of HPLC to confirm each content and stability. The
      pharmaceutical company is qualified by Good Manufacturing Practice (GMP) certification in
      Taiwan.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'September 2011',
                                              'type' => 'Actual'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '6 days',
                                      'measure' => 'appetite score',
                                      'description' => 'The investigators detect the patients\' appetite condition at the 1st,3rd and 6th day.',
                                      'safety_issue' => 'Yes'
                                    },
                 'intervention' => {
                                   'other_name' => 'Herbal Medicine Group',
                                   'intervention_type' => 'Drug',
                                   'arm_group_label' => 'herbal medicine',
                                   'description' => 'Intervention group
2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;
each package was given to each patient four times a day (three time after meal and one time before sleep);
each patient received the usual medication of the hospice ward at the same time;
record the patients\' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;
record the patients\' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.',
                                   'intervention_name' => 'DaHuang GanTsao Tang'
                                 },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '1',
                 'arm_group' => {
                                'arm_group_type' => 'Active Comparator',
                                'description' => 'Intervention group
1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;
2. each package was given to each patient four times a day (three time after meal and one time before sleep);
3. each patient received the usual medication of the hospice ward at the same time;
4. record the patients\' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;
5. record the patients\' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.',
                                'arm_group_label' => 'herbal medicine'
                              },
                 'overall_official' => {
                                       'affiliation' => 'Changhua Christian Hospital',
                                       'role' => 'Study Chair',
                                       'last_name' => 'Yu De LIU, Master'
                                     },
                 'brief_title' => 'DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients',
                 'study_design' => 'Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care',
                 'location' => {
                               'status' => 'Recruiting',
                               'contact' => {
                                            'email' => 'lude961031@gmail.com',
                                            'phone' => '886-988-285196',
                                            'last_name' => 'Y D LIU, Master'
                                          },
                               'contact_backup' => {
                                                   'email' => 'a884215@gmail.com',
                                                   'phone' => '886-937-251181',
                                                   'last_name' => 'S C YANG, Master'
                                                 },
                               'facility' => {
                                             'name' => 'Changhua Christan Hospital',
                                             'address' => {
                                                          'country' => 'Taiwan',
                                                          'zip' => '500',
                                                          'city' => 'Changhua City',
                                                          'state' => 'Changhua Country'
                                                        }
                                           }
                             },
                 'acronym' => 'TCM',
                 'id_info' => {
                              'secondary_id' => 'Protocol Record 100610',
                              'nct_id' => 'NCT01503346',
                              'org_study_id' => '100610'
                            },
                 'overall_contact' => {
                                      'email' => 'lude961031@gmail.com',
                                      'phone' => '886-988-285196',
                                      'last_name' => 'Y D LIU, Master'
                                    },
                 'firstreceived_date' => 'November 7, 2011',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'January 2012',
                 'keyword' => 'Appetite Loss',
                 'source' => 'Changhua Christian Hospital',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Yu-De Liu'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Changhua Christian Hospital'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'March 2012',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => "Taking Herbal Formula\x{ff1a}DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients in Late-stage\x{ff1a}A Clinical Control Trial Study",
                 'enrollment' => {
                                 'content' => '30',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Anorexia'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      Appetite loss is a severe and common symptom among late-stage cancer patients, and it causes
      great the anxiety for the patient\'s family. In TCM theory, the investigators call these
      patients are in block and repulsion condition. The investigators try to set a study to use
      the herbal medicine solution taken in frequent small amounts by cancer patients in
      late-stage to improve the appetite loss condition. Through this method, the investigators
      not only want to improve the quality of life of cancer patients in late-stage but also set a
      valuable treatment.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'Taiwan'
                                       },
                 'responsible_party' => {
                                        'investigator_full_name' => 'Yu-De Liu',
                                        'investigator_affiliation' => 'Changhua Christian Hospital',
                                        'responsible_party_type' => 'Sponsor-Investigator',
                                        'investigator_title' => 'Principal Investigator'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '20 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  Terminal cancer patients in hospice ward

          -  Patients with appetite loss condition

          -  Ages between 20 to 80 years old

          -  No history of diabetes

        Exclusion Criteria:

          -  Entered the stage of dying patients

          -  Receiving other traditional Chinese medicine
      '
                                              },
                                  'maximum_age' => '80 Years',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 2',
                 'lastchanged_date' => 'January 3, 2012',
                 'start_date' => 'March 2011',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01503346',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'overall_contact_backup' => {
                                             'email' => 'a884215@gmailc.om',
                                             'phone' => '886-937-251181',
                                             'last_name' => 'S C YANG, Master'
                                           },
                 'condition' => 'Non-organic Loss of Appetite'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Taking Herbal Formulaï¼DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients in Late-stageï¼A Clinical Control Trial Study
time_frame	6 days
measure	appetite score
description	The investigators detect the patients' appetite condition at the 1st,3rd and 6th day.
safety_issue	Yes
other_name	Herbal Medicine Group
intervention_type	Drug
arm_group_label	herbal medicine
description	Intervention group
2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;
each package was given to each patient four times a day (three time after meal and one time before sleep);
each patient received the usual medication of the hospice ward at the same time;
record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;
record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.
intervention_name	DaHuang GanTsao Tang
Keyword:Appetite Loss
Lead sponsor: Other; Yu-De Liu
Collaborator: Other; Changhua Christian Hospital
Intervention MeSH	NOT FOUND
Condition MeSH:Anorexia
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01319422

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'No',
                                     'authority' => 'United States: Food and Drug Administration'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      Multiple Myeloma (MM) is a common hematologic malignancy characterized by clonal expansion
      of transformed plasma cells (PCs) in the bone marrow1. Over the past decade, the
      introduction of immunomodulatory agents (such as thalidomide and lenalidomide) and
      proteasome inhibitors (such as bortezomib) as effective therapies has altered the
      therapeutic landscape for multiple myeloma (MM). Following the approval and establishment of
      thalidomide-containing regimens, such as melphalan, prednisone and thalidomide (MPT) and
      Thal/Dex, as the standard first-line therapy for newly diagnosed MM (NDMM), lenalidomide in
      combination with dexamethasone (RD) was approved for the treatment of patients with
      previously treated MM1. However, even with these newly approved agents, MM remains an
      incurable disease and most patients will eventually relapse and progress after multiple
      lines of different therapeutic regimens including both lenalidomide as well as bortezomib.
      Thus there remains a continued need to identify newer agents to maintain long term disease
      control in these patients.

      Thalidomide and its immune-modulatory analogue lenalidomide have clinical activity in
      myeloma. Pomalidomide, a thalidomide analogue, is an immunomodulatory agent that displays
      similar anti-angiogenic activity, but far greater anti-proliferative and immunomodulatory
      activity, compared to the parent drug. Pomalidomide and lenalidomide have been shown to
      possess very similar pharmacological properties in vitro, including anti-angiogenic,
      immunomodulatory and anti-proliferative properties. However a unifying molecular mechanism
      for these diverse effects has been elusive. Pomalidomide and lenalidomide have significantly
      greater capacity for enhanced costimulation, leading to enhanced activation of innate and
      adaptive immune cells compared to Thalidomide. Recent studies have yielded the surprising
      finding that these agents can mediate rapid biologic effects on human monocytes and T cells
      in culture leading to activation of RhoA GTPases, and enhanced actin polymerization. Changes
      in actin cytoskeleton may also contribute to the capacity to these drugs to enhance the
      formation of immune synapses, Pomalidomide has also been shown to stimulate
      antibody-dependent cytotoxic T-cell activity (ADCC) in preclinical models.

      At tolerated doses (MTD = 2 mg QD and 5 mg QOD), pomalidomide has been shown to be active in
      subjects with relapsed or refractory multiple myeloma (MM) (study CC-4047-00-001).  In 45
      subjects who received doses of pomalidomide ranging, by cohort, up to 10 mg daily, the most
      commonly occurring dose-limiting toxicity (DLT) was reversible neutropenia.  As with other
      IMiDs administered to subjects receiving concomitant systemic steroids, deep vein thrombosis
      (DVT) was seen (in 1 subject each in this study and in its subsequent named patient supply
      rollover program).

      Recently, preliminary efficacy and safety data from an ongoing phase II study, led by Martha
      Lacy at Mayo Clinic, were published.  Sixty patients with relapsed or refractory multiple
      myeloma were enrolled.  Pomalidomide (CC-4047) was given orally at a dose of 2 mg daily on
      days 1-28 of a 28-day cycle and dexamethasone was given orally at a dose of 40 mg daily on
      days 1, 8, 15, 22 of each cycle.  Patient also received aspirin 325 mg once daily for
      thromboprophylaxis.  The study endpoints were the response rate in patients taking
      pomalidomide plus dexamethasone including patients with lenalidomide resistant refractory
      multiple myeloma, and safety of pomalidomide plus dexamethasone. Responses were recorded
      using the criteria of the International Myeloma Working Group. Thirty eight patients
      achieved objective response (63%) including CR in 3 patients (5%), VGPR in 17 patients
      (28%), and PR in 18 patients (30%).   The CR + VGPR rate was 33%.  Grade 3 or 4 hematologic
      toxicity occurred in 23 patients (38%) and consisted of anemia in three patients (5%),
      thrombocytopenia in two patients (3%) and neutropenia in 21 (35%).  Among those that
      developed grade 3/4 neutropenia, all first experienced the neutropenia in cycle 1-3; no new
      patients experienced grade 3/4 neutropenia in cycle 4 or later.  The most common
      non-hematological grade 3/4 toxicities were fatigue (17%) and pneumonia (8%).  Other grade
      3/4 non-hematological toxicities that occurred in less than 5% included diarrhea,
      constipation, hyperglycemia, and neuropathy.  One patient (1.6%) had a thromboembolic event
      of deep vein thrombosis.

      Another dosing regimen for Pomalidomide involved 21/28 day dosing, as in the current dosing
      regimen for Lenalidomide. In this trial the recommended dose for phase II testing was
      determined to be 4 mg, 21/28 d. Clinical response (greater than or equal to a partial
      response (PR)) was observed in 7/25 (28%) patients. While both regimens seem to be
      clinically active, it is unclear at present as to which regimen leads to greater immune
      activation or clinical activity.

      In addition to MM, pre-clinical data and the prior experience with thalidomide and
      lenalidomide in the treatment of patients with myelofibrosis with myeloid metaplasia (MMM)
      provided the rationale for the use of pomalidomide in patients with MMM. This is further
      supported by the results of a Celgene sponsored trial (MMM-001) which indicated that
      pomalidomide therapy at 0.5 mg or 2 mg/day +/- an abbreviated course of prednisone is well
      tolerated in patients with myelofibrosis and active in the treatment of anemia.

      However, these studies did not monitor proximate pharmacodynamic events (such as might occur
      within hours of drug exposure), and link these to downstream effects, including clinical
      activity and toxicity. Our hypothesis is that the proximate effects of these drugs
      (including drug induced changes in F-actin) and early phosphorylation events will be
      sensitive and quantitative surrogates of subsequent effects including activation of tumor
      antigen specific T cells as well as innate immune cells. Understanding the correlation
      between pharmacodynamics of these effects with downstream activation using quantitative
      assays will facilitate rational development of these agents as immunomodulatory drugs in
      diverse settings and may also allow optimization of drug delivery to both reduce potential
      toxicity, and enhance efficacy.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'May 2014',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => [
                                      {
                                        'time_frame' => 'Efficacy assessments will be made after the first two cycles of therapy (approximately 56 days--each cycle is 28 days)',
                                        'measure' => 'To compare the clinical activity in terms of response rate following continuous or intermittent dosing regimens.',
                                        'description' => 'All partial and complete responses must be confirmed with another efficacy assessment in no less than 4 weeks apart.',
                                        'safety_issue' => 'No'
                                      },
                                      {
                                        'time_frame' => 'After the initial efficacy assessment at the completion of cycle 2 (at approximately 56 days), efficacy assessments will be made after every other cycle (approximately every 56 days).',
                                        'measure' => 'To compare the clinical activity in terms of response rate following continuous or intermittent dosing regimens.',
                                        'description' => 'All partial and complete responses must be confirmed with another efficacy assessment in no less than 4 weeks apart.',
                                        'safety_issue' => 'No'
                                      }
                                    ],
                 'intervention' => {
                                   'other_name' => 'CC-4047',
                                   'intervention_type' => 'Drug',
                                   'arm_group_label' => [
                                                        'Pomalidomide 2 mg/d days 1-28 of a 28 day cycle',
                                                        'Pomalidomide 4 mg/d days 1-21 of a 28 day cycle'
                                                      ],
                                   'description' => 'Comparison of different dosages and schedules of drug',
                                   'intervention_name' => 'Pomalidomide'
                                 },
                 'intervention_browse' => {
                                          'mesh_term' => 'Thalidomide'
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'arm_group_label' => 'Pomalidomide 2 mg/d days 1-28 of a 28 day cycle'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'arm_group_label' => 'Pomalidomide 4 mg/d days 1-21 of a 28 day cycle'
                                }
                              ],
                 'overall_official' => {
                                       'affiliation' => 'Yale University',
                                       'role' => 'Principal Investigator',
                                       'last_name' => 'Madhav Dhodapkar, M.D.'
                                     },
                 'brief_title' => 'Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => {
                               'investigator' => [
                                                 {
                                                   'role' => 'Sub-Investigator',
                                                   'last_name' => 'Dennis Cooper, M.D.'
                                                 },
                                                 {
                                                   'role' => 'Sub-Investigator',
                                                   'last_name' => 'Francine Foss, M.D.'
                                                 },
                                                 {
                                                   'role' => 'Sub-Investigator',
                                                   'last_name' => 'Peter Marks, M.D.'
                                                 },
                                                 {
                                                   'role' => 'Sub-Investigator',
                                                   'last_name' => 'Stuart Seropian, M.D.'
                                                 },
                                                 {
                                                   'role' => 'Sub-Investigator',
                                                   'last_name' => 'Nikolai Podolstev, M.D., Ph.D.'
                                                 }
                                               ],
                               'status' => 'Recruiting',
                               'contact' => {
                                            'email' => 'madhav.dhodapkar@yale.edu',
                                            'phone' => '203-785-4144',
                                            'last_name' => 'Madhav Dhodapkar, M.D.'
                                          },
                               'facility' => {
                                             'name' => 'Yale University',
                                             'address' => {
                                                          'country' => 'United States',
                                                          'zip' => '06520',
                                                          'city' => 'New Haven',
                                                          'state' => 'Connecticut'
                                                        }
                                           }
                             },
                 'id_info' => {
                              'nct_id' => 'NCT01319422',
                              'org_study_id' => 'HIC 1011007607'
                            },
                 'overall_contact' => {
                                      'email' => 'madhav.dhodapkar@yale.edu',
                                      'phone' => '203-785-4144',
                                      'last_name' => 'Madhav Dhodapkar, M.D.'
                                    },
                 'firstreceived_date' => 'March 14, 2011',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'July 2011',
                 'keyword' => [
                              'myeloma',
                              'multiple myeloma',
                              'pomalidomide',
                              'immunomodulatory'
                            ],
                 'source' => 'Yale University',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Yale University'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'Industry',
                                                 'agency' => 'Celgene Corporation'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'November 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma',
                 'enrollment' => {
                                 'content' => '48',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Multiple Myeloma',
                                                      'Neoplasms, Plasma Cell'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      Lenalidomide has clinical activity in myeloma. The closely related compound, Pomalidomide,
      may have clinical activity in patients who have previously been treated with lenalidomide
      and who no longer respond  to it. The mechanism of anti-tumor effects of these drugs has
      been attributed to several effects including anti-angiogenesis, immune activation, and
      anti-proliferative effects. Recent studies have suggested that these agents can mediate
      surprisingly rapid biologic effects on human monocytes and T cells. Our hypothesis is that
      the proximate effects of these drugs will be sensitive and quantitative surrogates of
      subsequent effects including activation of tumor antigen specific T cells as well as innate
      immune cells. Understanding the correlation between the pharmacodynamics of these effects
      with downstream activation using quantitative assays will facilitate the rational
      development of pomalidomide as immune-modulatory drug in diverse settings as well as its
      optimal development in myeloma therapy.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'is_section_801' => 'Yes',
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => 'Research blood draw will be obtained at baseline, and at 2-4 hr (on day 1), 1 wk, and 4 wk after initiation of cycles 1 and 2.',
                                          'measure' => 'To compare the effect of continuous versus intermittent regimens on F actin polymerization in PBMC and activation of tumor antigen-specific T cells, as well as innate lymphocytes (NK or NKT cells).',
                                          'description' => 'Correlation to be determined upon completion of study treatment',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Research bone marrow aspirate is obtained at baseline and after completion of 2 cycles of therapy (approximately 56 days)',
                                          'measure' => 'To correlate drug induced biologic effects with adverse effects and clinical responses.',
                                          'description' => 'Research bone marrow aspirate is obtained to assess response (optional, but recommended), and to document complete remission, if applicable. Correlation to be determined upon completion of study treatment',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => 'Research blood draw will be obtained at baseline, and at 2-4 hr (on day 1), 1 wk, and 4 wk after initiation of cycles 1 and 2.',
                                          'measure' => 'To correlate the drug induced proximate changes with effects on cytokine profile.',
                                          'description' => 'Correlation to be determined upon completion of study treatment',
                                          'safety_issue' => 'No'
                                        }
                                      ],
                 'responsible_party' => {
                                        'name_title' => 'Madhav Dhodapkar, M.D.',
                                        'organization' => 'Yale University'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => "
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent form.

          -  Age \x{2265}18 years at the time of signing the informed consent form.

          -  Able to adhere to the study visit schedule and other protocol requirements.

          -  Relapsed / Refractory Multiple Myeloma following at least two prior standard
             therapies including    lenalidomide. Induction therapy followed by autologous stem
             cell transplantation (ASCT) is considered one regimen.

          -  Patients must be refractory to prior lenalidomide therapy.  For the purpose of this
             protocol, refractory will be defined as history of progression on a regimen
             containing full or maximally tolerated dose of lenalidomide administered for a
             minimum of at least one complete cycle of therapy.

          -  All patients must have measurable disease defined as one or more of the following
             criteria:

               -  Serum monoclonal protein greater than 10 g/L, serum immunoglobulin free light
                  chain (FLC) more than 10 mg/dL and an abnormal FLC ratio, urine light-chain
                  excretion > 200 mg/24 h, measurable soft tissue plasmacytoma that has not been
                  irradiated, or greater than 30% plasma cells in bone marrow.

          -  All previous cancer therapy, including radiation, hormonal therapy and surgery, must
             have been discontinued at least 2 weeks prior to treatment in this study.

          -  ECOG performance status of \x{2264} 2 at study entry (see Appendix D).

          -  Laboratory test results within these ranges:

               -  Absolute neutrophil count \x{2265} 1.0 x 1000/uL

               -  Platelet count \x{2265}  75 x 1000/uL

               -  Serum creatinine \x{2264} 2.5 mg/dL

               -  Total bilirubin \x{2264} 2 mg/dL

               -  AST (SGOT) and ALT (SGPT) \x{2264} 5 x ULN

          -  Disease free of prior malignancies for \x{2265} 5 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma \"insitu\" of the cervix
             or breast.

          -  Females of childbearing potential (FCBP)\x{2020} must have a negative serum or urine
             pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of starting pomalidomide and must either commit to
             continued abstinence from heterosexual intercourse or begin TWO acceptable methods of
             birth control, one highly effective method and one additional effective method AT THE
             SAME TIME, at least 28 days before she starts taking pomalidomide.  FCBP must also
             agree to ongoing pregnancy testing.  Men must agree to use a latex condom during
             sexual contact with a FCBP even if they have had a vasectomy.  All patients must be
             counseled at a minimum of every 28 days about pregnancy precautions and risks of
             fetal exposure. See Appendix A and B: Risks of Fetal Exposure, Pregnancy Testing
             Guidelines and Acceptable Birth Control Methods, AND also Education and Counseling
             Guidance Document.

          -  Able to take aspirin (81 mg) daily as prophylactic anticoagulation (patients
             intolerant to ASA may use warfarin or low molecular weight heparin).

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed
             while taking pomalidomide).

          -  Women of child-bearing potential who are unwilling to use a dual method of
             contraception; and men who are unwilling to use a condom.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          -  Use of any other experimental drug or therapy within 28 days of baseline.

          -  Known hypersensitivity to thalidomide or lenalidomide.

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide, pomalidomide or similar drugs.

          -  Any prior use of pomalidomide.

          -  Concurrent use of other anti-cancer agents or treatments.

          -  Known positive for HIV or active infectious hepatitis, B or C.

          -  Grade 3 or 4 peripheral neuropathy
      "
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'July 5, 2011',
                 'phase' => 'Phase 2',
                 'start_date' => 'June 2011',
                 'is_fda_regulated' => 'Yes',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01319422',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => 'Multiple Myeloma'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Clinical and Pharmacodynamic Comparison of Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
time_frame	Efficacy assessments will be made after the first two cycles of therapy (approximately 56 days--each cycle is 28 days)
measure	To compare the clinical activity in terms of response rate following continuous or intermittent dosing regimens.
description	All partial and complete responses must be confirmed with another efficacy assessment in no less than 4 weeks apart.
safety_issue	No
time_frame	After the initial efficacy assessment at the completion of cycle 2 (at approximately 56 days), efficacy assessments will be made after every other cycle (approximately every 56 days).
measure	To compare the clinical activity in terms of response rate following continuous or intermittent dosing regimens.
description	All partial and complete responses must be confirmed with another efficacy assessment in no less than 4 weeks apart.
safety_issue	No
other_name	CC-4047
intervention_type	Drug
arm_group_label	Pomalidomide 2 mg/d days 1-28 of a 28 day cycle
arm_group_label	Pomalidomide 4 mg/d days 1-21 of a 28 day cycle

description	Comparison of different dosages and schedules of drug
intervention_name	Pomalidomide
Keywords:myeloma; multiple myeloma; pomalidomide; immunomodulatory
Lead sponsor: Other; Yale University
Collaborator: Industry; Celgene Corporation
Intervention MeSH:Thalidomide
Condition MeSH:Multiple Myeloma; Neoplasms, Plasma Cell
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01327586

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => [
                                                    'United States: Institutional Review Board',
                                                    'United States: Federal Government'
                                                  ]
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'September 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => 'Month 0,1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12',
                                      'measure' => 'Proportion of Urine toxicology tests without cocaine',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'intervention_type' => 'Behavioral',
                                     'arm_group_label' => 'ATM',
                                     'description' => 'Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex',
                                     'intervention_name' => 'ATM'
                                   },
                                   {
                                     'intervention_type' => 'Behavioral',
                                     'arm_group_label' => 'Individual Drug Counseling',
                                     'description' => 'Standard individualized drug counseling, modified from that described by Woody and colleagues',
                                     'intervention_name' => 'Individual Drug Counseling'
                                   }
                                 ],
                 'has_expanded_access' => 'No',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'arm_group_label' => 'ATM'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'arm_group_label' => 'Individual Drug Counseling'
                                }
                              ],
                 'number_of_arms' => '2',
                 'overall_official' => {
                                       'affiliation' => 'Yale University',
                                       'role' => 'Principal Investigator',
                                       'last_name' => 'Marc I Rosen, M.D.'
                                     },
                 'brief_title' => 'Abstinence-Linked Money Management Multisite',
                 'study_design' => 'Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'Karen.Ablondi@yale.edu',
                                              'phone' => '203-974-7294',
                                              'last_name' => 'Karen Ablondi, MPH'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'karen.ablondi@yale.edu'
                                                   },
                                 'facility' => {
                                               'name' => 'Greater Bridgeport Mental Health Center',
                                               'address' => {
                                                            'country' => 'United States',
                                                            'zip' => '06610',
                                                            'city' => 'Bridgeport',
                                                            'state' => 'Connecticut'
                                                          }
                                             }
                               },
                               {
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'Karen.Ablondi@Yale.edu',
                                              'phone' => '203-974-7294',
                                              'last_name' => 'Karen Ablondi, MPH'
                                            },
                                 'facility' => {
                                               'name' => 'Capitol Region Mental Health Center',
                                               'address' => {
                                                            'country' => 'United States',
                                                            'zip' => '06112',
                                                            'city' => 'Hartford',
                                                            'state' => 'Connecticut'
                                                          }
                                             }
                               }
                             ],
                 'id_info' => {
                              'nct_id' => 'NCT01327586',
                              'org_study_id' => 'R01DA12952 from VACHS account'
                            },
                 'firstreceived_date' => 'February 2, 2011',
                 'overall_contact' => {
                                      'email' => 'karen.ablondi@yale.edu',
                                      'phone' => '2039747294',
                                      'last_name' => 'Karen Ablondi, MPH'
                                    },
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'March 2011',
                 'keyword' => [
                              'disability',
                              'substance abuse',
                              'cocaine abuse',
                              'dual diagnosis',
                              'representative payee',
                              'HIV risk reduction'
                            ],
                 'source' => 'Yale University',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Yale University'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'NIH',
                                                 'agency' => 'National Institute on Drug Abuse (NIDA)'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'January 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Abstinence-Linked Money Management Multisite',
                 'enrollment' => {
                                 'content' => '120',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Cocaine-Related Disorders',
                                                      'Substance-Related Disorders'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      Randomized clinical trial comparing a money management-based intervention involving storage
      and management of client funds, substance abuse counseling, and risk reduction counseling to
      individualized drug counseling.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'secondary_outcome' => {
                                        'time_frame' => 'Month 0, 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12',
                                        'measure' => 'Unprotected sexual encounters',
                                        'description' => 'ACASI-measured',
                                        'safety_issue' => 'No'
                                      },
                 'responsible_party' => {
                                        'name_title' => 'Marc I. Rosen, M.D.',
                                        'organization' => 'Yale University School of Medicine'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  Enrolled in ambulatory psychiatric treatment at one of the participating clinics

          -  Receives SSI or SSDI payments

          -  Able to provide written informed consent

          -  Cocaine use within the last 60 days as evidenced by either a positive toxicology
             screen or self-reports

        Exclusion Criteria:

          -  Has a conservator of person

          -  A history of violence towards clinical providers or predatory violence

          -  Suicidal plans or intent; homicidal plans or intent.  Suicidal or homicidal ideation
             will not be exclusion criteria

          -  Physiological dependence on alcohol, illicit opiates or illicit sedatives as
             evidenced by a history of four weeks of daily use of these substances; and either
             tolerance or withdrawal (as defined by DSM IV-TR).  The "standard withdrawal scales"
             referred to in DSM IV-TR will be the CIWA-AR (Sullivan et al., 1989) and the Clinical
             Opiate Withdrawal Scale (Wesson and Ling, 2003), with P.I. review because signs on
             the CIWA-AR such as "aware of sounds around you" may reflect psychiatric illness, not
             withdrawal

          -  Will not be able to complete the twelve months of the study because of anticipated
             incarceration or move

          -  Had been enrolled in the ongoing study

          -  Unable to speak and understand English
      '
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 2',
                 'lastchanged_date' => 'March 31, 2011',
                 'start_date' => 'December 2009',
                 'link' => {
                           'url' => 'http://www.behaviorchange.yale.edu'
                         },
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01327586',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => [
                                'Mentally Ill Chemical Abuse',
                                'Cocaine Abuse',
                                'Cocaine Dependence',
                                'Polysubstance Abuse'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Abstinence-Linked Money Management Multisite
time_frame	Month 0,1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
measure	Proportion of Urine toxicology tests without cocaine
safety_issue	No
intervention_type	Behavioral
arm_group_label	ATM
description	Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
intervention_name	ATM
intervention_type	Behavioral
arm_group_label	Individual Drug Counseling
description	Standard individualized drug counseling, modified from that described by Woody and colleagues
intervention_name	Individual Drug Counseling
Keywords:disability; substance abuse; cocaine abuse; dual diagnosis; representative payee; HIV risk reduction
Lead sponsor: Other; Yale University
Collaborator: NIH; National Institute on Drug Abuse (NIDA)
Intervention MeSH	NOT FOUND
Condition MeSH:Cocaine-Related Disorders; Substance-Related Disorders
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01413035

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => 'China: Food and Drug Administration'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      1. Intervention Details: Biological: umbilical cord/placenta-derived mesenchymal stem cells;
      Drug: 1. Oral Hypoglycemic Drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al.
      2. Insulins.

        1. 1st transplantation: after finishing all required examines according to protocol in Day
           0, umbilical cord/placenta-derived MSCs are transplanted intravenously.

        2. 2nd transplantation: after finishing all required examines in Day 90, umbilical
           cord/placenta-derived-MSCs are transplanted intravenously if the effects of MSC are
           better than that before.

        3. At the same time, patients continue taking the oral hypoglycemic drugs, insulins or the
           combination of the oral hypoglycemic drugs and insulins which the patients have taken
           for controlling the higher blood sugar from Day 0 for 1 year. But the dose of the oral
           hypoglycemic drugs and insulins should be regulated according to the level of blood
           sugar.

      2. Detailed Description:

        1. To evaluate the feasibility and safety of transplantation treatment using umbilical
           cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus
           undergoing the oral hypoglycemic drugs, insulins or the combination of the oral
           hypoglycemic drugs and insulins.

        2. To assess efficacy of transplantation treatment using umbilical cord/placenta-derived
           mesenchymal stem cells in patients with type 2 diabetes mellitus undergoing the oral
           hypoglycemic drugs, insulins or the combination of the oral hypoglycemic drugs and
           insulins.

        3. This study will last 2 to 3 years. Participants will be randomly assigned to receive
           either MSC transplant and the oral hypoglycemic drugs or MSC transplant and insulins or
           MSC transplant and the combination of the oral hypoglycemic drugs and insulins
           (experimental group) or the oral hypoglycemic drugs or insulins or the combination of
           the oral hypoglycemic drugs and insulins (control group). Patients will undergo MSC
           transplant at the start of the study on Day 0 and take the oral hypoglycemic drugs,
           insulins or the combination of the oral hypoglycemic drugs and insulins for 1 year. As
           control, some patients take the oral hypoglycemic drugs, insulins or the combination of
           the oral hypoglycemic drugs and insulins for 1 year. At the same time, the dose of the
           oral hypoglycemic drugs and insulins should be regulated according to the level of
           blood sugar. After 3 months, patients will receive the second MSC transplantation.
           After six and twelve months from the first transplantation, patients will be evaluated.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'December 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '1 year',
                                      'measure' => 'To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus',
                                      'description' => "To assess efficacy of MSC through comparing the change of ITT, Hemoglobin A1c, FBG, PBG, C-peptide levels and T cell subsets with that of baseline.
The change of insulin resistance index(ITT) compared with baseline.
Rate of reducing exogenous insulin requirement compared with baseline.
The change of Fast blood glucose (FBG) and Postmeal blood glucose (PBG) compared with baseline.
A reduction of \x{2265}1% in HbA1c compared with baseline.
The change of C-peptide levels compared with baseline.
The change of T cell subsets compared with baseline.",
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => {
                                   'intervention_type' => 'Biological',
                                   'arm_group_label' => [
                                                        'MSC and the oral hypoglycemic drugs',
                                                        'MSC and insulins',
                                                        'MSC and the combination of drugs and insulins'
                                                      ],
                                   'description' => '1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.',
                                   'intervention_name' => 'MSC'
                                 },
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Insulin',
                                                         'Hypoglycemic Agents'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '3',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => '1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.',
                                  'arm_group_label' => 'MSC and the oral hypoglycemic drugs'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => '1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.',
                                  'arm_group_label' => 'MSC and insulins'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => '1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.',
                                  'arm_group_label' => 'MSC and the combination of drugs and insulins'
                                }
                              ],
                 'overall_official' => {
                                       'affiliation' => 'Department of Hematology of The 2nd Hospital of Shandong University',
                                       'role' => 'Principal Investigator',
                                       'last_name' => 'chengyun zheng, Ph. D'
                                     },
                 'brief_title' => 'Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Type 2 Diabetes',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment',
                 'location' => {
                               'status' => 'Recruiting',
                               'contact' => {
                                            'email' => 'chengyun.zheng@ki.se, kdx2002@126.com',
                                            'phone' => '+86-531-85875635',
                                            'last_name' => 'chengyun zheng, Ph. D'
                                          },
                               'facility' => {
                                             'name' => 'Department of Hematology of the 2nd Hospital of Shandong University',
                                             'address' => {
                                                          'country' => 'China',
                                                          'zip' => '250033',
                                                          'city' => 'Jinan',
                                                          'state' => 'Shandong'
                                                        }
                                           }
                             },
                 'id_info' => {
                              'nct_id' => 'NCT01413035',
                              'org_study_id' => 'diabetes'
                            },
                 'overall_contact' => {
                                      'email' => 'chengyun.zheng@ki.se, kdx2002@126.com',
                                      'phone' => '+86-531-85875635',
                                      'last_name' => 'chengyun zheng, Ph. D'
                                    },
                 'firstreceived_date' => 'August 5, 2011',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'July 2011',
                 'keyword' => [
                              'Diabetes',
                              'Diabetes Medicines: Oral Hypoglycemic Drugs and Insulins.',
                              'Umbilical Cord/placenta-Derived MSC',
                              'Transplantation'
                            ],
                 'source' => 'Shandong University',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Shandong University'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'July 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Safety/Efficacy Assessed Study on Transplantation Therapy Using Human Umbilical Cord/Placenta-derived Mesenchymal Stem Cells for Type 2 Diabetes Mellitus',
                 'enrollment' => {
                                 'content' => '30',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Diabetes Mellitus',
                                                      'Diabetes Mellitus, Type 2'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells
      (MSCs) derived from human umbilical cord/placenta at a dose of 1.0E+6 MSC/kg for type 2
      diabetes.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'China'
                                       },
                 'is_section_801' => 'Yes',
                 'secondary_outcome' => {
                                        'time_frame' => '1 year',
                                        'measure' => 'To evaluate the incidence and severity of adverse events of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus',
                                        'description' => 'To evaluate if there have occured the adverse everts such as fever, allergy, et al. and their severity.',
                                        'safety_issue' => 'Yes'
                                      },
                 'responsible_party' => {
                                        'name_title' => 'Chengyun Zheng',
                                        'organization' => 'Department of Hematology of the 2nd Hospital of Shandong University'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'Accepts Healthy Volunteers',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => "
        Inclusion Criteria:

          -  Free will taking part in the study and ability to provide written informed consent

          -  Type 2 diabetes mellitus (as guideline WHO, 1999)

          -  Age 18-80 years old, Male/Female

          -  19\x{2264}Body mass index (BMI)\x{2264}30\x{338f}/\x{33a1}

          -  Fast blood glucose (FBG)\x{2265}7.0 mmol/L, and HbAc1\x{2265}7\x{ff05}

          -  Intravenous insulin tolerance test\x{ff08}ITT\x{ff09}indicate patient being insulin resistance

          -  Not pregnant or nursing

          -  No moderate or sever organ dysfunction: Ejection fraction>45%; Creatinine <176 mmol/L

          -  No active severe viral or fungus infection

        Exclusion Criteria:

          -  Severe concurrent medical condition (e.g., serious heart disease, lung disease, or
             hematopoietic dysfunction, or liver dysfunction, or kidney dysfunction)

          -  Active infection requiring treatment

          -  Unexplained febrile illness

          -  Known immunosuppressive disease, e.g. HIV infection, or hepatitis B or C infection

          -  Psychiatric condition that would limit informed consent

          -  Patient has enrolled another clinical trial study within last 4 weeks.
      "
                                              },
                                  'maximum_age' => '80 Years',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'August 8, 2011',
                 'phase' => 'Phase 1/Phase 2',
                 'start_date' => 'July 2011',
                 'is_fda_regulated' => 'Yes',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01413035',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => 'Type 2 Diabetes'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Safety/Efficacy Assessed Study on Transplantation Therapy Using Human Umbilical Cord/Placenta-derived Mesenchymal Stem Cells for Type 2 Diabetes Mellitus
time_frame	1 year
measure	To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus
description	To assess efficacy of MSC through comparing the change of ITT, Hemoglobin A1c, FBG, PBG, C-peptide levels and T cell subsets with that of baseline.
The change of insulin resistance index(ITT) compared with baseline.
Rate of reducing exogenous insulin requirement compared with baseline.
The change of Fast blood glucose (FBG) and Postmeal blood glucose (PBG) compared with baseline.
A reduction of â¥1% in HbA1c compared with baseline.
The change of C-peptide levels compared with baseline.
The change of T cell subsets compared with baseline.
safety_issue	No
intervention_type	Biological
arm_group_label	MSC and the oral hypoglycemic drugs
arm_group_label	MSC and insulins
arm_group_label	MSC and the combination of drugs and insulins

description	1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
intervention_name	MSC
Keywords:Diabetes; Diabetes Medicines: Oral Hypoglycemic Drugs and Insulins.; Umbilical Cord/placenta-Derived MSC; Transplantation
Lead sponsor: Other; Shandong University
Intervention MeSH:Insulin; Hypoglycemic Agents
Condition MeSH:Diabetes Mellitus; Diabetes Mellitus, Type 2
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01015352

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => "France: Afssaps - Agence fran\x{e7}aise de s\x{e9}curit\x{e9} sanitaire des produits de sant\x{e9} (Saint-Denis)"
                                   },
                 'detailed_description' => {
                                           'textblock' => "
      Phase II Study of Azacitidine (Vidaza\x{ae}) Combined to Epoetin Beta (NeoRecormon\x{ae}) in IPSS
      Low-risk and Intermediate-1 MDS Patients, Resistant to ESA

      The Primary Endpoint of this study is to determine the major erythroid response rate after 6
      courses, assessed according to IWG 2000 criteria.

      The Secondary Endpoints are to determine the percentage of major HI-E and minor HI-E after 4
      and 6 courses according to IWG 2000, the HI-E IWG 2006 criteria, the duration of erythroid
      response, the red blood cell transfusion independence at 4 and 6 months, the overall
      survival and time to IPSS progression and the toxicity (NCI-CTAE).

      The trial will enroll 98 patients (49 patients per arm)

      Treatment in arm A:

      Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses Dosing of each
      subsequent course will be adapted according to extrahematological toxicity and cytopenias.

      In responders after 6 courses of azacitidine according to IWG 2000 criteria (both minor and
      major erythroid responses of HI-E) 12 identical additional maintenance courses will be
      delivered every 28 days, unless relapse occurs (according to IWG 2000 criteria).

      Treatment in arm B:

      \x{2022} Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses.

      (dosing of each subsequent course will be adapted according to extra hematological toxicity
      and cytopenias) AND

      \x{2022} Epoetin beta : 60000U weekly SQ injections Dosing of epoetin beta will be adapted
      according to current ASH-ASCO guidelines and black box warning of epoetin beta. Epoetin beta
      therapy may therefore be interrupted, in case of response to azacitidine, as soon as a
      hemoglobin level of 12g/dl is achieved on two sequential bimonthly blood count measurements.

      A 40% dose reduction of epoetin beta will be required if:

        -  Hb level rise of 1 g/dl is observed within two weeks

        -  Hb level exceeds 11g/dl

      In responders after 6 courses of azacitidine + epoetin beta, according to IWG 2000 criteria
      (both minor and major erythroid responses of HI-E) 12 identical additional maintenance
      courses of azacitidine will be delivered every 28 days, unless relapse occurs (according to
      IWG 2000 criteria) Epoetin beta will be administered as described above.

      In both arms, each subsequent course will be delivered

        -  In absence of persistent grade >2 non-hematological toxicity

        -  In absence of rehospitalisation for severe bleeding, infection or febrile neutropenia
           and non-hematological toxicity following the previous course

        -  If neutrophil counts are > 1G/l or > 50% of baseline neutrophil counts

        -  If platelets are > 75G/l or > 50% of baseline platelets counts

      In case of persistent cytopenia, blood counts will be at least checked every 2 weeks, and
      the next course delayed until resolution of cytopenia, as defined above.

      In case of persistence of cytopenia beyond day 56 of the preceding course, an new evaluation
      of the disease, using clinical examination, blood and bone marrow examinations +/-
      cytogenetics will be mandatory before eventually pursuing azacitidine at lower dosing
      levels.
    "
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'June 2012',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => 'after 6 courses of treatment in the respective treatment arm',
                                      'measure' => 'To determine the major erythroid response rate after 6 courses, assessed according to IWG 2000 criteria',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => "Vidaza\x{ae}",
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => [
                                                          'Arm A',
                                                          'Arm B'
                                                        ],
                                     'description' => 'Azacitidine 75mg/sqm SQ per day for 5 days every 28 days',
                                     'intervention_name' => 'Azacitidine'
                                   },
                                   {
                                     'other_name' => 'Epoetin beta : 60000U weekly SQ injections',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Arm B',
                                     'description' => "Epoetin beta : 60000U weekly SQ injections
NeoRecormon\x{ae}",
                                     'intervention_name' => 'Epoetin beta'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Azacitidine',
                                                         'Epoetin Alfa'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.',
                                  'arm_group_label' => 'Arm A'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND
Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)
12 additional maintenance courses are planned in responders',
                                  'arm_group_label' => 'Arm B'
                                }
                              ],
                 'overall_official' => [
                                       {
                                         'affiliation' => "Groupe Francophone des My\x{e9}lodysplasies",
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Simone Boehrer, MD'
                                       },
                                       {
                                         'affiliation' => "Groupe Francophone des My\x{e9}lodysplasies",
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Claude Gardin, MD'
                                       }
                                     ],
                 'brief_title' => 'Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Ghandi Damaj, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'damaj.gandhi@chu-amiens.fr',
                                              'phone' => '03 22 45 59 15',
                                              'last_name' => 'Ghandi DAMAJ, MD'
                                            },
                                 'facility' => {
                                               'name' => 'CHU d\'Amiens',
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '80054',
                                                            'city' => 'Amiens'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Mathilde Hunault, MD'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'mahunault@chu-angers.fr',
                                              'phone' => '02 41 35 44 75',
                                              'last_name' => 'Mathilde Hunault, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Angers",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '49033',
                                                            'city' => 'Angers'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Bohrane Slama, MD'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'bslama@ch-avignon.fr',
                                              'phone' => '04 32 75 31 32',
                                              'last_name' => 'Bohrane Slama, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Avignon",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '84000',
                                                            'city' => 'Avignon'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => "Fr\x{e9}d\x{e9}ric Bauduer, MD"
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'fbauduer@chicb.com',
                                              'phone' => '05 59 44 38 41',
                                              'last_name' => "Fr\x{e9}d\x{e9}ric Bauduer, Dr"
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital de la C\x{f4}te Basque",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '64100',
                                                            'city' => 'Bayonne'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Claude Gardin, MD'
                                                   },
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'Simone Boehrer, MD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'claude.gardin@avc.aphp.fr',
                                              'phone' => '01 48 95 70 54',
                                              'last_name' => 'Claude Gardin, MD'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'simone.boehrer@avc.aphp.fr',
                                                     'phone' => '01 48 95 70 07',
                                                     'last_name' => 'Simone Boehrer, MD'
                                                   },
                                 'facility' => {
                                               'name' => 'Hopital Avicenne',
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '93009',
                                                            'city' => 'Bobigny'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Bachra Chouffi, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'b.chouffi@ch-boulogne.fr',
                                              'phone' => '03 21 99 82 02',
                                              'last_name' => 'Bachra Chouffi, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Boulogne Sur Mer",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '62321',
                                                            'city' => 'Boulogne Sur Mer'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => "St\x{e9}phane Cheze, MD"
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'cheze-s@chu-caen.fr',
                                              'phone' => '02 31 27 23 60',
                                              'last_name' => "St\x{e9}phane Cheze, MD"
                                            },
                                 'facility' => {
                                               'name' => "Hopital Cl\x{e9}menceau",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '14033',
                                                            'city' => 'Caen'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Denis Caillot, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'denis.caillot@chu-dijon.fr',
                                              'phone' => '03 80 29 36 45',
                                              'last_name' => 'Denis Caillot, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital le Bocage",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '21034',
                                                            'city' => 'Dijon'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Sylvie Castaigne, PR'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'scastaigne@chu-versailles.fr',
                                              'phone' => '01 39 63 82 96',
                                              'last_name' => 'Sylvie Castaigne, Pr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Versailles",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '78157',
                                                            'city' => 'Le Chesnay'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Christian Rose, PR'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'rose.christian@ghicl.net',
                                              'phone' => '03 20 87 45 32',
                                              'last_name' => 'Christian Rose, Pr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Saint Vincent",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '59020',
                                                            'city' => 'Lille'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Bruno Quesnel, PR'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'bquesnel@chru-lille.fr',
                                              'phone' => '03 20 44 66 40',
                                              'last_name' => 'Bruno Quesnel, Pr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Huriez",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '59037',
                                                            'city' => 'Lille'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Dominique Bordessoule, PR'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'bordessoule.URCH@chu-limoges.fr',
                                              'phone' => '05 55 05 66 42',
                                              'last_name' => 'Dominique Bordessoule, Pr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Limoges",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '87046',
                                                            'city' => 'Limoges'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Eric Wattel, PR'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'wattel@lyon.fnclcc.fr',
                                              'phone' => '04 72 11 74 01',
                                              'last_name' => 'Eric Wattel, Pr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Edouard Herriot",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '69437',
                                                            'city' => 'Lyon'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Norbert Vey, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'veyn@marseille.fnclcc.fr',
                                              'phone' => '04 31 22 36 95',
                                              'last_name' => 'Norbert Vey, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Paoli-Calmettes",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '13273',
                                                            'city' => 'Marseille'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => "Agn\x{e8}s Guerci-Bresler, MD"
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'a.guerci@chu-nancy.fr',
                                              'phone' => '03 83 15 32 81',
                                              'last_name' => "Agn\x{e8}s Guerci-Bresler, Dr"
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Brabois",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '54511',
                                                            'city' => 'Nancy'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Jacques Delaunay, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'jacques.delaunay@chu-nantes.fr',
                                              'phone' => '02 40 08 32 07',
                                              'last_name' => 'Jacques Delaunay, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital H\x{f4}tel Dieu",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '44035',
                                                            'city' => 'Nantes'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Laurence Legros, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'legros.l@chu-nice.fr',
                                              'phone' => '04 92 03 58 44',
                                              'last_name' => 'Laurence Legros, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Archet1",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '06202',
                                                            'city' => 'Nice'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => "Mich\x{e8}le Schoenwald, MD"
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'michele.schoenwald@chr-orleans.fr',
                                              'phone' => '02 38 22 95 52',
                                              'last_name' => "Mich\x{e8}le Schoenwald, Dr"
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital La Source",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '45067',
                                                            'city' => "Orl\x{e9}ans"
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => "Herv\x{e9} Dombret, PR"
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'herve.dombret@sls.aphp.fr',
                                              'phone' => '01 42 49 96 43',
                                              'last_name' => "Herv\x{e9} Dombret, Pr"
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Saint Louis",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '75475',
                                                            'city' => 'Paris'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => "Fran\x{e7}oise Isnard, MD"
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'francoise.isnard@sat.aphp.fr',
                                              'phone' => '01 49 28 26 22',
                                              'last_name' => "Fran\x{e7}oise ISNARD, Dr"
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Saint Antoine",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '75571',
                                                            'city' => 'Paris'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Annalisa Andreoli, MD'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'annalisa.andreoli@1rb.aphp.fr',
                                              'phone' => '01 49 95 83 85',
                                              'last_name' => 'Annalisa Andreoli, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Lariboisi\x{e8}re",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '75475',
                                                            'city' => 'Paris'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => "Fran\x{e7}ois Dreyfus, PR"
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'francois.dreyfus@cch.aphp.fr',
                                              'phone' => '01 58 41 21 20',
                                              'last_name' => "Fran\x{e7}ois Dreyfus, Pr"
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Cochin",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '75679',
                                                            'city' => 'Paris'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Laurence Sanhes, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'laurence.sanhes@ch-perpignan.fr',
                                              'phone' => '04 68 61 64 48',
                                              'last_name' => 'Laurence SANHES, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Mar\x{e9}chal Joffre",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '66046',
                                                            'city' => 'Perpignan'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Lydia Roy, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'l.roy@chu-poitiers.fr',
                                              'phone' => '05 49 44 43 07',
                                              'last_name' => 'Lydia Roy, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Jean-Bernard",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '86021',
                                                            'city' => 'Poitiers'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Chantal Himberlin, MD'
                                                 },
                                 'status' => 'Not yet recruiting',
                                 'contact' => {
                                              'email' => 'chimberlin@chu-reims.fr',
                                              'phone' => '03 26 78 36 44',
                                              'last_name' => 'Chantal Himberlin, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Reims",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '51092',
                                                            'city' => 'Reims'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Aspasia Stamatoullas, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'astamatoullas@rouen.fnclcc.fr',
                                              'phone' => '02 32 08 22 88',
                                              'last_name' => 'Aspasia Stamatoullas, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Henri Becquerel",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '76038',
                                                            'city' => 'Rouen'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Shanti Natajaran-Ame, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'shanti.ame@chru-Strasbourg.fr',
                                              'phone' => '03 88 12 76 70',
                                              'last_name' => 'Shanti Natajaran-Ame, Dr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Hautepierre",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '67098',
                                                            'city' => 'Strasbourg'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Odile Beyne-Rauzy, PR'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'beynerauzy.o@chu-toulouse.fr',
                                              'phone' => '05 61 77 96 77',
                                              'last_name' => 'Odile Beyne-Rauzy, Pr'
                                            },
                                 'facility' => {
                                               'name' => "H\x{f4}pital Purpan",
                                               'address' => {
                                                            'country' => 'France',
                                                            'zip' => '31059',
                                                            'city' => 'Toulouse'
                                                          }
                                             }
                               }
                             ],
                 'id_info' => {
                              'nct_id' => 'NCT01015352',
                              'org_study_id' => 'GFM-Aza-Epo-2008-01'
                            },
                 'overall_contact' => {
                                      'email' => 'simone.boehrer@avc.aphp.fr',
                                      'phone' => '01 48 95 70 07',
                                      'last_name' => 'Simone Boehrer, MD'
                                    },
                 'firstreceived_date' => 'November 17, 2009',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'November 2009',
                 'keyword' => 'Myelodysplastic Syndromes',
                 'source' => 'Groupe Francophone des Myelodysplasies',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Groupe Francophone des Myelodysplasies'
                                               },
                               'collaborator' => [
                                                 {
                                                   'agency_class' => 'Industry',
                                                   'agency' => 'Celgene Corporation'
                                                 },
                                                 {
                                                   'agency_class' => 'Industry',
                                                   'agency' => 'Roche Pharma AG'
                                                 }
                                               ]
                             },
                 'completion_date' => {
                                      'content' => 'June 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => "A Phase II Study of Azacitidine (Vidaza\x{ae}) Combined to Epoetin Beta (NeoRecormon\x{ae}) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA",
                 'enrollment' => {
                                 'content' => '98',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Myelodysplastic Syndromes',
                                                      'Preleukemia'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The study is aimed to treat low-risk MDS patients,who are dependent on red-blood cell
      transfusion due to disease-related anemia, and who have a proven resistance towards
      treatment with erythropoetin-stimulating agents (ESA). The study randomizes patients to
      receive a treatment with the demethylating agent 5-azacytidine alone or in combination with
      an ESA. The study thus evaluates, if efficacy of 5-azacytidine, notably on the red-blood
      cell transfusion-dependence is comparable/inferior to a combination treatment with
      azacitidine and an ESA (that is if 5-azacytidine can overcome the resistance towards ESA).
      Being a phase II study, the study assesses, duration of erythroid response, overall survival
      and time to progression as well as toxicity.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'France'
                                       },
                 'secondary_outcome' => {
                                        'time_frame' => 'after 4 and 6 months of treatment until the end of study',
                                        'measure' => 'Degree and duration of erythroid response (including red blood cell transfusion independence),overall survival and time to progression and toxicity',
                                        'safety_issue' => 'Yes'
                                      },
                 'responsible_party' => {
                                        'name_title' => 'Simone BOEHRER',
                                        'organization' => 'Groupe Francophone des Myelodysplasies'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

        MDS defined as

          -  RCMD, RA with or without ring sideroblasts

          -  RAEB 1, or CMML 1, if WBC < 13 G /l according to the WHO classification

          -  with a low or int-1 IPSS score AND

          -  primary or secondary resistance to epoetin alpha/ beta (> 60000 U/w) or darbepoetin
             (> 250ug/w), administered for at least 12 weeks

          -  requirement of RBC transfusions > 4 U in the previous 8 weeks

          -  Aged 18 years or more

          -  Adequate contraception, if relevant

          -  Negative pregnancy test if relevant

          -  Written Informed consent

          -  Ability to participate to a clinical trial and adhere to study procedures

          -  Health insurance

        Exclusion Criteria:

          -  Therapy-related MDS (after chemo- or radiotherapy for a previous neoplasm or immune
             disorder)

          -  Patients with a planned allogeneic bone marrow transplantation

          -  Creatininemia >1.5 upper normal value or estimated Ccr less than 30ml/mn

          -  ALAT and  ASAT >2.5 upper normal value

          -  Bilirubin >2N, except unconjugated  hyperbilirubinemia due to MDS-related
             dyserythropoiesis

          -  Heart failure  NYHA > II

          -  Known allergy to mannitol

          -  Other tumor, unstable for the last three years, except in situ uterine carcinoma or
             basal skin tumor

          -  ECOG > 2

          -  Life expectancy less than 3 months
      '
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'November 17, 2009',
                 'phase' => 'Phase 2',
                 'start_date' => 'February 2009',
                 'link' => {
                           'url' => 'http://www.gfmgroup.org',
                           'description' => '(Website of the french group of MDS)'
                         },
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01015352',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'overall_contact_backup' => {
                                             'email' => 'claude.gardin@avc.aphp.fr',
                                             'phone' => '01 48 95 70 54',
                                             'last_name' => 'Claude Gardin, MD'
                                           },
                 'condition' => 'Myelodysplastic Syndromes'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA
time_frame	after 6 courses of treatment in the respective treatment arm
measure	To determine the major erythroid response rate after 6 courses, assessed according to IWG 2000 criteria
safety_issue	No
other_name	Vidaza®
intervention_type	Drug
arm_group_label	Arm A
arm_group_label	Arm B

description	Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
intervention_name	Azacitidine
other_name	Epoetin beta : 60000U weekly SQ injections
intervention_type	Drug
arm_group_label	Arm B
description	Epoetin beta : 60000U weekly SQ injections
NeoRecormon®
intervention_name	Epoetin beta
Keyword:Myelodysplastic Syndromes
Lead sponsor: Other; Groupe Francophone des Myelodysplasies
Collaborator: Industry; Celgene Corporation
Collaborator: Industry; Roche Pharma AG
Intervention MeSH:Azacitidine; Epoetin Alfa
Condition MeSH:Myelodysplastic Syndromes; Preleukemia
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01432080

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'No',
                                     'authority' => [
                                                    'Canada: Ethics Review Committee',
                                                    'Canada: Health Canada'
                                                  ]
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'December 2012',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => '6 months following diagnosis of the viral respiratory tract infection',
                                      'measure' => 'Cumulative incidence of new chronic lung disease',
                                      'description' => 'The incidence rate of new non-infectious pulmonary complications within the 6 month follow-up period will be calculated. Non-infectious pulmonary complications include new airflow obstruction, new restrictive lung disease, and new mixed obstruction/restriction as measured by spirometry at study enrolment, 2 and 8 weeks following viral infection, and by full pulmonary function tests at 3 and 6 weeks following viral infection.',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => [
                                                     'Deltasone',
                                                     'Steroids'
                                                   ],
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'SAMS',
                                     'description' => 'Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.',
                                     'intervention_name' => 'Prednisone'
                                   },
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'SAMS',
                                     'description' => 'Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months',
                                     'intervention_name' => 'Azithromycin'
                                   },
                                   {
                                     'other_name' => 'Singulair',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'SAMS',
                                     'description' => 'Montelukast 10 mg PO qhs for 3 months',
                                     'intervention_name' => 'Montelukast'
                                   },
                                   {
                                     'other_name' => [
                                                     'Budesonide',
                                                     'Formoterol'
                                                   ],
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'SAMS',
                                     'description' => 'Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months',
                                     'intervention_name' => 'Symbicort'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Prednisone',
                                                         'Montelukast',
                                                         'Azithromycin',
                                                         'Symbicort'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'No Intervention',
                                  'description' => 'Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.',
                                  'arm_group_label' => 'Standard of Care'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).',
                                  'arm_group_label' => 'SAMS'
                                }
                              ],
                 'overall_official' => [
                                       {
                                         'affiliation' => 'Maisonneuve-Rosemont Hospital',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Elizabeth F Krakow, MD,CM, FRCPC'
                                       },
                                       {
                                         'affiliation' => 'Maisonneuve-Rosemont Hospital',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Sandra Cohen, MD, FRCPC'
                                       }
                                     ],
                 'brief_title' => 'Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention',
                 'location' => {
                               'investigator' => [
                                                 {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Elizabeth F Krakow, MD,CM, FRCPC'
                                                 },
                                                 {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Sandra Cohen, MD, FRCPC'
                                                 }
                                               ],
                               'status' => 'Recruiting',
                               'contact' => {
                                            'email' => 'johanne_blais.hmr@ssss.gouv.qc.ca',
                                            'phone_ext' => '3295',
                                            'phone' => '(514) 252-3400',
                                            'last_name' => 'Johanne Blais'
                                          },
                               'contact_backup' => {
                                                   'email' => 'sandra.cohen@umontreal.ca',
                                                   'phone' => '(514) 252-3404',
                                                   'last_name' => 'Sandra Cohen, MD, FRCPC'
                                                 },
                               'facility' => {
                                             'name' => "Maisonneuve-Rosemont Hospital (H\x{f4}pital Maisonneuve-Rosemont)",
                                             'address' => {
                                                          'country' => 'Canada',
                                                          'zip' => 'H1T 2M4',
                                                          'city' => 'Montreal',
                                                          'state' => 'Quebec'
                                                        }
                                           }
                             },
                 'id_info' => {
                              'nct_id' => 'NCT01432080',
                              'org_study_id' => 'HMR1102'
                            },
                 'firstreceived_date' => 'September 8, 2011',
                 'overall_contact' => {
                                      'email' => 'johanne_blais.hmr@ssss.gouv.qc.ca',
                                      'phone_ext' => '3295',
                                      'phone' => '(514) 252-3400',
                                      'last_name' => 'Johanne Blais'
                                    },
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'January 2012',
                 'source' => 'Maisonneuve-Rosemont Hospital',
                 'keyword' => [
                              'Pulmonary disease, chronic obstructive',
                              'Viral respiratory tract infections',
                              'Respiratory syncytial viruses',
                              'Influenza virus A',
                              'Influenza virus B',
                              'Transplantation, Allogeneic'
                            ],
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Maisonneuve-Rosemont Hospital'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'The Canadian Blood and Marrow Transplant Group'
                                               }
                             },
                 'official_title' => 'Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study',
                 'enrollment' => {
                                 'content' => '70',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => [
                                                      'Bronchiolitis',
                                                      'Bronchiolitis Obliterans',
                                                      'Lung Diseases',
                                                      'Pneumonia',
                                                      'Respiratory Tract Infections',
                                                      'Lung Diseases, Interstitial',
                                                      'Cryptogenic Organizing Pneumonia'
                                                    ]
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      For many patients with blood cancers, stem cell transplantation from a family member or from
      an unrelated donor remains the only potentially curative option. Unfortunately, up to 40% of
      patients develop chronic lung disease after the transplant, which substantially increases
      the risk of death in the long-term.  Currently, patients with transplant-related lung
      disease are treated with some combination of steroids and other immunosuppressant drugs, but
      only about 1 out of 5 improve.

      The importance of our study is that the investigators aim to prevent the development of
      transplant-related chronic lung disease in the first place. Because a strong risk factor for
      such chronic lung disease is a prior viral respiratory tract infection, the investigators
      think there is a window of opportunity to intervene. As soon as "cold and flu" symptoms
      start, the investigators will treat patients with a combination of drugs aimed at
      eliminating damaging immune responses triggered by the virus. In the absence of such
      treatment, the investigators believe these lung-damaging immune responses would persist even
      after the virus disappears. Our hope is that preventive treatment might avoid the
      development of chronic lung disease, and this would substantially increase long-term
      survival in our transplant patients.

      This is a pilot study. Once feasibility is established, the investigators will seek to
      expand this study into a definitive clinical trial.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'Canada'
                                       },
                 'is_section_801' => 'Yes',
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => '6 months following the diagnosis of viral respiratory tract infection',
                                          'measure' => 'Prevalence of non-infectious pulmonary complications',
                                          'description' => 'Non-infectious pulmonary complications (NIPCs) include airflow obstruction, restrictive lung disease, and mixed obstruction/restriction as determined by pulmonary function tests. The prevalence of NIPCs will be determined among subjects surviving to 6 months post viral respiratory tract infection.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '6 months post viral respiratory tract infection',
                                          'measure' => 'Long-term functional impairment as defined by need for supplemental oxygen',
                                          'description' => 'The percentage of subjects needing at least 1 month of supplemental oxygen on most days per week, not counting the period of symptomatic viral respiratory tract infection, will be determined in both arms.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '6 months post viral respiratory tract infection',
                                          'measure' => 'Patient-perceived long-term functional impairment',
                                          'description' => 'A FACT-BMT questionnaire will be administered at baseline and again to subjects surviving 6 months post respiratory tract infection to measure patient-perceived functional impairment.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Every 2 weeks until virus is no longer detectable',
                                          'measure' => 'Time to clearance of viral infection',
                                          'description' => 'Subjects in whom a respiratory virus is detected will undergo repeat testing every 2 weeks until the virus is no longer detectable. This is an exploratory analysis. The natural history of many of these community-acquired viruses in the transplant population is not known.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '21 days after enrolment',
                                          'measure' => 'Incidence of progression to respiratory failure',
                                          'description' => 'This endpoint includes admission to hospital because of documented desaturation, need for supplemental oxygen, and need for mechanical ventilation.',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => 'Within 21 days after enrolment',
                                          'measure' => 'Incidence of bacterial or fungal superinfection',
                                          'description' => 'The incidence of secondary bacterial and fungal pneumonias will be compared in the two arms, to verify that the added immunosuppression does not contribute to further infectious complications.',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => 'Within 6 months after enrolment',
                                          'measure' => 'Incidence of various other infectious complications',
                                          'description' => 'The incidence of various other infectious complications, specifically including but not limited to CMV reactivations and CMV disease, zoster, and septicemia will be monitored in both arms.',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => '3 months post enrolment',
                                          'measure' => 'Overall survival from date of viral respiratory tract infection',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '6 months post enrolment',
                                          'measure' => 'Overall survival from date of viral respiratory tract infection',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '6 months post enrolment',
                                          'measure' => 'Overall survival from date of transplant to end of study follow-up',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '1 year post-transplant',
                                          'measure' => 'Overall survival at 1 year post-transplant',
                                          'description' => 'This measure will be applied to the group overall and also analyzed according to subgroups of patients presenting viral respiratory tract infections within 30 days of transplant, 31-100 days of transplant, and 101-365 days of transplant.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '6 months post enrolment',
                                          'measure' => 'Cumulative incidence of death attributable to transplant associated lung disease',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '6 months post enrolment',
                                          'measure' => 'Cumulative incidence of death from other causes',
                                          'safety_issue' => 'No'
                                        }
                                      ],
                 'responsible_party' => {
                                        'investigator_full_name' => 'Elizabeth Krakow',
                                        'investigator_affiliation' => 'Maisonneuve-Rosemont Hospital',
                                        'responsible_party_type' => 'Principal Investigator',
                                        'investigator_title' => 'Fellow in Hematopoietic Cell Transplantation'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  Allogeneic transplant within the prior 1 year

          -  Age greater than or equal to 18 years

          -  Capable of informed consent

          -  Neutrophil engraftment has occurred

          -  This is the first clinically-recognized episode of viral respiratory tract infection
             after transplant

        Exclusion Criteria:

          -  Proof or high suspicion for bacterial, fungal or any non-viral microorganism causing
             pneumonia

          -  CMV, VZV or HSV pneumonia

          -  Prior diagnosis of a chronic transplant-related non-infectious pulmonary complication
             (ex: BO, COP)

          -  Treating physician believes the risk of systemic steroids is too great

          -  Currently receiving prednisone at or greater than 0.25 mg/kg/day or the equivalent
             dose of another steroid

          -  Currently receiving pentostatin

          -  Mycophenolate  initiated de novo or increased within the past 4 weeks

          -  Use of inhaled corticosteroids within the past 2 weeks for at least 1 week

          -  Haploidentical or T-cell depleted graft

          -  Lack of pre-transplant pulmonary function tests

          -  Evidence of a prior symptomatic viral respiratory tract infection following
             transplant, whether treated or not

          -  Allergy or adverse reaction to any of the study drugs

          -  Relapse or progression of the underlying malignancy

          -  Palliative care
      '
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'phase' => 'Phase 2',
                 'lastchanged_date' => 'January 8, 2012',
                 'start_date' => 'September 2011',
                 'link' => {
                           'url' => 'http://www.sct-hmr.org/en/',
                           'description' => 'Maisonneuve-Rosemont Hospital\'s Stem Cell Transplant Program'
                         },
                 'is_fda_regulated' => 'Yes',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01432080',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => [
                                'Respiratory Tract Infections',
                                'Bronchiolitis Obliterans',
                                'Cryptogenic Organizing Pneumonia',
                                'Lung Diseases, Interstitial'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study
time_frame	6 months following diagnosis of the viral respiratory tract infection
measure	Cumulative incidence of new chronic lung disease
description	The incidence rate of new non-infectious pulmonary complications within the 6 month follow-up period will be calculated. Non-infectious pulmonary complications include new airflow obstruction, new restrictive lung disease, and new mixed obstruction/restriction as measured by spirometry at study enrolment, 2 and 8 weeks following viral infection, and by full pulmonary function tests at 3 and 6 weeks following viral infection.
safety_issue	No
other_name	Deltasone
other_name	Steroids

intervention_type	Drug
arm_group_label	SAMS
description	Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
intervention_name	Prednisone
intervention_type	Drug
arm_group_label	SAMS
description	Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
intervention_name	Azithromycin
other_name	Singulair
intervention_type	Drug
arm_group_label	SAMS
description	Montelukast 10 mg PO qhs for 3 months
intervention_name	Montelukast
other_name	Budesonide
other_name	Formoterol

intervention_type	Drug
arm_group_label	SAMS
description	Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
intervention_name	Symbicort
Keywords:Pulmonary disease, chronic obstructive; Viral respiratory tract infections; Respiratory syncytial viruses; Influenza virus A; Influenza virus B; Transplantation, Allogeneic
Lead sponsor: Other; Maisonneuve-Rosemont Hospital
Collaborator: Other; The Canadian Blood and Marrow Transplant Group
Intervention MeSH:Prednisone; Montelukast; Azithromycin; Symbicort
Condition MeSH:Bronchiolitis; Bronchiolitis Obliterans; Lung Diseases; Pneumonia; Respiratory Tract Infections; Lung Diseases, Interstitial; Cryptogenic Organizing Pneumonia
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01058395

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => 'United States: Food and Drug Administration'
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      The purpose of this preliminary study is to test the hypothesis that administration of
      minocycline to humans with moderate and severe TBI is both safe and feasible in the acute
      post-injury setting, and to characterize its disposition and effects on biomarkers of
      traumatic CNS injury in a Phase IIa trial. The data collected will serve as the basis for a
      larger Phase IIb clinical trial in a randomized placebo-controlled parallel group design, to
      investigate further its potential safety and efficacy as a therapeutic agent for severe
      human TBI.

      Tetracycline derivatives, including doxycycline and minocycline, have been shown to be
      neuroprotective when given after traumatic brain injury (TBI) and ischemia in rodents.  In
      particular, reduced lesion volume and improved neurological outcome have been demonstrated
      following minocycline treatment of TBI. The proposed mechanism for these observations is
      multifactorial, and includes inhibition of microglial activation, caspase-mediated
      apoptosis, and the excitotoxic N-methyl-D-aspartic acid (NMDA) pathway.  Because comparable
      inflammatory, excitotoxic and apoptotic pathways have also been implicated in human TBI, we
      hypothesize that administration of minocycline will confer neuroprotection after moderate to
      severe TBI in that milieu as well, with the potential for significant clinical benefit.
      Minocycline is highly lipophilic, and thus penetrates the human central nervous system
      (CNS).  In addition, it has been shown to be safe when used in non-traumatic human
      neurological disorders.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'September 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => [
                                      {
                                        'time_frame' => '3 months',
                                        'measure' => 'Disability Rating Scale',
                                        'safety_issue' => 'Yes'
                                      },
                                      {
                                        'time_frame' => '7 days',
                                        'measure' => 'Drug levels, toxicity.',
                                        'safety_issue' => 'Yes'
                                      }
                                    ],
                 'intervention' => {
                                   'intervention_type' => 'Drug',
                                   'arm_group_label' => [
                                                        '800 mg loading followed by 200 mg Q12',
                                                        '800 mg loading followed by 400 mg Q12'
                                                      ],
                                   'description' => 'Minocycline will be delivered in an open-label randomized study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.',
                                   'intervention_name' => 'Minocycline'
                                 },
                 'intervention_browse' => {
                                          'mesh_term' => 'Minocycline'
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '2',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Physiologic data will be collected before, during and after study drug administration to monitor for drug effects and toxicity on 7 patients.  Specifically, patients will be monitored for development of gastrointestinal irritation, diarrhea, and phototoxicity by history and physical examination.  Hepatotoxicity and super-infections including pseudomembranous colitis will be monitored by serum studies of liver enzymes and white-blood cell counts along with appropriate microbiologic cultures.',
                                  'arm_group_label' => '800 mg loading followed by 200 mg Q12'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Physiologic data will be collected before, during and after study drug administration to monitor for drug effects and toxicity on 7 patients. Specifically, patients will be monitored for development of gastrointestinal irritation, diarrhea, and phototoxicity by history and physical examination. Hepatotoxicity and super-infections including pseudomembranous colitis will be monitored by serum studies of liver enzymes and white-blood cell counts along with appropriate microbiologic cultures.',
                                  'arm_group_label' => '800 mg loading followed by 400 mg Q12'
                                }
                              ],
                 'overall_official' => [
                                       {
                                         'affiliation' => 'Wayne State University',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Jay M Meythaler, MD'
                                       },
                                       {
                                         'affiliation' => 'Wayne State University, Detroit Receiving Hospital',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Robert Welch, MD'
                                       },
                                       {
                                         'affiliation' => 'Wayne State University Dept. PM&R Oakwood',
                                         'role' => 'Study Director',
                                         'last_name' => 'Kristina Freese, PA'
                                       },
                                       {
                                         'affiliation' => 'Oakwood Hospital Dearborn, Trauma Surgery Director',
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'John Fath, MD'
                                       }
                                     ],
                 'brief_title' => 'Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)',
                 'study_design' => 'Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'investigator' => [
                                                   {
                                                     'role' => 'Principal Investigator',
                                                     'last_name' => 'John Fath, MD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Aisha Violette, MD'
                                                   },
                                                   {
                                                     'role' => 'Sub-Investigator',
                                                     'last_name' => 'Alan Brockhurst, MD'
                                                   }
                                                 ],
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'John.Fath@Oakwood.org',
                                              'phone' => '313-982-5440',
                                              'last_name' => 'John Fath, MD'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'Aisha.Violette@Oakwood.org',
                                                     'phone' => '3139825440',
                                                     'last_name' => 'Aisha Violette, MD'
                                                   },
                                 'facility' => {
                                               'name' => 'Oakwood Hospital',
                                               'address' => {
                                                            'country' => 'United States',
                                                            'zip' => '48124',
                                                            'city' => 'Dearborn',
                                                            'state' => 'Michigan'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Sub-Investigator',
                                                   'last_name' => 'Coplin William, MD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'email' => 'rwelch@med.wayne.edu',
                                              'phone' => '313-993-2534',
                                              'last_name' => 'Robert Welch, MD'
                                            },
                                 'contact_backup' => {
                                                     'email' => 'jmeythal@med.wayne.edu',
                                                     'phone' => '313-438-7373',
                                                     'last_name' => 'Jay M Meythaler, MD'
                                                   },
                                 'facility' => {
                                               'name' => 'Detroit Receiving Hospital',
                                               'address' => {
                                                            'country' => 'United States',
                                                            'zip' => '48201',
                                                            'city' => 'Detroit',
                                                            'state' => 'Michigan'
                                                          }
                                             }
                               }
                             ],
                 'acronym' => 'TBI',
                 'id_info' => {
                              'secondary_id' => 'IND# 104298',
                              'nct_id' => 'NCT01058395',
                              'org_study_id' => '#H133A080044 -01'
                            },
                 'overall_contact' => {
                                      'email' => 'jmeythal@med.wayne.edu',
                                      'phone' => '313-438-7373',
                                      'last_name' => 'Jay M Meythaler, MD'
                                    },
                 'firstreceived_date' => 'January 19, 2010',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'January 2012',
                 'keyword' => [
                              'Traumatic Brain Injury',
                              'Minocycline',
                              'Outcome'
                            ],
                 'source' => 'Wayne State University',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Wayne State University'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'January 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans',
                 'enrollment' => {
                                 'content' => '14',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Brain Injuries'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The purpose of this study is:

        1. To assess the safety and feasibility of minocycline administration after TBI in a dose
           escalation study at two different doses over 7 days.

        2. To assess the pharmacokinetic characteristics of two different dosing regimens of
           minocycline in TBI patients, the effect on biochemical markers of neuroprotective
           mechanisms, and effect on neurobehavioral and functional outcome.

        3. To begin initial assessment of the efficacy of minocycline as a therapeutic agent for
           severe human TBI.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'is_section_801' => 'Yes',
                 'secondary_outcome' => {
                                        'time_frame' => '7 days, 3 months',
                                        'measure' => 'Liver enzymes and white-blood cell counts along with appropriate microbiologic cultures, Disability Rating Scale (DRS), Symbol Digit Modalities Test (SDMT), California Verbal Learning Test - 2nd Edition, Trails B, and SF-12',
                                        'safety_issue' => 'Yes'
                                      },
                 'responsible_party' => {
                                        'investigator_full_name' => 'Jay M Meythaler',
                                        'investigator_affiliation' => 'Wayne State University',
                                        'responsible_party_type' => 'Principal Investigator',
                                        'investigator_title' => 'MD'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          -  Male , 18 to 75 years of age, irrespective of race;

          -  Ability to provide written informed consent or have legal representative provide
             written informed consent;

          -  Must be enrolled in the study within 6 of injury and meet the following criteria:

               -  GCS score of 12 or less within the first 4 hours of injury;

               -  Evidence of neurological injury on computer tomography (CT) of the head;

               -  No known allergy to minocycline or other contraindication to receiving this
                  medication.

          -  Presence of central venous catheter;

          -  Participants must not have a known life-threatening disease prior to the brain
             injury:  However, individuals with a stable medical illness in the opinion of the
             investigator may be allowed to enter the study;

          -  Participants are not to be on any other interventional studies aimed at enhancing
             neurorecovery;

          -  Participants are not to be receiving immunosuppressant agents prior to study
             enrollment.

        Exclusion Criteria:

          -  Participant is a female;

          -  Participants, guardians or legal representatives who are unwilling to cooperate with
             the investigation;

          -  Participants who have received any other investigational drug within 30 days of
             injury;

          -  Participants known to have severe ischemic heart disease or congestive heart failure,
             myocardial infarction, spinal cord injury with ongoing deficits, cancer or any other
             severe illnesses that in the opinion of the investigator would affect the assessment
             of therapy;

          -  Participants with an ongoing neurological disease/condition or previous stroke or
             TBI;

          -  Known clinical sequelae of spinal cord injury;

          -  Massive cerebral hemisphere or brainstem hematoma, incompatible with survival;

          -  History of major depression requiring the use of the medication at the time of
             injury;

          -  Multiple trauma which in the opinion of the investigator, would jeopardize the
             assessment of therapy;

          -  Participants who have any type of penetrating head injury;

          -  Participants receiving chronic steroid treatment;

          -  Participants receiving isotretinoin;

          -  Lack of informed consent signed by either the participant or the subject\'s legal
             representative;

          -  Prior TBI, brain tumor, cerebral vascular event, or other stable brain insult;

          -  Prior history of Pseudotumor cerebri ;

          -  Patients with known renal failure, BUN/ Creatinine 20:1; creatinine > 2 mg/dl;

          -  Patients with known hepatic failure, AST/ALT> 3 x Upper Limit of  Normal;

          -  Thrombocytopenia < 75,000/mm;

          -  Known allergy or sensitivity to any of the tetracyclines or any of the components of
             the product formulation.
      '
                                              },
                                  'maximum_age' => '75 Years',
                                  'gender' => 'Male'
                                },
                 'lastchanged_date' => 'January 1, 2012',
                 'phase' => 'Phase 1/Phase 2',
                 'start_date' => 'February 2010',
                 'is_fda_regulated' => 'Yes',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01058395',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'overall_contact_backup' => {
                                             'email' => 'drhoney@wayne.edu',
                                             'last_name' => 'Denise M Rhoney, PhD'
                                           },
                 'condition' => 'Traumatic Brain Injury'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Phase I Study of Minocycline in a Dose Escalation Study as a Safe, Efficacious Therapeutic Intervention for Moderate and Severe TBI in Humans
time_frame	3 months
measure	Disability Rating Scale
safety_issue	Yes
time_frame	7 days
measure	Drug levels, toxicity.
safety_issue	Yes
intervention_type	Drug
arm_group_label	800 mg loading followed by 200 mg Q12
arm_group_label	800 mg loading followed by 400 mg Q12

description	Minocycline will be delivered in an open-label randomized study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
intervention_name	Minocycline
Keywords:Traumatic Brain Injury; Minocycline; Outcome
Lead sponsor: Other; Wayne State University
Intervention MeSH:Minocycline
Condition MeSH:Brain Injuries
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01385553

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => 'United States: Institutional Review Board'
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'December 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => [
                                      {
                                        'time_frame' => 'Baseline (Start of Tx), 4 month follow-up, 7 month follow-up',
                                        'measure' => 'Decrease in Verbal and Physical Aggression',
                                        'description' => 'Conflict Tactics Scale and the TimeLine Follow-back calendar interview',
                                        'safety_issue' => 'Yes'
                                      },
                                      {
                                        'time_frame' => 'weekly  for months 1-4, 7 month followup',
                                        'measure' => 'Decrease in Substance Abuse',
                                        'description' => 'urinalysis results and self report',
                                        'safety_issue' => 'Yes'
                                      },
                                      {
                                        'time_frame' => 'baseline, 4  month, 7 month follow-up',
                                        'measure' => 'Decrease in Negative Parenting Behavior',
                                        'description' => 'IOWA, Adult child relationship questionnaire, Parental Acceptance Rejection Questionnaire',
                                        'safety_issue' => 'Yes'
                                      }
                                    ],
                 'intervention' => [
                                   {
                                     'other_name' => 'Integrated Father Treatment for Domestic Violence',
                                     'intervention_type' => 'Behavioral',
                                     'arm_group_label' => 'Fathers for Change',
                                     'description' => 'FATHERS FOR CHANGE  comprises 16, 60 minute sessions of  treatment utilizing components of three evidence based practices:  SADV-CBT, Behavioral Couple Therapy and Child-Parent Psychotherapy.  The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and  the impact of violence on children,  4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.',
                                     'intervention_name' => 'Fathers for Change'
                                   },
                                   {
                                     'other_name' => 'IDC',
                                     'intervention_type' => 'Behavioral',
                                     'arm_group_label' => 'Individual Drug Counseling',
                                     'description' => 'Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient\'s ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.',
                                     'intervention_name' => 'Individual Drug Counseling'
                                   }
                                 ],
                 'has_expanded_access' => 'No',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'arm_group_label' => 'Individual Drug Counseling'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'arm_group_label' => 'Fathers for Change'
                                }
                              ],
                 'number_of_arms' => '2',
                 'overall_official' => {
                                       'affiliation' => 'Yale University',
                                       'role' => 'Principal Investigator',
                                       'last_name' => 'Carla S Stover, Ph.D.'
                                     },
                 'brief_title' => 'Fathers for Change for Men With Co-occurring Domestic Violence and Substance Abuse',
                 'study_design' => 'Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment',
                 'location' => {
                               'investigator' => {
                                                 'role' => 'Principal Investigator',
                                                 'last_name' => 'Carla Stover, Ph.D.'
                                               },
                               'status' => 'Recruiting',
                               'contact' => {
                                            'email' => 'carla.stover@yale.edu',
                                            'phone' => '203-785-2048',
                                            'last_name' => 'Carla Stover, Ph.D.'
                                          },
                               'contact_backup' => {
                                                   'email' => 'caroline.easton@yale.edu',
                                                   'phone' => '203-974-5730',
                                                   'last_name' => 'Caroline Easton, Ph.D.'
                                                 },
                               'facility' => {
                                             'name' => 'Yale University',
                                             'address' => {
                                                          'country' => 'United States',
                                                          'zip' => '06510',
                                                          'city' => 'New Haven',
                                                          'state' => 'Connecticut'
                                                        }
                                           }
                             },
                 'id_info' => {
                              'secondary_id' => '1K23DA023334-01A2',
                              'nct_id' => 'NCT01385553',
                              'org_study_id' => '1003006541'
                            },
                 'firstreceived_date' => 'June 14, 2011',
                 'overall_contact' => {
                                      'email' => 'carla.stover@yale.edu',
                                      'phone' => '203-785-2048',
                                      'last_name' => 'Carla S Stover, Ph.D.'
                                    },
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'June 2011',
                 'source' => 'Yale University',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Yale University'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'NIH',
                                                 'agency' => 'National Institute on Drug Abuse (NIDA)'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'June 2014',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Randomized Trial of Fathers for Change: An Intervention for Fathers With Co-Occuring Domestic Violence and Substance Abuse',
                 'enrollment' => {
                                 'content' => '40',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Substance-Related Disorders'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      Social service systems rarely acknowledge the status of men as fathers in the
      conceptualization and delivery of treatment for substance abuse or domestic violence.
      Although there has been extensive focus on the treatment of mothers who abuse substances,
      are victims of intimate partner violence (IPV) (defined as physical aggression and/or
      psychological abuse and control at the hands of an intimate partner), or maltreat their
      children there has been little consideration of the need for interventions for fathers with
      histories of co-morbid IPV and substance abuse.  It is estimated that between 10 and 17.8
      million children are witness to violence in their homes each year.  National and regional
      samples indicate 50-70% of families impacted by IPV and the typically co-occurring substance
      abuse have children under the age of seven.  Large percentages of these men continue to live
      with or have consistent contact with their young children despite aggression and substance
      use.

      Court mandated treatments for perpetrators of domestic violence have become the norm,
      however the efficacy of these treatments is questionable and most do not speak to the
      broader needs of batterers and their families.  How batterer\'s treatments might impact
      parenting and father-child relationships and the psychosocial functioning of children is
      vastly understudied and not currently understood.  Since batterer treatments are court
      mandated and require tremendous financial and community resources, the efficacy of these
      interventions in stopping the cycle of domestic violence and improving the health and
      well-being of the batterer, his partner and children is crucial.  There are currently NO
      evidence-based treatments that address co-morbid substance abuse and domestic violence
      perpetration with emphasis on paternal parenting and the father-child relationship.
      Consequently, the proposed psychotherapy development project will develop and evaluate the
      potential efficacy of a novel, relational parent intervention for fathers with co-morbid
      substance abuse and IPV who have young children.  The goals of this intervention are to
      decrease aggression and substance abuse by increasing focus on fathering and an improved
      father-child relationship.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'United States'
                                       },
                 'responsible_party' => {
                                        'name_title' => 'Carla Smith Stover',
                                        'organization' => 'Yale University School of Medicine Child Study Center'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Inclusion Criteria:

          1. meet current DSM-IV criteria for substance abuse and who have used a substance within
             the 60 days prior to screening;

          2. have a police reported incident of IPV (pushing, slapping, kicking) within 6 months
             of referral;

          3. have at least one biological child under the age of 7 with whom they reside or have
             at least weekly visitation.

        Exclusion Criteria:

          1. Have histories of severe physical violence (e.g. choking, causing hospitalization);

          2. Men who have an active NO CONTACT protective order pertaining to their partner or
             child;

          3. Men whose female partners indicate that they do not want the child to participate;

          4. If the female partner indicates that she believes her child is afraid of his/her
             father and will NOT want to participate;

          5. Men who are currently in withdrawal from substances and in need of detoxification;

          6. Have cognitive impairment or a lifetime history of any psychotic or bipolar disorder;
             or

          7. Are currently suicidal or homicidal.
      '
                                              },
                                  'maximum_age' => '60 Years',
                                  'gender' => 'Male'
                                },
                 'reference' => {
                                'PMID' => '17364418',
                                'citation' => 'Easton CJ, Mandel DL, Hunkele KA, Nich C, Rounsaville BJ, Carroll KM. A cognitive behavioral therapy for alcohol-dependent domestic violence offenders: an integrated substance abuse-domestic violence treatment approach (SADV). Am J Addict. 2007 Jan-Feb;16(1):24-31.'
                              },
                 'phase' => 'Phase 1/Phase 2',
                 'lastchanged_date' => 'June 29, 2011',
                 'start_date' => 'June 2011',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01385553',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => [
                                'Domestic Violence',
                                'Substance Abuse',
                                'Parenting'
                              ]
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Randomized Trial of Fathers for Change: An Intervention for Fathers With Co-Occuring Domestic Violence and Substance Abuse
time_frame	Baseline (Start of Tx), 4 month follow-up, 7 month follow-up
measure	Decrease in Verbal and Physical Aggression
description	Conflict Tactics Scale and the TimeLine Follow-back calendar interview
safety_issue	Yes
time_frame	weekly  for months 1-4, 7 month followup
measure	Decrease in Substance Abuse
description	urinalysis results and self report
safety_issue	Yes
time_frame	baseline, 4  month, 7 month follow-up
measure	Decrease in Negative Parenting Behavior
description	IOWA, Adult child relationship questionnaire, Parental Acceptance Rejection Questionnaire
safety_issue	Yes
other_name	Integrated Father Treatment for Domestic Violence
intervention_type	Behavioral
arm_group_label	Fathers for Change
description	FATHERS FOR CHANGE  comprises 16, 60 minute sessions of  treatment utilizing components of three evidence based practices:  SADV-CBT, Behavioral Couple Therapy and Child-Parent Psychotherapy.  The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and  the impact of violence on children,  4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
intervention_name	Fathers for Change
other_name	IDC
intervention_type	Behavioral
arm_group_label	Individual Drug Counseling
description	Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
intervention_name	Individual Drug Counseling
Keyword	NOT FOUND
Lead sponsor: Other; Yale University
Collaborator: NIH; National Institute on Drug Abuse (NIDA)
Intervention MeSH	NOT FOUND
Condition MeSH:Substance-Related Disorders
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01489228

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'Yes',
                                     'authority' => [
                                                    'Bolivia: Ministry of Health',
                                                    'Bolivia: Ethics Committee',
                                                    'Spain: Ethics Committee'
                                                  ]
                                   },
                 'detailed_description' => {
                                           'textblock' => '
      Chagas disease (CD) ranks among the world\'s most neglected diseases. In Latin America, 21
      countries are endemic for CD with an estimated 108 million people at risk of contracting the
      disease. Estimates from the 1980s indicated that some 16 million to 18 million individuals
      were infected. In the 1990s, after a series of multinational control initiatives, estimates
      of the number of infected people were revised to 9.8 million in 2001. The estimated burden
      of disease in terms of disability-adjusted life years (DALYs) declined from 2.7 million in
      1990 to 586,000 in 2001. Recent estimates from Pan American Health Organization (PAHO, 2006)
      indicate 7.54 million infected people and 55,185 new cases per year.

      The only two medicines available - benznidazole (BZN) and nifurtimox (NFX) - are known to
      cause serious toxicity with unsatisfactory cure rates, especially when used in adult chronic
      CD patients.

      Novel antifungal triazole derivatives have arisen as alternative treatments for CD. They
      inhibit T. cruzi ergosterol biosynthesis, which is essential for parasite growth and
      survival, and have pharmacokinetic properties suitable for the treatment of this
      disseminated intracellular infection. Several triazole derivatives have been tested in
      animal models of CD, including D08701, posaconazole, ravuconazole (RAV), albaconazole, and
      TAK-187. In particular, RAV has previously been shown to have potent in vitro and in vivo
      activities, inducing parasitological cure in mice with acute infections, including those
      caused by benznidazole-resistant strains of T. cruzi.  Suppressive activity was also seen in
      dog models.

      E1224 is a water-soluble monolysine salt form of the RAV pro-drug. It is a broad-spectrum
      triazole antifungal with in vitro activity against most Candida and Aspergillus species,
      some non-Aspergillus species of filamentous fungi, Cryptococcus, dermatophytes, and fungi
      that cause the endemic mycoses.

      RAV was evaluated extensively in animal models and in human trials including Phase 2 safety
      and efficacy trials in oropharyngeal and esophageal candidiasis and onychomycosis, and for
      prevention of invasive fungal infections in hematopoietic stem cell transplant recipients.

      With the benign safety profile and the encouraging results of animal studies and favorable
      pharmacokinetics, E1224 is considered a priority candidate for clinical development for the
      treatment of Chagas\' disease.

      The general objective of this phase II trial is to determine whether each of three different
      dosing regimens of E1224 are efficacious and safe in eradicating T. cruzi parasitemia in
      individuals with the chronic indeterminate form of CD, in comparison to placebo.
    '
                                         },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'August 2012',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => {
                                      'time_frame' => 'Day 65 (end of treatment)',
                                      'measure' => 'Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment',
                                      'description' => 'To determine whether at least one of three dosing regimens of orally administered E1224 is more efficacious than placebo in individuals with chronic indeterminate CD, by determining the number of patients who convert from positive to negative in serial, qualitative PCR test results',
                                      'safety_issue' => 'No'
                                    },
                 'intervention' => [
                                   {
                                     'other_name' => 'E1224 (prodrug for active ingredient Ravuconazole)',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => [
                                                          'High Dose E1224',
                                                          'Low Dose E1224',
                                                          'Short Dose E1224'
                                                        ],
                                     'description' => '100 mg tablets',
                                     'intervention_name' => 'E1224'
                                   },
                                   {
                                     'other_name' => 'Benznidazole (N-benzil-2-nitro-1-imidazolacetamida)',
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Benznidazol',
                                     'description' => '100mg tablets',
                                     'intervention_name' => 'Benznidazole'
                                   },
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Placebo',
                                     'description' => 'tablets',
                                     'intervention_name' => 'Placebo'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => 'Benzonidazole'
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '5',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'High Dose (HD -  8weeks) Group',
                                  'arm_group_label' => 'High Dose E1224'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Low Dose (LD - 8 weeks) Group',
                                  'arm_group_label' => 'Low Dose E1224'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Short Dose (SD - 4 weeks) Group',
                                  'arm_group_label' => 'Short Dose E1224'
                                },
                                {
                                  'arm_group_type' => 'Placebo Comparator',
                                  'description' => 'Placebo (8 weeks) Group',
                                  'arm_group_label' => 'Placebo'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => "BZN (Laborat\x{f3}rio do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days",
                                  'arm_group_label' => 'Benznidazol'
                                }
                              ],
                 'overall_official' => [
                                       {
                                         'affiliation' => 'Drugs for Neglected Diseases initiative',
                                         'role' => 'Study Director',
                                         'last_name' => 'Isabela Ribeiro, MD'
                                       },
                                       {
                                         'affiliation' => "Universidad Mayor San Sim\x{f3}n. Cochabamba, Bolivia.",
                                         'role' => 'Principal Investigator',
                                         'last_name' => 'Faustino Torrico, PhD'
                                       },
                                       {
                                         'affiliation' => 'CRESIB - Centre de Recerca en Salut Internacional de Barcelona, Spain.',
                                         'role' => 'Principal Investigator',
                                         'last_name' => "Joaquim Gasc\x{f3}n, PhD"
                                       }
                                     ],
                 'brief_title' => 'Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment',
                 'location' => [
                               {
                                 'investigator' => {
                                                   'role' => 'Principal Investigator',
                                                   'last_name' => 'Faustino Torrico, PhD'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'last_name' => 'Faustino Torrico, PhD'
                                            },
                                 'contact_backup' => {
                                                     'last_name' => 'Cristina Alonso, MD'
                                                   },
                                 'facility' => {
                                               'name' => "Plataforma de Atenci\x{f3}n Integral a los Pacientes con Enfermidad de Chagas",
                                               'address' => {
                                                            'country' => 'Bolivia',
                                                            'city' => 'Cochabamba'
                                                          }
                                             }
                               },
                               {
                                 'investigator' => {
                                                   'role' => 'Sub-Investigator',
                                                   'last_name' => 'Lourdes Ortiz, MSc'
                                                 },
                                 'status' => 'Recruiting',
                                 'contact' => {
                                              'last_name' => 'Lourdes Ortiz, MSc'
                                            },
                                 'facility' => {
                                               'name' => "Plataforma de Atenci\x{f3}n Integral a los Pacientes con Enfermidad de Chagas",
                                               'address' => {
                                                            'country' => 'Bolivia',
                                                            'city' => 'Tarija'
                                                          }
                                             }
                               }
                             ],
                 'id_info' => {
                              'nct_id' => 'NCT01489228',
                              'org_study_id' => 'DNDi-CH-E1224-001'
                            },
                 'overall_contact' => {
                                      'email' => 'falves@dndi.org',
                                      'phone' => '+552122152941',
                                      'last_name' => 'Fabiana P Alves, PhD'
                                    },
                 'firstreceived_date' => 'November 24, 2011',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'December 2011',
                 'keyword' => 'Chagas Disease',
                 'source' => 'Drugs for Neglected Diseases',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Other',
                                                 'agency' => 'Drugs for Neglected Diseases'
                                               },
                               'collaborator' => {
                                                 'agency_class' => 'Industry',
                                                 'agency' => 'Eisai Co., Ltd.'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'December 2013',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => 'Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease',
                 'enrollment' => {
                                 'content' => '230',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Chagas Disease'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      This study will assess the safety and efficacy of E1224, a pro-drug of ravuconazole, in
      individuals with chronic indeterminate Chagas disease recruited in research centres in
      Tarija and Cochabamba, Bolivia.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'Bolivia'
                                       },
                 'is_section_801' => 'Yes',
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => '4, 6 and 12 months follow-up',
                                          'measure' => 'Consistently negative serial qualitative PCR as a measure of sustained parasitological eradication',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Day 8, 15, 36 , 65 and at 4, 6 and 12 months follow-up',
                                          'measure' => 'Qualitative PCR as a measure of parasite eradication',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Day 8, 15, 36, 65 and at 4, 6 and 12 months follow-up',
                                          'measure' => 'Quantitative PCR as a measure of change in parasite load over time',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Day 65 and at 4, 6 and 12 months after treatment',
                                          'measure' => 'Incidence of serological conversion to negative and changes in titers over time as measured by conventional and non-conventional serologies',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Day 36 , 65 and at 4, 6 and 12 months follow-up',
                                          'measure' => 'Changes in the levels of biomarkers over time: brain natriuretic peptide, troponin T, selected prothrombotic factors, lytic antibodies, apolipoprotein A1 and multiplex serodiagnostic assay',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Day 0 (pre-dose), Day 1 (after 1st dose), Day 2, Day 3, steady-state phase (D8-D50), at the end of treatment (D65) and at the 4 months follow-up visit',
                                          'measure' => 'Area under the plasma concentration versus time curve (AUC), Peak Plasma Concentration (Cmax), Minimum Plasma Concentration (Cmin), Clearance, Volume of Distribution , and Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole',
                                          'description' => 'Samples for population pharmacokinetics parameters of ravuconazole and benznidazole will be collected at randomly selected time points on Days 1, 2 and 3.',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Up to 12 months follow-up',
                                          'measure' => 'Incidence and severity of adverse events (clinical and laboratory)',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => 'Up to 12 months follow-up',
                                          'measure' => 'Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation',
                                          'safety_issue' => 'Yes'
                                        },
                                        {
                                          'time_frame' => 'Up to 12 months follow-up',
                                          'measure' => 'Early and late predictors of sustainable response to treatments',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => 'Day 8, 15, 36, 65, and at 4, 6 months and 12 months follow-up',
                                          'measure' => 'Correlation of pharmacokinetic parameters with parasitological response, changes in biomarkers and safety outcomes',
                                          'safety_issue' => 'Yes'
                                        }
                                      ],
                 'responsible_party' => {
                                        'responsible_party_type' => 'Sponsor'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => '
        Screening Criteria:

          -  Age >18 to < 50 years

          -  Weight > 40 kg

          -  Diagnosis of T. cruzi infection by conventional serology (a minimum of two out of
             three positive tests [enzyme linked immunosorbent assay (ELISA), indirect
             immunofluorescence (IIF), or hemagglutination inhibition (HAI)])

          -  Signed, written informed consent form

          -  No signs and/or symptoms of the chronic cardiac and/or digestive form of CD

          -  No acute or chronic health conditions that may interfere with the efficacy and/or
             safety evaluation of the study drug

          -  No formal contraindication to BZN and E1224

          -  No known history of hypersensitivity, allergic, or serious adverse reactions to the
             study drugs

          -  No history of CD treatment with BZN or NFX at any time in the past

          -  No history of systemic treatment with itraconazole, ketoconazole, posaconazole,
             isavuconazole, or allopurinol in the past

        Inclusion Criteria:

          -  Confirmed diagnosis of T. cruzi infection by serial qualitative PCR AND Conventional
             serology

          -  Women in reproductive age must have a negative serum pregnancy test at screening,
             must not be breastfeeding, and consistently use and/or have partner consistently use
             an adequate contraceptive method

          -  Normal ECG at screening

        Exclusion Criteria:

          -  Abnormal laboratory test values at screening for the following parameters: total
             White Blood Cells (WBC) count, platelet count, alanine transaminase (ALT), aspartate
             transaminase (AST), total bilirubin, or creatinine; or gamma-glutamyl transferase
             (GGT)

          -  History of alcohol abuse or any other drug addiction (as specified in the Study
             Manual of Operations)

          -  Any condition that prevents the patient from taking oral medication

          -  Any concomitant use of antimicrobial or antiparasitic agents
      '
                                              },
                                  'maximum_age' => '50 Years',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'December 19, 2011',
                 'phase' => 'Phase 2',
                 'start_date' => 'June 2011',
                 'link' => {
                           'url' => 'http://www.dndi.org',
                           'description' => 'Drugs for Neglected Diseases initiative'
                         },
                 'is_fda_regulated' => 'Yes',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01489228',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => 'Chronic Chagas Disease, Indeterminate'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease
time_frame	Day 65 (end of treatment)
measure	Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment
description	To determine whether at least one of three dosing regimens of orally administered E1224 is more efficacious than placebo in individuals with chronic indeterminate CD, by determining the number of patients who convert from positive to negative in serial, qualitative PCR test results
safety_issue	No
other_name	E1224 (prodrug for active ingredient Ravuconazole)
intervention_type	Drug
arm_group_label	High Dose E1224
arm_group_label	Low Dose E1224
arm_group_label	Short Dose E1224

description	100 mg tablets
intervention_name	E1224
other_name	Benznidazole (N-benzil-2-nitro-1-imidazolacetamida)
intervention_type	Drug
arm_group_label	Benznidazol
description	100mg tablets
intervention_name	Benznidazole
intervention_type	Drug
arm_group_label	Placebo
description	tablets
intervention_name	Placebo
Keyword:Chagas Disease
Lead sponsor: Other; Drugs for Neglected Diseases
Collaborator: Industry; Eisai Co., Ltd.
Intervention MeSH:Benzonidazole
Condition MeSH:Chagas Disease
### END TRIAL DATA ###

CLINICAL TRIAL: NCT01507103

 ##### 
$VAR1 = bless( {
                 'oversight_info' => {
                                     'has_dmc' => 'No',
                                     'authority' => [
                                                    'Austria: Agency for Health and Food Safety',
                                                    'Belgium: Federal Agency for Medicinal Products and Health Products',
                                                    "France: Afssaps - Agence fran\x{e7}aise de s\x{e9}curit\x{e9} sanitaire des produits de sant\x{e9} (Saint-Denis)",
                                                    'Germany: Paul-Ehrlich-Institut',
                                                    'Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)',
                                                    'Portugal: National Pharmacy and Medicines Institute'
                                                  ]
                                   },
                 'study_type' => 'Interventional',
                 'primary_completion_date' => {
                                              'content' => 'June 2013',
                                              'type' => 'Anticipated'
                                            },
                 'primary_outcome' => [
                                      {
                                        'time_frame' => '4 months',
                                        'measure' => 'Change from baseline of tumor-infiltrating lymphocytes (TILs) evaluated by immunohistochemical analysis',
                                        'safety_issue' => 'No'
                                      },
                                      {
                                        'time_frame' => '4 months',
                                        'measure' => 'Change from baseline in the Enzyme-linked Immunosorbent Spot (ELISPOT) Level of Mucin-1 (MUC1) -specific T cells',
                                        'safety_issue' => 'No'
                                      },
                                      {
                                        'time_frame' => '4 months',
                                        'measure' => 'Change from baseline in the Enzyme-linked Immunosorbent Spot (ELISPOT) Level of Carcinoembryonic antigen (CEA)-specific T cells',
                                        'safety_issue' => 'No'
                                      }
                                    ],
                 'intervention' => [
                                   {
                                     'intervention_type' => 'Other',
                                     'arm_group_label' => 'Chemoradiation Therapy, L-BLP25 with Cyclophosphamide',
                                     'description' => "Radiotherapy: 45-52 grays (Gy) applied for five weeks. Oral capecitabine (825 mg/m\x{b2} twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.",
                                     'intervention_name' => 'Chemoradiation Therapy'
                                   },
                                   {
                                     'intervention_type' => 'Drug',
                                     'arm_group_label' => 'Chemoradiation Therapy, L-BLP25 with Cyclophosphamide',
                                     'description' => "Cyclophosphamide (day-3) 300 mg/m\x{b2}",
                                     'intervention_name' => 'Cyclophosphamide'
                                   },
                                   {
                                     'intervention_type' => 'Biological',
                                     'arm_group_label' => 'Chemoradiation Therapy, L-BLP25 with Cyclophosphamide',
                                     'description' => "L-BLP25 806 \x{b5}g per vaccination once weekly for 8 weeks (concomitant to chemoradiation), then 7-9 days prior to surgery.",
                                     'intervention_name' => 'L-BLP25'
                                   },
                                   {
                                     'intervention_type' => 'Other',
                                     'arm_group_label' => 'Chemoradiation Therapy, L-BLP25',
                                     'description' => "Radiotherapy (45-52 Gy) applied for five weeks. Oral capecitabine (825 mg/m\x{b2} twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.",
                                     'intervention_name' => 'Chemoradiation Therapy'
                                   },
                                   {
                                     'intervention_type' => 'Biological',
                                     'arm_group_label' => 'Chemoradiation Therapy, L-BLP25',
                                     'description' => "L-BLP25 806 \x{b5}g per vaccination once weekly for 8 weeks (concomitant to chemoradiation), then 7-9 days prior to surgery",
                                     'intervention_name' => 'L-BLP25'
                                   },
                                   {
                                     'intervention_type' => 'Other',
                                     'arm_group_label' => 'Chemoradiation Therapy',
                                     'description' => "Radiotherapy (45-52 Gy) applied for five weeks. Oral capecitabine (825 mg/m\x{b2} twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.",
                                     'intervention_name' => 'Chemoradiation Therapy'
                                   }
                                 ],
                 'intervention_browse' => {
                                          'mesh_term' => [
                                                         'Antineoplastic Agents',
                                                         'Cyclophosphamide',
                                                         'Immunosuppressive Agents',
                                                         'Molecular Mechanisms of Pharmacological Action'
                                                       ]
                                        },
                 'has_expanded_access' => 'No',
                 'number_of_arms' => '3',
                 'arm_group' => [
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => "Following randomization, subjects in this investigational arm will receive, within 3 days of their treatment assignment, a single intravenous (i.v.) infusion of 300 mg/m\x{b2} (to a maximum of 600 mg) cyclophosphamide three days before the first L-BLP25 vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with L-BLP25 (primary treatment phase) followed by vaccinations with L-BLP25 7-9 days prior to surgery.",
                                  'arm_group_label' => 'Chemoradiation Therapy, L-BLP25 with Cyclophosphamide'
                                },
                                {
                                  'arm_group_type' => 'Experimental',
                                  'description' => 'Following randomization, subjects in this investigational arm will receive, within 3 days of their treatment assignment, the first L-BLP25 vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with L-BLP25 (primary treatment phase) followed by vaccinations with L-BLP25 7-9 days prior to surgery.',
                                  'arm_group_label' => 'Chemoradiation Therapy, L-BLP25'
                                },
                                {
                                  'arm_group_type' => 'Active Comparator',
                                  'description' => 'Following randomization, subjects in this comparator arm will receive, within 3 days of their treatment assignment, standard neoadjuvant treatment.',
                                  'arm_group_label' => 'Chemoradiation Therapy'
                                }
                              ],
                 'overall_official' => {
                                       'affiliation' => 'Merck KGaA',
                                       'role' => 'Study Director',
                                       'last_name' => 'Prof. Sonia Quaratino'
                                     },
                 'brief_title' => 'L-BLP25 (Stimuvax) in Rectal Cancer',
                 'study_design' => 'Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment',
                 'location' => {
                               'investigator' => {
                                                 'role' => 'Principal Investigator',
                                                 'last_name' => 'Prof. Theo Ruers'
                                               },
                               'status' => 'Recruiting',
                               'facility' => {
                                             'name' => 'NKI (Nederlands Kanker Instituut)',
                                             'address' => {
                                                          'country' => 'Netherlands',
                                                          'city' => 'Amsterdam'
                                                        }
                                           }
                             },
                 'acronym' => 'SPRINT',
                 'id_info' => {
                              'secondary_id' => '2011-000847-25',
                              'nct_id' => 'NCT01507103',
                              'org_study_id' => 'EMR063325-013'
                            },
                 'overall_contact' => {
                                      'email' => 'service@merck.de',
                                      'phone' => '+49 6151 72 5200',
                                      'last_name' => 'Contact: Merck KGaA Communications Center for EU Recruiting Sites'
                                    },
                 'firstreceived_date' => 'January 6, 2012',
                 'overall_status' => 'Recruiting',
                 'verification_date' => 'January 2012',
                 'keyword' => [
                              'L-BLP25 (Stimuvax)',
                              'Cyclophosphamide',
                              'Mode of action',
                              'Neoplasms',
                              'Neoplasms by Site',
                              'Carcinomas',
                              'Antineoplastic Agents,',
                              'Neoadjuvant',
                              'Radiotherapy Pharmacologic Actions',
                              'Immunosuppressive Agents',
                              'Immunologic Function',
                              'Therapeutic Uses',
                              'Molecular Mechanisms of Pharmacological Action'
                            ],
                 'source' => 'Merck KGaA',
                 'sponsors' => {
                               'lead_sponsor' => {
                                                 'agency_class' => 'Industry',
                                                 'agency' => 'Merck KGaA'
                                               }
                             },
                 'completion_date' => {
                                      'content' => 'June 2013',
                                      'type' => 'Anticipated'
                                    },
                 'official_title' => "A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax\x{ae} (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy",
                 'enrollment' => {
                                 'content' => '87',
                                 'type' => 'Anticipated'
                               },
                 'condition_browse' => {
                                       'mesh_term' => 'Rectal Neoplasms'
                                     },
                 'brief_summary' => {
                                    'textblock' => '
      The objective of this mechanistic study is to determine the impact of L-BLP25 vaccine on the
      mucinous glycoprotein 1 - (MUC1) specific immune response in patients with newly diagnosed
      rectal cancer who are eligible for neoadjuvant therapy.

      L-BLP25 is designed to induce an immune response that may lead to immune rejection of tumor
      tissues that aberrantly express MUC1 antigen. MUC1 is highly expressed in all colorectal
      cancers and since the adaptive immune system plays a role in the prognosis of rectal cancer,
      it is reasonable to speculate that the vaccination with L BLP25 might boost the
      tumor-specific immune response and increase the number of TILs.
    '
                                  },
                 'location_countries' => {
                                         'country' => 'Netherlands'
                                       },
                 'secondary_outcome' => [
                                        {
                                          'time_frame' => '4 months',
                                          'measure' => 'Immunological changes from baseline in the tumor microenvironment',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '4 months',
                                          'measure' => 'Immunological changes compared to baseline in peripheral blood',
                                          'safety_issue' => 'No'
                                        },
                                        {
                                          'time_frame' => '4 months',
                                          'measure' => 'Immunological Response to Treatment in Relation to Microsatellite Instability (MSI) Status',
                                          'safety_issue' => 'No'
                                        }
                                      ],
                 'responsible_party' => {
                                        'responsible_party_type' => 'Sponsor'
                                      },
                 'eligibility' => {
                                  'healthy_volunteers' => 'No',
                                  'minimum_age' => '18 Years',
                                  'criteria' => {
                                                'textblock' => "
        Inclusion Criteria:

          1. Male and female subjects with histologically documented resectable rectal
             adenocarcinoma in stage II-IV.

          2. Availability of  tumor biopsy sufficient for immunological analysis.

          3. Indication to receive neoadjuvant concomitant chemoradiotherapy consisting of a
             radiation dose of 45-52 Gy and capecitabine 825 mg/m\x{b2} orally twice daily. The use of
             an equivalent schedule based on 5-fluorouracil (5-FU) is acceptable.

          4. Imaging not older than 4 weeks to document absence of metastatic disease.

          5. Eastern Cooperative Oncology Group (ECOG) performance 5. status of 0 or 1.

          6. Written informed consent.

          7. 18 years of age.

        Exclusion Criteria:

          1. Previous chemotherapy and/or previous radiotherapy of the pelvic region.

          2. Relapsing disease.

          3. Previous vaccination with any MUC1 vaccine and other therapeutic cancer vaccines.

          4. Previous organ transplantation (bone marrow or solid organs).

          5. Subjects with metastatic disease (except for solitary, resectable liver or lung
             metastases).

          6. Inadequate hematological function (i.e. platelet count < 140*10^9/L, or WBC <
             2.5*10^9/L, or hemoglobin < 90 g/L). Clinically significant hepatic dysfunction (i.e.
             alanine aminotransferase [ALT] > 2.5 times upper limit of normal [ULN], or aspartate
             aminotransferase [AST] > 2.5*ULN, or bilirubin >  1.5*ULN). Inadequate renal function
             (i.e. serum creatinine > 1.5*ULN).

          7. Autoimmune diseases.

          8. Recognized immunodeficiency disease including cellular immunodeficiencies,
             hypogammaglobulinemia or dysgammaglobulinemia; subjects who have hereditary or
             congenital immunodeficiencies.

          9. Any preexisting medical condition requiring chronic steroid or immunosuppressive
             therapy.

        Additional exclusion criteria also apply.
      "
                                              },
                                  'maximum_age' => 'N/A',
                                  'gender' => 'Both'
                                },
                 'lastchanged_date' => 'January 6, 2012',
                 'phase' => 'Phase 2',
                 'start_date' => 'January 2012',
                 'is_fda_regulated' => 'No',
                 'required_header' => {
                                      'download_date' => 'ClinicalTrials.gov processed this data on October 16, 2013',
                                      'url' => 'http://clinicaltrials.gov/show/NCT01507103',
                                      'link_text' => 'Link to the current ClinicalTrials.gov record.'
                                    },
                 'condition' => 'Rectal Cancer'
               }, 'WebService::ClinicalTrialsdotGov::Study' );

 ##### 
Study Title: A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax® (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy
time_frame	4 months
measure	Change from baseline of tumor-infiltrating lymphocytes (TILs) evaluated by immunohistochemical analysis
safety_issue	No
time_frame	4 months
measure	Change from baseline in the Enzyme-linked Immunosorbent Spot (ELISPOT) Level of Mucin-1 (MUC1) -specific T cells
safety_issue	No
time_frame	4 months
measure	Change from baseline in the Enzyme-linked Immunosorbent Spot (ELISPOT) Level of Carcinoembryonic antigen (CEA)-specific T cells
safety_issue	No
intervention_type	Other
arm_group_label	Chemoradiation Therapy, L-BLP25 with Cyclophosphamide
description	Radiotherapy: 45-52 grays (Gy) applied for five weeks. Oral capecitabine (825 mg/m² twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.
intervention_name	Chemoradiation Therapy
intervention_type	Drug
arm_group_label	Chemoradiation Therapy, L-BLP25 with Cyclophosphamide
description	Cyclophosphamide (day-3) 300 mg/m²
intervention_name	Cyclophosphamide
intervention_type	Biological
arm_group_label	Chemoradiation Therapy, L-BLP25 with Cyclophosphamide
description	L-BLP25 806 µg per vaccination once weekly for 8 weeks (concomitant to chemoradiation), then 7-9 days prior to surgery.
intervention_name	L-BLP25
intervention_type	Other
arm_group_label	Chemoradiation Therapy, L-BLP25
description	Radiotherapy (45-52 Gy) applied for five weeks. Oral capecitabine (825 mg/m² twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.
intervention_name	Chemoradiation Therapy
intervention_type	Biological
arm_group_label	Chemoradiation Therapy, L-BLP25
description	L-BLP25 806 µg per vaccination once weekly for 8 weeks (concomitant to chemoradiation), then 7-9 days prior to surgery
intervention_name	L-BLP25
intervention_type	Other
arm_group_label	Chemoradiation Therapy
description	Radiotherapy (45-52 Gy) applied for five weeks. Oral capecitabine (825 mg/m² twice daily) or 5FU, started at the first day of radiotherapy and given 5-7 days per week during the time of radiotherapy.
intervention_name	Chemoradiation Therapy
Keywords:L-BLP25 (Stimuvax); Cyclophosphamide; Mode of action; Neoplasms; Neoplasms by Site; Carcinomas; Antineoplastic Agents,; Neoadjuvant; Radiotherapy Pharmacologic Actions; Immunosuppressive Agents; Immunologic Function; Therapeutic Uses; Molecular Mechanisms of Pharmacological Action
Lead sponsor: Industry; Merck KGaA
Intervention MeSH:Antineoplastic Agents; Cyclophosphamide; Immunosuppressive Agents; Molecular Mechanisms of Pharmacological Action
Condition MeSH:Rectal Neoplasms
### END TRIAL DATA ###

